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Chapter 1 
Introduction and Aim of the Thesis 
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I~ n the late 1960s, when the high mortality of myocardial infarction had caused a high level of public awareuess, the National Institutes of Health, USA, decided to fund _~ projects directly related to the experimental treatment of infarcts, to develop animal 
models best suited to study infarct size after coronary occlusion, and to develop quantitative 
methods in animals and in man to measure infarcts. Many drugs, natural compounds, and 
physical methods were tested in the early phase of pragmatism and only a few forms of 
therapy met expectations when the measurements of infarct size became more precise. The 
most effective of these interventions, which is potentially able to reduce infarct size when 
applied within a certain window of time, is reperfusion. 1 
In the initiated basic pathophysiological studies two major determinant factors of the 
progression of infarct size had been identified, the myocardial oxygen consumption during 
coronary occlusion and the amount of collateral blood flow. 2 But although drugs were found 
able to effectively reduce myocardial oxygen consumption, their infarct size reducing 
properties remained limited since they were depending on the reperfusion of the ischemic 
myocardium. 
In the early 1980s cardiologists became able to reopen freshly occluded coronary vessels,) 4 
thereby instituting reperfusion in a variety of patients. Nevertheless, sometimes the effect on 
myocardial infarct symptoms of vascular reopening procedures was very limited despite 
successfull reperfusion.s Either regional contractile function remained depressed for hours or 
even days after successful reperfusion, although the myocardium at risk was stmcturally 
salvaged - termed myocardial "stunning''<i - or reperfusion had damaged the myocardium in 
addition to ischemia - termed "reperfusion injury".18 
Following Heyndrickx's observation of long-lasting contractile dysfunction C'sh1l1ning") 
following a brief ischemic episode, several laboratories became interested in the mechanism 
of stunned myocardimu9 10 ! I and it soon became apparent that multiple short coronary 
occlusions were not additive in their damaging effect but rather exerted, paradoxically, a 
protection in subsequent long occlusions. It was Jenning's group, who had termed this 
phenomenon "ischemic preconditioning" .12 They have shown that repeated S min coronary 
occlusions with 5 minutes of reperfusion interspersed in dogs condition the myocardium in 
such a way that a long occlusion, usually lethal for some myocytes at risk, does not lead to 
infarction, or it produces only very small ones. This finding contradicted the cOJUlUon opinion 
in the early 1980s. It found its basis in several reports, which implicated both severe depletion 
of adenosine triphosphate (ATP)13 and accumulation of glycolytic intermediates l4 in the 
pathogenesis of lethal ischemic cell injury. Reimer et al" reported in 1986 that ATP 
resynthesis after a single episode of ischemia was very slow, taking as much as 4 days to 
recover after a IS-minute coronary artery occlusion. The delayed metabolic recovery led to 
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the assumption that repeated, brief episodes of ischemia, such as occur with angina pectoris, 
might cause cumulative ATP depletion and eventually result in myocardial necrosis. Using 
four cycles of 5 minutes of coronary m1ery occlusion followed by 5 minutes of reperfusion 
Jenning's group could neither observe a cumulative depletion of ATP nor cell deathY They 
concluded that intermittent feperfusion prevented cumulative injury by washing out ischemic 
catabolites, slowing down A TP depletion, and restoring the capacity for anaerobic glycolysis 
in subsequent ischemic episodes. These results obtained in dogs have also been rep0l1ed by 
many other laboratories '6 [118 and opened up a new avenue of investigation. 
Aim oflile Iilesis: 
The thesis focuses on the pharmacological modulation of ischemic preconditioning. The first 
step was to establish an animal model, that allowed a high reproducibility of the size of the 
area at risk of ischemia and the subsequent myocardial infarction. I Furthermore, the model 
should be useful to assess the effects of drugs, which Illay be subsequently be used in clinical 
settings. 
In chapter 2 we tried to extend the observations in dogs of Murry et alP to the pig heart 
which differs from that of the dog e.g. in the lack of a collateral circulation. Reduction of 
oxygen demand in the presence of a measurable collateral flow (in the canine heart up to 30% 
of normal flow) was believed to playa key role in preconditioning of canine myocardium. 
Since the porcine heart has no collateral blood flow, the reduction in myocardial oxygen 
demand, if of the same magnitude as in the dog (i.e. 30%) should produce different effects 
because the demand-supply ratio in pigs becomes infinitively high. 
In pigs with nearly identical regions at ischemic risk, infarct size of porcine myocardium 
produced by a 60 min coronary artery occlusion preconditioned with two 10 min episodes of 
ischemia each followed by 30 min of reperfusion, was limited to about 20% of that in animals 
which were subjected to only 60 min of ischemia. Tracer microspheres were used to measure 
blood flow to the risk area, which was in every case virtually nil during ischemia. Obviously a 
different explanation for the effects of preconditioning had to be found. 
\Ve assumed that energy savings accruing from the acontractile units of stunned myocardium 
were responsible for the reduction in infarct. But tIus turned out not to be case. Firstly, the 
only moderate reduction of the measured myocardial oxygen consumption in our study was 
unable to explain the dramatic effect of preconditiOlung on infarct size. 19 Secondly, we 
attempted to prevent regional dysfunction by pretreating pigs with a calcium channel blocker 
prior to the preconditioning period. Swine myocardium, which was not stunned when 
pretreated with i.c. nifedipine although subjected to two cycles of 10 min coronmy artery 
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occlusion and 30 min reperfusion, nevertheless exhibited a marked reduction in infarct size 
following 60 min of sustained ischemia. II The results implicated that myocardial stunning is 
not a prerequisite for ischemic preconditioning and that stUlllling and preconditioning are not 
related phenomena. These observations in pigs were perfectly in line with other reports in 
different species 20 21 including dogs, 22 mandating for other preconditioning mechanisms. 
In the mid 1980 several dog studies were reported, 23 24 2S indicating that pre~administration of 
super oxide dismutase and catalase can blunt the preconditioning effects of brief ischemia, 
suggesting that oxygen free radical species produced during the initial episodes of brief 
ischemia might be important in the development of tolerance to subsequent longer episodes of 
ischemia. However, we could demonstrate that these observations can not be extended to the 
pig which differs from that of the dog by the absence of xanthine oxidase,26 which is proposed 
to be a major source of oxygen free radicals in dogs.27 Using SOD and catalase in relatively 
(with regard to the literature) high intravascular concentrations in the above mentioned 
preconditioning protocol, we observed a similar reduction of infarct size compared with only 
preconditioned pigs, and no alteration of stunning.JJJ This is in line with further evidence by 
Koning et al 28. In a two stage coronary occlusion model, which allowed no reperfusion 
between the partial (70% reduction of basal coronary blood flow) and the complete occlusion, 
the protective effect of ischemic preconditioning was observed. As oxygen free radical bursts 
are supposed to be related to reperfusion, this model questions a significant role of oxygen 
radicals in the course of ischemic preconditioning, too. Thus, most animal results favour 
preconditioning mechanisms independent of intravascular oxygen free radical formation. 
In 1983, the ATP-sensitive potassium channel was discovered in guinea pig ventricular 
myocytes by Noma29 using the patch~clamp technique. Noma found that the probability of tlus 
potassium charmel being open was regulated primarily by intracelluar concentrations of ATP 
(= ATP-sensitive potassiulU channel). These channels have been shown to exist in other 
tissues, such as pancreas, central nervous system, smooth muscle, skeletal muscle, and 
kidl~ey.3o 31 Subsequently, other important modulators of this channel have been identified, 
including pH, lactate, the ATP! ADP ratio, and nucleotides. Since the ATP~sensitive potassium 
channel is rapidly opened during ischemia or hypoxia and results in a marked shortening of 
action potential duration and rapid loss of contractile activity, Noma29 proposed that these 
chalUlels may play an important cardioprotective role. 
As cady as 1985 Lamping and Gross32 reported about cardioprotective properties of 
nicorandil, a hybride between a nitrate and an opener of ATP~sensiti\'e potassium channels. 
Interestingly, the cardioprotective properties seem neither to be attributable to the nitrate 
moiety ofnicorandil 33 3-1 nor to its vasodilatory effects.35 Auchampach et al 3637 provided finn 
evidence that the positive effects of nicorandil on postischemic dysfunction, stunning, were a 
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result of opening A TPRsensitive potassium channels. The subsequent development of 
selective modulators of the A TP-sensitive potassium channel (that is, channel openers38 such 
as cromakalim, aprikalim, and bimakalim and channel antagonists3940 sllch as glibcnclamide, 
tolbutamide, and sodium-5-hydroxydecanoate) allowed to obtain considerable evidence that 
opening of A TP-sensitive potassium channels is cardioprotcctive;H while blocking these 
channels is pro ischemic resulting in a delay of the subsequent recovery of myocardial 
contractile function or in an increase in the ultimate extent of myocardial infarction following 
ischemia and reperfusionY 
Chapter 3 describes the hemodynamic and cardioprotective effects of bimakalim,43 a 
compound under development by Merck KGaA as an antianginal, cardioprotective agent.44 It 
provides evidence that the results of the Gross group obtained in dogs45 46 can be extended to 
other mammalian species. Furthermore, it showed that A TP-sensitive potassium channel 
openers a) are only effective when applied prior to an ischemic insult and b) exhibit an effect 
on the myocardium independent of their hemodynamic actions. Thus, cardioselective 
potassium channel openers could be developed47 for the prophylactic trcatment of myocardial 
infarction,48 which would lack the blood pressure lowering effects with subsequent reflex 
tachycardia of the first generation of potassium channel openers,49 such as cromakalimo or 
bimakalim. 
In chapter 4 we evaluated the hemodynamic and cardioprotective prope11ies of U-89232, 
about the first compound claimed to be a Hcardioselective" potassium channel opener.51 
However, the inventors could not reverse the cardioprotective effect of U-89232 in rabbits 
using glibenclamide, which questions whether the cromakalim analog was still a potassium 
channel opener. 52 Using our pig model we could demonstrate that not only the 
cardioprotective effect of U-89232 is sensitive to glibenclamide and the effect is as 
pronounced as with the vasoactive potassium channel opener bimakaIim, but that the 
cardioprotective properties can be observed in the complete absence of any hemodynamic 
changes. 
Stimulated by the results of Gross and Auchampach,53 who showed that intravenous 
administration of glibenciamide 10 minutes prior to or immediately upon reperfusion 
following the initial 5-minute ischemic period completely abolished the beneficial effect of 
ischemic preconditioning in anesthetized dogs, we used glibenciamide in our pig model to 
block either the effects of the potassium channel opener bimakalim or ischemic 
preconditioning. 
Chaptel' 5 describes the effects of the pharmacological modulation of ATP-sensitive 
potassium chatmcls on infarct size, myocardial stunning, and glycolytic breakdown products. 
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Interestingly, the effects of an ATP-sensitive potassium channel blocker on infarct size and 
myocardial stunning were divergent. \Vhile glibenclamide blocked the infarct size reducing 
effect of preconditioning it enhanced postischemic contractile dysfunction,lV which provides 
further evidence that ischemic preconditioning and myocardial stunning are not related 
phenomena.54 55 Furthermore, for ease of comparison the cardioprotection by pharmacological 
opening of ATP-sensitive potassium channels and by ischemic preconditioning, the "original 
pig model" was modified. In the original model, preconditioning was established by two 
cycles of 10 minutes coronary artery occlusion while we now only used a single cycle. 
Consistent with observations in dogs,56 a single cycle of ischemia was as protective as twoY 
which speaks in favour of the proposal that ischemic preconditiong is an all or nothing 
response to briefischemia.286ti 
Today there is little doubt that openers of ATP-sensitive potassium channels possess 
cardioprotective properties. They represent a new class of drugs that may offer exciting new 
therapeutic opportunities under conditions in which a reduction of consequences of an episode 
of ischemia is desirable.57 Possible clinical applications include various forms of angina, 
myocardial infarction with early thrombolysis and cardiac surgery. However, their clinical use 
could be limited, since Cohen et al58 reported that conscious rabbits can become tolerant to 
multiple episodes of ischemia. \Vhen the rabbits experienced a 5-minute coronary occlusion 
and 10 minutes of reperfusion before a 30 minute coronary artery occlusion, they were 
protected, but not if the sustained ischemia was preceeded by 40 to 65 five-minute occlusions 
during a 3- to 4-day period. If an ischemia-free interval of 2.5 to 3 days was interposed, 
protection was again evident. This observation is consistent with results obtained in 
anesthetized rats,59 dogs,60 and pigs.6 ! 
Chapter 6 provides evidence that ATP-sensitive potassium channels play an important role in 
the chain of events leading to cardioprotection and that pharmacological activation of ATP-
sensitive potassium channels may OVercome the limitations of preconditioning with ischemia. 
These results increase the clinical importance of potassium channel openers as they reassure 
the cardioprotective effectiveness of this pharmacological approach at any time. 
Most of the preconditioning models used today incorporate complete restoration of 
myocardial reperfusion after the first ischemic episode in order to obtain preconditioning's 
protection.62 Ovize et al 63 showed in dogs that moderate ischemia caused by a 50% reduction 
in myocardial blood flow failed to reduce infarct size during a subsequent 60 minute coronary 
artery occlusion unless intermittent reperfusion was allowed. These results supported the 
proposal by Murry et aIM that ischemic preconditioning at least in part relies on the outwash 
of metabolites, such as lactate, thereby reducing the cellular load of catabolites during the 
subsequent sustained ischemic episode. However, the generalism of this proposal for all 
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mammalian species has been questioned, since it has been shown in pigs that preconditioning 
protection is possible without intermittent reperfusion.65 66 
Nevcl1heless, the other intracellular alterations observed by Murry et a!. have been confinued 
by many other investigators in different species. They had all ill conmlon, that ischemic 
preconditioning resulted in reduced rates of glycolysis and high energy phosphate depletion, 
better preservation of pH, and myocardial ultrastmcture during the slistained coronary artery 
occlusion.67 68 69 70 In 1993 Steenbergen et 7al observed in isolated perfused rat hearts that 
preconditioning attenuated the increase of intracellular Ca2+, Na+, and H during ischemia, 
most likely because of reduced stimulation of Na+-H+ and Na+ _Ca2+ 27 exchange. Their data 
suggested that pharmacological interventions that minimize ionic derangements during 
ischemia are associated with cardioprotection. 
To investigate the role of the Na+ -lr exchanger in ischemia and reperfusion, the specific 
inhibitor Hoe 694 was used." Chapfer 7 describes the effects of Hoe 694 in our established 
pig model. Hoe 694, when applied prior to 60 minutes of ischemia, reduced infarct size to the 
same extent as did ischemic preconditioning. The cardioprotective potential of Na+-Ir 
exchange inhibition has been confirmed by several investigators in pigs,73 rabbits,14 and rats.75 
Thus, when Hoe 694 was applied with the onset of reperfusion, it was able to significantly 
limit infarct size, providing evidence for the existence of injury. In none of the doses tested in 
pilot studies (0.3 mg - 21 mg/kg/15 min) Hoe 694 exerted any hemodynamic effect. 
The pronounced cardioprotective properties in the absence of any hemodynamic effects make 
specific Na+-I-r exchange inhibitors very promising from a clinical point of view. Given as 
adjunct therapy in numerous reperfusion protocols and in the prevention of myocardial 
infarction these dmgs may prove useful to limit ischemic damage and thereby reduce 
mortality of myocardial infarction. 
Interestingly, Bugge and Ytrehus76 noted that inhibition of the Na+-H+ exchange in the isolated 
rat heart is additive to the protection afforded by ischemic preconditioning. Although 
activation of protein kinase C (PKC) on one hand seems to be involved in mediating 
protective effects of ischemic preconditioning,77 78 PKC may on the other hand activate the 
Na+ -H+ exchanger.7!} so This secondary activation of the Nt! -PI exchanger may counteract to 
some degree the protective effects associated with the initial PKC activation and may explain, 
why inhibition of the Na+-H+ exchanger could be of additional benefit to ischemic 
preconditioning as observed by Bugge and Ytrehus76. However, further experiments are 
necessary to elucidate this possibility, which could be of clinical importance. 
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Ischemic Preconditioning Reduces Infarct 
Size in Swine Myocardium 
Robert J. Schott, Sven Rohmann, Ellen R. Braun, and Wolfgang Schaper 
We evaluated the hypothesis that stunning snine myocardium with brief ischemia reduces 
oxygen demand in the stunned region and Increases tolerance of myocardium to longer periods 
of ischemia. Wall function was quantified \lith ultrasonic crystals aligned to measure wall 
thickening, and stunning was achic\'cd uilh two cycles of left anterior descending coronary 
artery (LAD) occlusion (10 minutes) and reperfusion (30 minutes), after which the lAD was 
occluded for 60 minutes and reperfused for 90 minutes. Infarct size (as a percent of risk region) 
was then determined by incubating myocardium with para-nitro blue fetrazoliurn. Regional 
oxygen demand was measured as myocardial oxygen consumption before the 60-minute LAD 
occlusion in the stunned region; tracer microspheres were used to determine blood flow, and 
blood from the anterior intencntricular vein and left atrium was used to calculate oxygen 
saturations. Mler the second reperfusion period, wall thickening In the stunned region was 
reduced to 1.4±2.4% compared uith 36.7±2.S% (mean±SEM) before ischemia (p<O.OOI). 
Regional myocardial oxygen consumption after stunning (3.I±O.7 ml OJ/min/IOO g) was no 
different from regional myocardial oxygen consumption before stunning (3.7±O.6 ml 0 1/ 
min/IOO g). In the nine pigs "preconditioned" by stunning, infarct size was IO.4±6.3% of the 
risk region compared uith 4S.0±12.7% in the six control pigs subjected to 60 minutes of 
ischemia without prior stunning (p<O.OOS). The risk regions were similar (14.4±1.S% "so 
14.6±1.9% of the left ventricle, preconditioned vs. control pigs, respecth'ely). We conclude that 
stunning swine myocardium nith two cycles of a IO·mlnute LAD occlusion followed by 
reperfusion increases ischemic tolerance but that changes in regional demand in stunned 
myocardium do not predict the marked reduction in infarct size that follows a subsequent 
6O·mlnute period of ischemia. (CirculatiQIl Research 1990j66:1133-1l42) 
M yocardium subjected to continuous, severe ischemia does not suffer irreversible injury if reperfused within 15-20 
minutes,l,2 Repeated periods of ischemia of less than 
15 minutes do not result in a cumulative injury if 
myocardium is reperfused between episodes of 
ischemia,l,J Paradoxically, repeated ischemia-
reperfusion cycles render the myocardium more 
resistant to infarction during subsequent longer epi-
sodes of ischemia, a phenomenon that has been 
termed "ischemic preconditioning."J The mecha-
nisms for ischemic preconditioning are not com-
pletely understood, although a number of important 
observations have been made, An initial period of 
brief ischemia followed by reperfusion has been 
shown to retard the consumption of high·energy 
phosphates during subsequent ischemic episodes:~-8 
Murry et aJ3-5 have also observed a reduction in 
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lactate accumulation in ischemic myocardium pre-
conditioned with prior episodes of ischemia; this 
observation has led them to hypothesize that the 
increased ischemic tolerance accrues from preserva-
tion of energy resources during ischemia andlor from 
a reduction in the accumulation of toxic catabolites. 
This same group has implicated oxygen free radicals 
in the mechanism of preconditioning.9 In a prelimi-
nary report, the protective effects of ischemic precon-
ditioning were blocked by the administration of 
superoxide dismutase and catalase. This suggests that 
free radical generation during the initial ischemia-
reperfusion cycles conditions the canine myocardium 
to the subsequent damage inflicted by 60 minutes of 
ischemia.9 
Brief episodes of ischemia and reperfusion also 
produce transient contractile dysfunction,lO termed 
"stunned myocardium,"" which in some models cor-
relates w)th decreased myocardial oxygen consump-
(ion (MVo1) in the ischemic region during rep'er-
fusion,12.i3 In swine, the effects of stunning on MVo2 
are controversial, Some investigators '4 have observed 
reduced MVOJ ; others lS have reported no changes in 
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MY02 of stunned swine myocardium. We assessed 
MYo2 in stunned myocardium as a measure of 
regional demand; we hypothesized that the de-
pressed contractile dysfunction that characterizes 
stunned myocardium reduces oxygen demand and 
that this contributes to the reduction in infarct size 
observed with ischemic preconditioning. Implicit in 
this hypothesis is the assumption that changes in 
regional demand before occlusion affect the evolu-
tion of necrosis during a subsequent ischemic epi-
sode, when metabolism becomes anaerobic and con-
tractile effort is rapidly supplanted by systolic 
bulging. 1O However, it is known that variations in 
global left ventricular demand at the onset of occlu-
sion affect the extent of necrosis during a subsequent 
ischemic episode.16 
We selected swine myocardium because of its 
similarity to human myocardium in two important 
respects: there are few native collaterals,17 and 
swine myocardium has no detectable xanthine oxi-
dase, which is one likely source of oxygen free 
radicals.l8•19 Therefore, we subjected stunned swine 
myocardium to 60 minutes of ischemia to determine 
whether tissue without xanthine oxidase activity 
would show an increase in ischemic tolerance and 
to determine if an increase in ischemic tolerance 
could be predicted by a decrease in demand asso-
ciated with stunned myocardium. 
Materials and Methods 
Experimental Preparation 
Male mixed-breed Landrace-type domestic pigs 
weighing 19-23 kg were sedated with 2 mg/kg i.m. 
azaperone (Stresnil, Janssen Pharmaceutica, Neuss, 
FRO) 30 minutes before anesthesia with 30 mg/kg 
Lv. pentobarbital. After tracheostomy, the pigs were 
mechanically ventilated with a respirator (Mark 7, 
Bird Products, Palm Springs, California) on room air 
supplemented with 2 I oxygen per minute. Frequent 
arterial blood gases were measured to guide adjust-
ment of ventilator seUings. Both internal jugular 
veins were cannulated with polyethylene catheters. 
Anesthesia was maintained wilh continuous infusion 
of pentobarbital at 3 mg/min through one jugular 
catheter; the other was used for fluid and drug 
administration. The right femoral artery was cannu-
lated with a polyethylene catheter, which was 
advanced to approximately the midaorta for contin-
uous recording of arterial pressure and withdrawal of 
reference blood samples. The heart was exposed 
through a midline thoracotomy and suspended in a 
pericardial cradle. The left anterior descending cor-
onary artery (LAD) was gently dissected free of 
surrounding tissue after the second branch. A loose 
ligature was placed around the vessel, which was 
subsequently occluded with a small vascular clip. A 
27-gauge butterfly needle was introduced into the 
epicardial veins for collection of the blood samples 
used for calculation of regional venous oxygen satu-
rations. The anterior interventricular vein, adjacent 
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FIGURE 1. Diagram of experimental design. Upper row of 
boxes cOllfaillS coronary occlusion (TCO) alld reper/usioll 
limes for preconditiolled hearts; lower row of boxes cOlllaillS 
TCO and reper/llsiolllimes for COlltrol hearts. Arrows indicate 
administration of lracer microspheres for blood flow detemlj-
lIatioll. AI the end of 'he filial 90-millllle reper/usioll, biopsies 
for high-per[onllallce chromatography were taken, before 
heart excision alld infarct size detenllillatioll. 
to the occlusion site, was cannulated in a similar 
fashion to obtain oxygen saturations from the stunned 
region. A catheter was placed in the left atrium for 
injection of tracer microspheres and intermittent 
monitoring of left atrial pressure, which was used to 
guide fluid replacement. A stiff polyethylene catheter 
with multiple side holes was advanced over a wire 
into the right atrium and inserted retrograde 
between 1 and 2 em into the terminal segment of the 
coronary sinus to allow collection of blood for the 
calculation of coronary sinus oxygen saturation. A 
micromanometer (Millar Instruments, Houston, 
Texas) was advanced via the carotid artery into the 
left ventricle for the continuous measurement of left 
ventricular pressure. Rectal temperature was moni-
tored throughout the experiment, and the chest 
cavity was covere<J with a plastic sheet and kept warm 
with a heat lamp. Myocardial function in the ischemic 
area was measured with 5-MHz ultrasonic crystals 
aligned transmurally to measure wall thickness_2o A 
brief «1O-second occlusion) was performed to iden-
tify the ischemic region, and the crystal pair was 
located centrally in the ischemic region. The inner 
crystal was advanced to the endocardium tangentially 
through a stab wound in the epicardium. The epicar-
dial crystal. attached to a Dacron patch, was then 
positioned on the epicardium with the aid of an 
oscilloscope and secured with two sutures. 
Experimelltal Design 
The experimental design is depicted in Figure 1. 
The pigs were divided into two groups: precondi-
tioned and control. Both groups underwent a 30-
minute control period. Preconditioned pigs were 
then subjected to two lO-minute occlusions followed 
by 30-minute reperfusions before the final60-minute 
occlusion and 90-minute reperfusion. Control pigs 
were subjected to only the 6O-minute occlusion fol-
lowed by 90 minutes of reperfusion. 
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Myocardial Blood Flow Measurements 
Blood flow measurements were made with 10 }lID 
tracer microspheres (New England Nuclear, Boston, 
Massachusetts) by using the reference withdrawal 
method.21 Approximately 2 million spheres labeled 
with IllSn, IOJRu, 46$C, wee, 51CO, and 95Nb were 
injected into the left atrium in random order. Refer-
ence blood was withdrawn at a constant rate (20 
ml/min) from the aortic catheter. After risk region 
and infarct size assessments were made at the con-
clusion of the experiment, each ring of the Jeft 
ventricle (approximately 1 em in width) was placed in 
formalin. After allowing at least 72 hours for fixation, 
the rings were removed from formalin and cut into 
4~16 sections depending on the size of the ring. Each 
section was further divided into approximately equal 
endocardial, mid myocardial, and epicardial samples, 
which were weighed (generally 50-300 mg) and 
placed into labeled tubes for gamma counting in a 
germanium solid-state well-type detector.21 The COOl-
pound spectrum was processed by a PDP-1l/24 
computer for generation of blood flow maps for 
each ring. From the first microsphere injection 
during ischemia, three perfusion patterns were dis-
cerned: normally perfused tissue, ischemic tissue 
(which averaged < 10 ml/min/lOO g of flow during 
occlusion), and mixed tissue. Blood flow during 
reperfusion in the previously identified ischemic 
tis~ue was used for calculation of regional ischemic 
MVo2, whereas blood flow from all tissue was used 
for calculation of global MVo2• 
Risk Region and Infarct Size 
After 90 minutes of reperfusion, the LAD was 
reoccluded, and 10 ml of 10% fluorescein dye was 
injected into the left atrial catheter. After 1-2 min-
utes, the pig was killed with a bolus injection of KCI, 
and the heart was excised. Warm 2% agarose was 
injected into the left ventricle via the aortic root, and 
the heart was placed on ice. After the agarose gelled, 
the right ventricle was cut away, and the left ventricle 
was "bread loafed" into 4~6 rings approximately 1 em 
wide perpendicular to the LAD. The rings were 
weighed, and the risk region was traced onto an 
acetate sheet under a black light, which sharply 
defined the borders of the risk area, which was not 
perfused with fluorescein. Subsequently, the rings 
were incubated for 30-45 minutes in 0.125 g para-
nitro blue tetrazolium (p-NBT) per liter of phos-
phate buffer (pH 7.1) at 370 C; p-NBT stains nonin-
farcled tissue deep blue and leaves infarcted tissue 
pale.23 Rings were then photographed with a 
Polaroid MP-4 camera, and acetate tracings of the 
ring and infarcted region were planimetered with a 
graphics tablet. With these data, the percent risk 
region (area at risk divided by area of ring) was 
calculated for the top and bottom of each ring, and 
the average value for each ring was multiplied by the 
weight. The weights of the regions were summed and 
divided by the weight of the left ventricle to yield the 
percent of the left ventricle at risk and percent of the 
left ventricular risk region infarcted. 
Myocardial Oxy8'eu C01Jsumption 
MVo2 was determined in three regions of precon-
ditioned hearts at three time points: during the 
control period, at 25 minutes after the first repedu· 
sion, and at 25 minutes after the second reperfusion. 
The blood How for calculation of control MVo2 was 
obtained from normal region flow during the first 
lO-minute oc~lusion (Figure I). Oxygen saturation 
for global MVo2 determination was obtained from 
the coronary sinus and left atrium. Global and 
regional MVo2 at the first and second reperfusions 
were determined from blood flow measurements 
made concomitantly with the 9xygen saturation mea-
surements. The regional MVo2 represents oxygen 
consumption in the stunned region. Oxygen satura-
tions were obtained from the anterior inteIVentricu-
lar vein at the level of the occlusion. In six precon-
ditioned pigs, local nonischemic MVo2 was obtained 
by calculating the oxygen saturations in a small vein 
draining the anterolateral wall of the left ventricle and 
by using the blood flow data from the first ring, which 
in all cases was ou.tside the risk region. This seIVcd as 
a second control MVo2• All MV02 values were calcu-
lated in the following fashion: 
O2 saturation=oxyhemoglobin/(hemoglobin+oxy-
hemoglobin) 
O2 content=I.34xhemoglobinxOl saturation 
O2 extraction=left atrial O2 content-venous O2 con-
tent 
O2 consumption=Oz extractionxblood flow 
The hemoglobin was measured on a Sysmex micro-
cell counter (model CC180, Digitana AG, Ham-
burg, FRO) and was measured at the time of the 
second reperfusion. Blood samples for oxyhemoglo-
bin concentrations were kept on ice until measured 
on blood gas analyzer (model AVL 995, Bad Hom· 
burg, FRO) within 10 minutes from the time the 
sample was drawn. 
Biochemical Analysis 
At the conclusion of the final reperfusion period, 
biopsies from the risk and the control area were 
taken with a high-speed biopsy drill and frozen within 
10 seconds in liquid nitrogen until analysis. One half 
of the specimens was randomly selected from both 
the preconditioned and control groups for measure-
ment of ATP, creatine phosphate (CP). ADP, and 
AMP by ion-paired high-pressure liquid chromatog-
raphy. Briefly, the column used was a ILBondapak 
C-IS (250 mmx4 mm, 'to ILffi thick)(Waters. Milli-
pore, Milford, Massachusetts). Buffers were 100 mM 
ammonium phosphate with 6 mM tetrabutylamrno-
nium hydrogen sulfate as buffer A and 30% acetoni-
trile plus 70% buffer A as buffer B (as modified by K. 
Hashizume in this laboratory). Step I was 98% buffer 
A and 2% buffer B for 5.5 minutes isocratically. Step 
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2 was from 98% to 0% buffer A and from 2% to 
100% buffer B for IS minutes on a linear gradient. 
Step 3 was 100% buffer B for 4.5 minutes isocrati-
cally, and then the column was reequilibrated with 
the same buffer as in step 1 for about 35 minutes. 
Data Analysis 
Continuous recording of hemodynamic and wall 
thickness data was made on a Graphtec recorder 
(Watanabe Instruments, Japan). Recordings at time 
points of interest were made at a paper speed of 50 
mm/sec, and the data were collected from the record 
by hand. Wall thickness variables were averaged over 
five cycles at each time point and included end-
diastolic wall thickness (EDWT, defined at 20 msec 
before peak negative dP/dt) and end-systolic wall 
thickness (ESWT, defined at the onset of peak posi-
tive dP/dt). These data were used to calculate the 
extent of wall thickening with the following fonnula: 
[(ESWT-EDWT)/EDWTjxlOO. Other variables 
include peak systolic pressure, mean arterial pressure, 
and heart rate. The double product was calculated by 
multiplying peak: systolic pressure by heart rate. 
Data arc reported as mean±SEM. For comparison 
of variables across time betwecn preconditioned and 
control groups, a two-factor analysis of variance 
(ANOVA) for repeated measures was used. When 
the ANOVA was significant, pair.vise comparisons 
were made with Student's t test with the significance 
level for the p values corrected with the Bonferroni 
method. For comparison across time in the precon-
ditioned group, a one-factor ANOVA of repeated 
measures was employed, with an identical post hoc 
testing strategy as for the two-factor ANOV A. A 
two·sample rank-sum test (Mann-Whitney U test) 
was used to test the differences between precondi-
tioned and control animals with regard to risk region 
and the precent of the risk region infarcted. 
Results 
Twenty-five pigs were randomly divided between a 
control group (f/=12) and a preconditioned group 
(11= 13). Three preconditioned pigs (23%) were 
excluded from the study because of intractable fibril-
lation. A fourth preconditioned pig fibrillated at the 
very end of the study as the fluorescein was injected, 
after biopsy. Because the risk region could not be 
determined, this pig was not included in the infarct 
analysis. (The heart was cut and incubated with 
p-NBT and noted to have minimal infarction.) Two 
preconditioned pigs were excluded from MVo2 analy-
sis because of technical problems with measurements 
(one with blood flow and the other with oxyhemoglo-
bin concentrations). Of the 10 preconditioned pigs 
included in the study, nine were analyzed for infarct 
size, and eight were analyzed for oxygen consump-
tion. Two control pigs were excluded because of 
fibrillation (16.7%); one was excluded for poor wall 
function in the control state, and the other was 
excluded because the risk area was only 6% of the 
left ventricle (13% of the risk region was noted to be 
infarcted in this pig). Two control pigs were excluded 
because of failure to demonstrate reperfusion with 
the microspheres; the pattern of reperfusion was 
consistent with spasmN or arterial thrombus in one 
animal, and in the second animal, the gamma counter 
failed to detect activity above background in any of 
the tissue specimens with reperfusion. (The experi-
ment was otherwise completed, and 34% of the risk 
region was infarcted.) This left six pigs, which formed 
the control group. 
Hemodynamic and Wall Function 
Hemodynamic and wall thickness data are summa-
rized in Table 1. The preconditioned pigs remained 
remarkably stable throughout each of the occlusions 
and reperfusions and did not vary significantly from 
the control pigs immediately, before and during the 
60-minute occlusion with regard to heart rate, mean 
arterial pressure, or double product. For precondi-
tioned pigs, heart rate, mean arterial pressure, or 
double product did not vary from control values at 
any time point throughout the entire experiment. 
The changes in wall function through each of the 
brief occlusions and reperfusions for the precondi· 
tioned pigs arc presented in Figure 2. 
Myocardial Blood Flow 
Myocardial blood flow values are summarized in 
Table 2. Myocardial blood How for preconditioned 
and control pigs was not different during the 60-
minute occlusion and subsequent reperfusion in 
either ischemic or nonischemic regions. There was no 
difference across time in endocardial, epicardial, or 
transmural blood flow by ANOVA in the nonisch-
emic regions in both preconditioned and control pigs. 
For ischemic region myocardial blood flow compari-
sons within the preconditioned group, the reperfu-
sion time points were grouped separately from the 
occlusion time points. Within the ischemic region, no 
differences were detected in endocardial, epicardial, 
or transmural blood flow during the three occlusions. 
The repeated-measures ANOVA was significant for 
the three reperfusion time points in the epicardial, 
endocardial, and transmural sections of ischemic 
tissue. Pair.vise testing with the Bonferroni correc-
tion for differences during reperfusion in the isch-
emic region of preconditioned pigs revealed a signif-
icant reduction in endocardial (p<0.OO5), epicardial 
(p<O.05), and transmural blood flow (p<O.Ol) 
between the first and second reperfusion periods. 
Thus, as the myocardium became nearly akinetic in 
the second reperfusion period, blood flow decreased 
transmurally to Ihis region. 
MyocardialOt),gell Consumption 
Global MVo2, local non ischemic MVo2• and 
regional (stunned) MVo2 is represented for precon-
ditioned pigs before occlusion and al the end of the 
first and second reperfusion periods in Figure 3. 
Althougt,l a tendency for global and local n<?nisch-
emic MVo2 to increase and for regional MVo2 to 
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TABLE 1. Hemodynamic and Wall Function Data 
Time period HR (beats/min) MAP (mm Hg) DP (/100) EDWf(mm) ESWT(mm) MVf (%) 
Preconditioned pigs (0-10) 
Control 96.0±3.1 61.7±2.7 72.6±3.8 5.2±O.2 1.0±O.3 36.7±2.5 
TCOI 94.0±2.7 58.6±2,4 72.3±S.S 4.4±OA 4.2±O.3· -4.0±4.S" 
REPl 965±2,4 57.1±3.6 68.7±4.8 S.I±O.2 5.9±OY 14.S±3.3· 
Te02 94.4±2.9 S4.9±3.5 65.1±4.5 4.6±O.2 4.I±O.2" -12.6±2.3· 
REP2 lOO.5±4.9 54.9±4.6 67.5±6.6 S.2±O.2 5.3±O.2· 1.4±2A" 
Te03 IOI.?:!:7.! 53.7±S.O 68.9±6.7 4.8±OA 4.4±OJ" -7.6±2.4" 
REP] llB.9±6.3 49.9±6.8 78.0±10.9 6.8±O.S SA±O.S -to.2±2.S· 
Control pigs (0=6) 
Control 95.0±6.2 62.3±4,4 ?O.I±S-O S.7±O.7 7.3±O.S 28.0±6.2 
Teo 99.2±6.2 57.5±4.7 61.1±10.3 4.7±O.8 4.2±O.8 -13,O±3.S 
REP 107.5±6.6 57.0±S.7 66.2±11.& ?S±O.S 7.4±O.9 -6.0±4.1 
Values are mean±SEM. HR, heart rate; MAP, mean arterial pressure; DP, double product (peak systolic pre$$ure 
limes HR); EDWT and ESWf, end-diastolic and end-systolic wall thickness, respectively, measured with ultrasonic 
crystals; I:J. Wf, change in waH thickness calculated by [(ESWf ~EDWT)!EDWT]X 100. Preconditioned and conlrol pigs 
underwent a 30-minute conlrol ptriod (Control). The preconditioned group was then subjected 10 a to-minute 
coronal)' occlusion (TCOl) followed by a 30·minute reperfusion (REPI) and a second to·minute occlusion (TC02) 
followed by a second 30·minute reperfusion (REP2); the group was then subjected to a final 6O·minute occlusion 
(TC03) followed by a 9O-minute reperfusion (REP3). The conlrol group was subjected only to a 6O·minule occlusion 
(TCO) followed by a 9O-minute reperfusion (REP). Values were obtained at 5 minutes into TCOI and TC02, at 25 
minutes into REPI and REP2, at 30 minutes into TC03 and TCO, and at IS minutes into REP3 and REP. 
·Significant decrease atp<O.OOl compared with all time points after the control period. 
tSignificant decrease atp<O.OOS compared with all time points a(ter the control period. 
tSignificant decrease atp<O.OOOl compared with control. 
decrease is evident, the values at the first and second 
reperfusion periods were not significantly different 
from the control period for the stunned region. This 
finding is consistent with previously reported swine 
data. IS To evaluate the dissociation evident in MVo2, 
we calculated the regionaVglobal MVo1 ratio. This 
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FIGURE 2. Graph showing ischemic regioll \Vall thickening 
ill preconditioned hearts measllred wilh ultra sollie cryslals. 
Wall thickenillg is calculated as follows: % ~WT 
=f(ESWT~EDJVT)lEDWTJxlOO, where ESWT alld 
EDwr are etld-systolic and end-diastolic waf[ thickness. 
respec({~'ely (see "Materials and Methods"). eON (coll/rol) is 
the 30·mirlllte period before lhe 10-minule corollary occlusions 
(TeOl alld Te02). REPl and REP2 are the 30-millllte 
repeifltsion periods. TC03 is the 6Q·millllle occlusioll followed 
by the filial 90-mimlle repeifusioll (REP3). Ischemic regioll 
waf! filllclion recOl'efS immediately w;I" repeiffls;oll after Ihe 
lO-l1l1ilflte occlusions, bill at the onset of the 6Q-miIJule 
occlusioll, this region is akinetic (sllltllled). 
ratio was 1.0±O_1 before occlusion and decreased to 
O.7±O.1 at the end of both the first and second 
reperfusion periods (p<O.OO5 by ANOVA of rc-
peated measures). The r<{lation between regional wall 
functiop and regional MVo2 was evaluated by plotting 
the MVo1 measured at each timc point (the control 
period and first and second reperfusions) against the 
simultaneously obtained regional wall thickening, 
which is presented in Figure 4. Thc relation is 
described by linear regreSSion with a slope of 5.0 (95% 
CI 0,7-9.4) and a y intercep.t 012.1 (r~0.47. p<O,05), 
A linear regression of MVo2 against regional wall 
thickening during only the first and second reperfu-
sions when the myocardium is stunned gives a similar 
slope (slope~5,2. r~O,62), 
Risk Region and Infarct Size 
The risk region and infarct size expressed as a 
percentage of risk region are presented in Figure 5. 
The risk regions were virtually identical (14.4± 1.5% 
for controls vs. 14.6± 1.9% for preconditioned pigs, 
p=NS). The risk area was kept intentionally small by 
occluding the LAD after the second branch, because 
large risk areas wcre associated with an unacceptably 
high incidence of fibrillation in pilot studies with 45 
minutes of LAD occlusion. The percent of the risk 
region infarcted was 48.0±12.7% for controls and 
1O.4±6.3% for preconditioned pigs (p<O.005 by 
Mann-Whitney U test). In preconditioned myocar-
dium, the infarcted tissue was generally spotty and 
scattered throughout the risk region. 
High-Perfonnallce Liqllid Chromatography Data 
Biopsy specimens from all experiments were 
divided randomly into Mo groups for biochemical 
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TABLE 2, MJocardlal Blood Flow DetermIned Wllh Tracer Mlcrospheres 
Nonischemic blood flow (mlJmin/IOO g) Ischemic blood flow (mVmin/IOO g) 
ENDO EPI TRANS ENDO EPI TRANS 
Precondilioned pigs (n-9) 
TCOI I018±16.l 111.2±8,7 106.7:!: 1 1.6 5.1±1.2 9.8±1.9 6.8±1.0 
REP! 123.7±32.1 115.0±16.0 117.8±23.9 132.8±37.3 123.5±23.2 12S.5±28.7 
TC02 IlO.7:!:2SA 106.8±14.6 106.6±!9.3 4.1±O.9 10.5±2.9 6.8±1.4 
REPl lO7.9±2S.5 97.8±14.1 94.2±20.9 97.0±28.3 93.8±18Y 93.8±22.0 
TC03 86.0±20.3 87.8±12.8 85.6±J5.7 3.1±O.6 7.2±1.9 4.7±l.O 
REP3 120.6±26.4 112.6±215 115.1:!:23.5 226.6±64,4 213.9±54.9 220.l±56.2 
Control pigs (n=6) 
TeO 92.1±lO.6 lOJ.8±7.l 97.7±7.7 7.0±2,4 9.l±1.1 7,7±1.3 
REP 106.2±lO.2 97.1±5,4 lOO.9±6.9 149.6±22.5 193,9±6,7 167.9±15,O 
Values are mean±SEM. ENDO, endocardial blood How; EPI, epicardial blood floW; TRANS, transmural blood flow. 
For preoonditioned pigs, values were obtained at 8 minutes into the first and seoond lO·minute ooronary ocdusions 
(TCOI and TCD2, respectively), at 25 minutes into the first and second 30·minute reperfusions (REPl and REP2, 
respectively), at 55 minutes into the 6O·minute occlusion (TC03), and at 2S minutes into the 9{I·minule reperfusion 
(REP3), For oontrol pigs, values were obtained at 55 minutes into the 6O·minute occlusion (TCO) and at 25 minutes 
into the 9{I·minute reperfusion (REP), Occlusion and reperfusion data were grouped separately for analysis. 
·p<O.05 \"$, REP]. . 
tp<O.OI \'5. REPI. 
tp<O.OO5 \"$. REPl. 
analysis. One half was available for high-perfor-
mance liquid chromatography analysis of CP, ATP, 
ADP, and AMP, with results reported in Table 3, All 
values are expressed as nanomoles per milligram of 
tissue (dry weight). The nonischemic region values 
were not different between preconditioned and con-
Hal animals, CP in the ischemic region of precondi-
tioned myocardium was equivalent to that in the 
nonischemic region at 90 minutes after the 60-minute 
ischemic period. However, CP remained depressed at 
less than half of the nonischemic region values in 
control hearts (p<O,QOS, paired t test), A similar 
trend is apparent in the ATP data although a statis-
tically significant separation was not achieved. 
"" Time 
FIGURE 3. Bar graph sllOwlng m),ocardial oxygen cOJlSllmp· 
lioll (MV01) calclIlated from Ihe ellfire left ventricle (global), 
a nonischemic cOlltrol regioll in the circumflex distribution, 
and from Ihe "sllIlIned" regiol/. Conlrol is 'he 30·minltte 
period before 'he first occlusiolJ. REP I alld REP 2 are the 
30'mill/lte reper/usioll periods after the JO·millute occlusions. 
MV01 is measured at 25 minules illfo REP I alld REP 2. 
Discussion 
Ischemic Preconditioning and Ischemic Tolerance 
The primary objective of this study was to assess 
the effects of stunning on ischemic tolerance in swine 
myocardium. Myocardium was subjected to two 10-
minute ischemic episodes, each followed by 30 min-
utes of reperfusion, which produced regional akinesis 
by the end of the second reperfusion period, Myo-
cardium "preconditioned"4 in this fashion has less 
than one quarter of the necrosis of myocardium that 
has not been stunned. despite the additional 20 
minutes of ischemia in the preconditioned pigs. The 
differences in infarct size between preconditioned 
and control pigs are not attributable to differences in 
the traditional detenninants of infarct size: risk 
regions and hemodynamics between the two groups 
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FIGURE 4. Scal(erplot of sil1l1tltalleollsly obtained regional 
myocardial Q.t}'gell consumption (AWOl) venus wall Illicken· 
ing (% ~wr; for precondi/ioned pigs before ischemia (COIl-
Irol) and 01 25 milllttes illfo each 30'minllfe reper/usiol/ pedod 
(Rep I alld Rep 2) after each 1O·mill/lle occlusion. Each 
experimenr is represented by Ihree time poinls. 
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FIGURE 5. Risk region (as percent of the left wllfric/e 
[% LV)) and infarct size (as percenl of the risk regioll (% 
RRJ) for preconditioned pigs and controls. ·p<O.OO5 VS. 
collflols by MUII1/-lYhitlley U test. 
were similar, and collateral transmural blood ftow to 
the ischemic region in swine was minimal « 10 
mi/min/IOO g in these experiments).'.24,25 These 
results are in close agreement with preconditioning 
effects reported by Murry ct a1,3 who observed a 75% 
reduction in infarct size after 40 minutes of LAD 
occlusion in dogs preconditioned with four 5-minute 
occlusions followed by 5-minute reperfusions. Li et 
aj26 have also observed a substantial (lO-fold) 
decrease in infarct size in dogs preconditioned with 
as little as 5 minutes of occlusion followed by 5 
minutes of reperfusion before a 60-minute circumflex 
occlusion. 
The mechanism of preconditioning is not completely 
understood although a number of researchers4 - s have 
observed that ATP depletion is slowed after an initial 
episode of ischemia. Murry et aP ha\'e speculated that 
this, coupled with reduccd catabolite accumulation 
after the initial periods of ischemia, could account for 
the protective effect of preconditioning. Furthemlore, 
CP stores exhibit an "overshoot" with reperfusion after 
brief peri?ds of ischemia,27,:zg making more energy 
stores available when entering a long period of isch-
emia. However, CP is depleted within minutes after the 
onset of ischemia, and the additional CP from the 
overshoot is probably not sufficient to sustain viability 
TABLE 3. Hlgb.Energy Phosphates 
Group 
Creatine 
phosphate 
Precand,Holled pigs 
Ischemic 33.8±2.1 
Nonischemic 35.9±3.0 
ConlTol pigs 
Ischemic \3.2±2.l" 
Nonischemic 27.9+4.2 
ATP 
5.5±O.1 
20.4±O.3 
4.0±tl.9 
20.3+ 1.4 
ADP AMP 
2.3±O,4 O.2±O.l 
2.9±0,4 O.3±O.l 
1.9±0.2 O.2±O.l 
3.0+0,4 0.3+0.1 
Values are mean±SEM and are in nanomoles per milligram of 
dry weight. Ischemic biopsies were taken from the center of the 
ischemic region 90 minutes after the final reper(usion; nonisch· 
emic specimens were taken from the lateral wall at the same time. 
·p<0.OO5 \~. preconditioned ischemic region myocardium. 
through 60 minutes of ischemia. Recently, it has been 
reported that preadministration of superoxide dismu-
tase and catalase can blunt the preconditioning effects 
of brief ischemia; this finding suggests that oxygen free 
radical species produced during the initial episodes of 
brief ischemia might be important in the development 
of tolerance to subsequent longer episodes of 
ischemia.9 Our demonstration of a preconditioning 
effect in myocardium devoid of xanthine oxidase 
activity19 suggests either another source of frce radicals 
(i.e., neutrophils29) or another mechanism for the pre-
conditioning effects of brief ischemia in pigs. 
We determined infarct size in myocardium reper-
fused for 90 minutes after the final occlusion period 
by incubating the myocardium with p·NBT. This 
established technique relies on the conversion of 
the tetrazolium salt to formazan in the presence of 
cofactors (nicotinamide adenine dinucleotides), 
which stain viable myocardium deep blue.23 Inf-
arcted tissue loses these cofactors during reperfu-
sion and remains pale and easily distinguishable 
from viable myocardium. The duration of reperfu-
sio~ periods u~ed with this technique has been quite 
vanable; 30 mmutes of reperfusion is the minimum 
time reported for the delineation of infarcted 
tissue.24 Recently, Fujiwara et apo compared 1-, 3-, 
and 7-hour reperfusion times after 1 hour of distal 
LAD occlusion in domestic swine and reported that 
1 hour of reperfusion was adequate for the delin-
eation of infarct size when cut specimens were 
incubated with p-NBT. In that study. infarct size 
was also determined with an immunohistochemical 
technique employing myoglobin antibodies, as well 
as with hematoxylin-eosin and Masson's trichrome 
staining of the myocardium. We have previously 
reported on the adequacy of p-NBT technique after 
90 minutes of reperfusion, with ultrastructural ver-
ification of infarction,23 
Myocardial Oxygen COllSflmptioll in 
Stunned Myocardium 
I).. second objective of this sludy was to measure 
MVo1 in stunned myocardium. We hypothesized that 
preconditioning might result from stunning; with 
ischemic disengagement of the contractile apparatus, 
oxygen demand would be lowered entering a subse-
quent ischemic period, This requires an important 
assumption: variations in regional demand under 
aerobic conditions at the onset of occlusion affect the 
evolution of myocardial necrosis under anaerobic 
conditions during occlusion. Previous experiments t6 
have demonstrated that variations in global demand 
before the onset of ischemia can alter the rate of 
necro~is after arterial occlusion, whereas alterations 
in MVo2 midway through a 90-minute occlusion do 
not affect the extent of necrosis. This finding suggests 
that the period immediately after occlusion in virgin 
myocardium is crilical, which is supported by the 
observation of Neely and Feuvray31 that there is a 
burst of anaerobic glycolysis immediately after occlu-
sion in virgin myocardium, with slowing of aerobic 
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glycolytic flux as ischemic catabolites (lactate, nicoti-
namide adenine dinucleotide, and H+) accu-
mulate.n .J.) The data of Murry et al5 indicate that the 
rate of ATP depletion and lactate production are 
greatest in the first 10 minutes after arterial occlu-
sion. We hypothesized that continued contractile 
effort after occlusion was responsible for the accel-
erated anaerobic flux and that the rate of anaerobic 
flux could be slowed by stunning the myocardil;lm. 
Our failure to observe a significant change in MYo2 
in stunned myocardium suggests that despite near 
akinesis, oxidative metabolism remains relatively 
constant. Thus, the marked protective effect cannot 
be explained by an appreciable decrease in regional 
demt!nd entering the ischemic period. 
MYol of stunned myocardium has been a continuing 
source of controversy, with groups reporting that MYo2 
is decreased,'2-'4 unchanged,15.34 or increased.35 nlis 
may reflect species differences as well as the heteroge-
neity found in the contractile effort in myocardium that 
is labeled "stunned." A recent brief report suggests that 
regional MYo2 is minimally reduced until function 
is depre~ed to the onset of systolic bulge, at which 
point MYo2 falls off rapidly}6 The akinetic stunned 
myocardium in the experiments reported here retains 
some residual contractile effort: the myocardium 
bulges 12% during the second occlusion but "recov-
ers" to akinesis with the second reperfusion. There-
fore, in addition to the basal metabolic requirements 
of myocardial tissue, which may. account for one 
fourth to one third of resting MVo2,')7 there is the 
contractile effort to maintain akinesis. 
With the necessity for small risk regions in these 
experiments, some function in the stunned region 
may artifactually result from "tethering" to normal 
myocardium, although Gallagher et apa have shown 
that this "functional border zone" extends for less 
than 0.5 cm in either direction from the perfusion 
boundary when ultrasonic crystals are aligned to 
measure wall thickness. 
Although we report that regi9nal MY02 did not 
change significantly from the MYo2 before stunning, 
the trend was for gradually decreased MYo2 in the 
stu.nned myocardium. In addition to (stunned). regional 
MY0l> we calculated left ventricular global MYo2 from 
the coronary sinus oxygen saturation and mean blood 
flow to the entire left ventricle. In a subset of six pigs, a 
second control MYol was measured in a normally 
contracting regi9n of myocardium in the left circumflex 
distribution. MYo2 in these control regions tended to 
increase after coronary occlusion. A change in hemo-
dynamics did not account for this, although it is known 
that the nonischentic regions of the myocardium com-
pensate with increased contractility during occ1usion39 
an~ that this may in tum account for the ihcrea~ed 
MYo2 in this region. When (stunned) regional MVo2 
wa~ compared With. the simultaneously obtained glqbal 
MYo2, regional MYo2 fell from 100% of global MYo2 
before occlusion to 70% of the global MYOl with 
stunning (p<O.005). This was accompanied by a fall in 
transmural blood flow from the first to the second 
reperfusion period; this fall is consistent with down-
regulation of blood flow in response to decreased 
oxygen demand.B Regional MY02 was weakly corre-
lated with regional wall function (r=0.47, p<0.05). 
MYOl before occlusion is relatively low (3.5±OA 
ml OJmin/lOO g) in this model. This is less than we 
have previously reported for swine using the 
Bretschneider equation,24 although it is consistent with 
other reports of measured MYol in swine.14 This may 
be a function of an open-chest preparationJ4 but also 
may reflect inclusion of small quantities of right 
ventricular venous effluent in our measurements of 
oxyhemoglobin from the interventricular vein and 
coronary sinus. The right ventricle has a lower oxygen 
consumption,40 which may have elevated the oxyhe-
moglobin concentrations that we measured. In addi-
tion, oxygen saturations from the stunned.region are 
included in the calculations of global MYo2 during 
the first and second reperfusion periods. 
High-Energy Phosphates 
CP levels from the preconditioned myocardium at 
90 minutes of reperfusion were twice that of myocar-
dium subjected to a single 6O-minute episode of 
ischemia, despite an additional 20 minutes of isch-
emia. Our conclusion is that preconditioned myo-
cardium is viable after 60 minutes of ischemia and is 
able to resume oxidative phosphorylation and 
replete CP stores. It is less likely that precondi-
tioned myocardium can preserve significant quanti-
ties of CP, which under normal circumstances is 
rapidly depleted after the onset of ischemia)) ATP 
and ADP were depleted to the same degree at 90 
minutes after the 60-minute occlusion in both pre-
conditioned and control myocardium. Regeneration 
of creatine kinase occurs quickly in stunned myo-
cardium28; however, ATP and ADP resynthesis 
requires days after brief ischemia.41 
Summary 
In summary, we demonstrated that two brief 
cycles of ischemia and reperfusion increase the 
ischemic tolerance of swine myocardium during a 
subsequent 6D-minute coronary occlusion. In addi-
tion to reducing the volume of infarcted myocar-
dium, preconditioning with ischemia was associated 
with restoration of CP stores 90 minutes after a 
6O-minute episode of ischemia. MYo2 in stunned 
myocardium was decreased when compared with 
sirJ}ultaneously measured global left ventricular 
MYo2; however, it was not decreased when com-
pared with preischemic regional MVo2• This sug-
gests that increases in ischemic tolerance are inde-
pendent of changes in regional m;ygen demand 
associated with stunning. The precise mechanisms 
by which ischemically primed myocardium can pro-
tect itself remain unclear. The extent of the infarct 
size reduction exceeds any that has been produced 
with pharmacological interventions and warrants 
further careful investigation. 
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Effect of bimakalim (EMD 52692), an opener of A TP 
sensitive potassium channels, on infarct size, 
coronary blood flow, regional wall function, and 
oxygen consumption in swine 
Sven Rohmann, Heinrich Weygandt, Pierre Schelling, Loe Kie Soei, Karl-Heinz Becker, 
Pieter D Verdouw, Inge Lues, and GUnther Hausler 
OlJjeclh'c: The aim was to assess whether bimakalim, an opener of ATP sensitive potassium channels, can 
reduce infarct size in swine myocardium. Methods: Experiments were perfonned in open chest pigs subjected 
to a 60 min occlusion of a branch of the left anterior descending coronary artery and to 2 h reperfusion. Five 
groups of animals were studied. In seven animals bimakalim infusion (3 /l-g·kg- l bolus over 5 min followed by 
0.1 flg·kg-l·min-I) was slmted at 45 min of coronary occlusion and continued until 60 min of reperfusioll (group 
A). while in seven other animals the bimakalim infusion was started 15 min before occlusion and also ended 
at 60 min of reperfusion (group B). In a further seven animals bimakalim infusion was started 15 min before 
coronary occlusion, but was stopped at the onset of ischaemia (group C). In the fourth group of animals (n::: 7), 
a hydralazine infusion (0.2 mg·kg- ' over 15 min) was started 15 min before the occlusion and also terminated 
at the start of occlusion. The dose of hydralazine was chosen such that it lowered arterial pressure to the S!lme 
extent !lS binmkalim. A fifth group of aninmls (n::: 7) received the vehicle and 5erved as controls. At the end 
of the protocol, infarct size (as percent of risk region) was detern~ined by incubating myocardium with 
p-nitrobluetetrazoJium. Regional myocardial oxygen consumption (MVO~) was calculated a~ the product of 
coronary blood flow (electromagnetic flowmeter) and the difference in the oxygen contents of the aorta and the 
interventricular vein accompanying the left anterior descending coronary artery. Regional wall function was 
quantified with ultrasonic crystals aligned to measure wall thickening (%tl WT). Results: In all pigs in which 
bimakalim treatment was started prior to the 60 min coronary occlusion. infarct size was significantly reduced 
rB: 22.4(SEM 4.5)%; C: 35.3(6.6)o/c] compared with 60.4{5.2)<K in pigs subjected to 60 min of ischaemia only 
I p< 0.05); drug-induced potassium channel opening during reperfusion had no effect fA: 56.6(4.1 )%J. Treatment 
with hydralazine did not reduce infarct size 159.4(4.3)9(1. Neither drug altered %ilWT; however. they reduced 
~'I\lO~ by 36.5% in B. by 27.11k in C. (lIId by 14.M1- in the hydralazine group. Conclusions: Bimakalim 
treatment prior to the onset of a 60 min coronary occlusion increa~e.~ the tolerance of pig myocardium to 
ischaemia. The data arc consistent with the hypothesis that bimakalim reduces infarct size by activation of cardiac 
ATP sensitive potassium channels and not through unloading of the heart because of its vasodilator effects. 
Cardiol'Qscular Research 1994;28:858-863 
Potassium channel activators are a chemically diverse group of compounds that are thought to open ATP sensitive potassium channels. thereby relaxing smooth 
muscle! : and shortening cardiac action potentials:' ~ These 
effects of potassium channel activators arc antagonised by 
glibenclamide. a relatively selective bloeker of ATP sensitive 
potas~ium channels in a number of tissue typeS.5" There is 
growing evidence th!lt these potassium channel activating 
compounds have an anti-ischaemic effect. as pinacidil and 
cromakalim have been shown to improve postreperfusion 
function and to reduce the release of lactate dehydrogenase 
(LDH) in an in vilro model of global ischaemia. The 
protective actions were fully reversed by glibendamide.6 
Furthennore, it has been proposed that potassium channel 
activation is involved in the phenomenon temled "ischaemic 
preconditioning", in which brief periods of coronary artery 
occlusion followed by reperfusion increase the tolerance of 
myocardium to subsequent longer episodes of ischaemia.7 In 
ischaemically preconditioned myocardium the development 
of myocardial necrosis during a subsequent coronary oc· 
c1usion is m!lrkedly delayed.~ 'I The a\'ailability of agonists 
and antagonists for ATP sensitive potassium channels 
enabled Gross and Auchampach llJ to study thi~ in more 
detail; the ATP sensitive potassium channel antagonist 
gJibenclamide blocked the protective effect of precondition· 
ing, while the ATP sensitive potassium channel opener RP 
52891 mimicked it in canine myocardium. 
We have recently reported that bimakalim. ll another 
potassium channel activator under development as an 
anti anginal drug, reduces infarct size in pigs. In this species 
bimakalim has been shown to decrease arterial blood 
pressure due to systemic vasodilatation, to increase heart 
rate, and to exert no effect on left ventricular filling pressure 
or myocardial contractility.!! The present study was per-
formed to analyse the nature of the cardioprolective effect of 
bimakalim. In order to test whether the protective effect is 
Department of Preclinical Cardiovascular Research, E !vJerck, Frankfurterslrassc 250. 0-64271 Darmstadt. Germany: 
S Rohmann. H Weygandt, P Schelling. K-H Becker. I Lues, G Housler; Laboratory for Experimental Cardiology, Thoraxcenter. 
Erasmus University Rotterdam, The Netherlands: L K Soei, P 0 Verdouw. Correspondence to Dr Rohmann. 
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related to alterations of myocardial contractility, coronary 
blood flow. or oxygen consumption (MV02) in healthy 
tissue prior to infarction we started bimakalim treatment 
before or during ischaemia and compared its effects with 
those of an cquihypotensivc dose of the vasodilator 
hydralazine. 
Methods 
The investigation (onfonfis with the GI/ide JOT the care alld IIU 0/ 
laboratory onimals published by the US National Institutes of Heallh 
(NIH publication No 85-23, revised 1985). 
£lperimel1lal desi.r.:11 
All 35 pigs undawent a 60 min left anterior descending coronary arter), 
occlusion followed by 120 min of reperfusion. The animals were 
divided into five groups. The design is depicted in fig I. Vehicle treated 
animals ser.'ed as controls. Bimakalim treatment was perfomled as 
follows: group A (n = 7) received bimakalim starting 4S min after 
coronary occlu,ion ant.! continued during the first 60 min of reperfusion: 
in group B (n = 7) bimakalim was infused from 15 min before occlusion 
until 60 min after start of reperfusion: animals ill group C (n = 7) 
received bimakalim ollly for 15 min before the onset of ischaemia. 
Hydralazine (n:= 7) was given in the ~ame way as bimakalim in 
group C. 
Erperimeillol preparation 
Thirty fi\'e mixed breed Landfllce·t)'pe domestic pigs of either sex 
weighing 23 and 29 kg were premedicated with ketamine-HCI (500 mg 
intromuscularly) 15 min prior to anaesthesia with intravenous chlora-
lose ([00 mg·kg·!). Following trache'.llomy pig~ \\ere mech~nic;l[[y 
ventil;lt~d with nitrous oxide supplement~d with oX)'gen ;II a ratio uf 
2:1. In UNa IU guide adjustment of ventilator ~eltiogs ;lrteri~l blood 
ga,es were me.l,ured repeatedly. Anae,lhesia \\',1', maintained by con-
tinuous infusion of pentobarbitone at 3 mg·kg-',h-
' 
through a eatheler 
in the rightjugul;lr vein. Arterial blood was sampled through a catheter 
placed in the right feflloml artery. while the right brachial artery wa<; 
cannulated with a polyethylene cJtheter, which was advanced \0 the 
a~cending aorta for l'ontilluouS ren1rding of arterial pre.~sure. An SF 
MillJr micwmanomeler wa<; advanced via the carotid urtery into the left 
ventride for cuminuou<; meawrement of left venlri~u!;lr pres~ure. The 
heart wa, e:>.p<.,-,ed through a midline IhnrJcotunl}, Jnd suspended in u 
paicardia! cr.Jd!e. The pro."(imal P.Jrt I,f the se("ond branch of the len 
anterior descending ("oronary artery wus carefully di<;sected free owr a 
length of 4 mm and a loose ligJture was placed uround Ihe vessel \~hich 
could be occluded with a smal! \"a~fular clip. Electromagnetic 11011' 
probes were SilUJted on the Ll-wending aortJ and the !eft anterior 
Control Reperfusion 
Baseline 
Time (min) -15 pre-TCO 45 60 
=~='---~ __ ---'_---"' ____ L_J 
75 120 180 
Group A 
Group B Aeperfusion 
Group C Aeperfusion 
Hvdralazine Reperfusion 
Figllre J Dnigll of llie .\111(~\". Bill/:= bill/aka/illl; TeO == loud 
I 1If"/1I1/1ry arlt',)· (/{"("/UI'illll; HYI/ra =: hydralazine. 
descending coronary artery proximal to Ihe occlusion sile. A Teflon 
catheter (Outer diumeler 0.8 nun) was placed inlo the epicurdia\ \'ein 
draining Ihe area ul risk. Rectal temperalUre was monitored throughout 
the experiment and the chest cavity was cowred with a plastic sheet 
Jnd kept WJrm with a heat lamp to keep body temperature betweell 
37'C und 38'C. Myocardial function in the ischaemic area wus 
measured with 5 mHz ultrasonic crystals aligned transmurally to 
measure waU thickness. A brief (<IO s) occlusion was performed to 
identify the ischaemic region and the crystal PJir was located centrally 
in this region. The inner crystal was ad"unced to the endocardium 
tangentially through a stab wound ill the epicardium. The epicardial 
crystal, attached to a Dacron patch. was positioned on the epicardium 
with the aid of an oscilloscope. and secured with three sutures. 
Following a stabilisatioll period of 30 min after surgery Ihe experi-
mental protocol was started. 
Risk region (llId il,jarc/ 5i::e 
Following a reperfusion period of 2 h. the coronary wery wus 
reoccluded Jnd [0 fill of 10% fluorescein dye were injected into the left 
atrium. After 1-2 min the pig was killed by electrical fibrillation with 
a 9 V buttery ulld the heart (."(cised. Wurm 2'k agaro,e was injected into 
the wntricle via the aortic root and the heart was kepi on ice. Afler the 
agarose had congeuled. Ihe right ventricle wus removed und the left 
wntricle was sliced into four to six rings perpendicular to the left 
anterior descending coronary arter)". Subsequently, the rings were 
weighed und the risk region traced onto an acetate sheet under 
blacklight. which sharply defined the borders of the risk areu not 
perfused with fluorescein. Incubation for 30 min in 1.25'k purunitro. 
bluetetruzo\ium in phosphate buffer (pH 7.1) at 37'C delineuted nOli-
infarcted tissue (deep blue) ulld infurcted tissue (pale). Rings were then 
photographed with a Polaroid camera and acetate trJ.dngs of the ring 
"nd infarcted region were determined by planimetr)'. TIle perant risk 
regiun tarea ut ri~k/Jrea of ring) Wa., l'a!culated for the top and bottom 
llf each ring and the mean \'ulue for e.Jch ring was multiplied by the 
weigh!. The weighl.-i of regions were summed and di\'ided by the \\eight 
of the left ventride to yield the percentage of the left ventricle at risk 
(,}RR) and percentage of Ihe left ventricular risk region infurcted 
MY(}("(/r(liai mygt'n ("(/I!.H/Illptirlll 
Arterial ami coronar)' venou, blood ~amples were obtuined 
anaerobkJ.lly for detemlination of pH. Po~. and P("o~ by \\ithdml\al of 
J.O till of b!ll<.ld from the aortk and anterior inlerwnlricuLlr win 
l',Hhcters ~imultaneou,ly_ Haemoglobin <.":oment. O~ satur.Jtion, blood 
Po~. ,!fId pH. were IIIcawred by a <.":"mputer aided blood ga, analyser. 
Oxygen "onwmption in the region of myocardium perfu~ed by the 
left anterior de.<;eending coronury artery W;lS computed by multiplying 
Ihe arteriovenous oxygen difference by Coronal)' blood !low_ de-
tefillined with the nowmeter probe pro);imal to the occlusion site. Since 
anterior interventricular \'ein blood Ilow corre~ponds to left unteriur 
de~cending coronary artcry inftu);, P Ihi~ method Jllows determinJlion 
of myocurdial oxygcn consumptilln in Ihe region perfu~ed by Ihis 
vesseL!' 
ulela/t't'.ltl"(/(/iO!l 
At contro!' at 3 min of repcrfu~i(lfl, ;lnd at 120 min of reperfusion 
~imultaneou<; arteriul and coronal)' wn(lUS blood ~ampJes were obtained 
for measurement of lactute concentr.Jtion. LaelUte extraction of the 
myocardium wus calculated uec(lrding to McFalls elll{I~: 
'f lactatc cxlractiun = [(;lrterial minus venous 
lactJlel'arteri~1 la,·tate! x 100 
Administration oj hill/a/wlilll 
Animals in Ihe treatment groups received bimakalim dissolwd in 
1-2-propandiol and isotonic saline, while the pigs in Ihe control group 
receiwd \"Chide 0-2-propandiol and isotonic saline) corresponding tu 
the time course of treatment of group B. Bimakalim was supplied as 
J sterile, non-pyrogenic. frecle dried solid. Prior to cach experiment it 
was dissoil'ed Jnd mhed in a J7'C wann ~odium chloride :<Iolution for 
injeclion (0.9~l. The bimakalim ~ulUlion was gi\"Cn as a colltinuous 
infusion via a femoral vein at a do,e of 0.1 flg·kg-I.min-' preceded by 
a bolus injeeti('n of J I-lg·kg I owr S min. 
Oatl/wlII/nis 
Cnntinuou's recording of haem(>d)'n~lIIic und wall thickne~~ d~t.J l\i" 
made on J paper recorder unt.! on a computer uided recording system. 
Re;;ordings at ttnl<.' poims or intere~t II ere made ;It a p~per ~peeJ ,,1' 100 
nUlI'S '. and the wul! thid..ne~~ dat .. were collected from the recnrding". 
Wall thickne.<~ variahles were <l\'erJged oWr 10 cycles at eueh time 
point und included ~y~lO!ie w.JlI thirknc's" IESWT. defined al 20 nh 
before peak negative dP/dt), and end di,\"tulie wall thickne~\ (EOWT_ 
dclined at the on,et of pc..!k ptl,iliw dP/ol). The,e \I,lt;l \\ere ,he,! hi 
calculate wallthid.ening ((f.lWT) \\ith the following f('nnul~: (ES\\'T-
EOWTllEDWT X 100. Other \'"riah]e. .. included peak left I"emric'ular 
sy.~\(llic pressure (LVSP. mm !lg). mean arlcri~1 pre,>sure (~Ir\I', 
mm Hg), anu heart r .. le (hc;ll~·min"11. TIle corona'l)' vuwular re.,j,t.!fII·c· 
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(dyn·~·cm ') Ila, \',l1culnted a~: dia.,tolk aortic blood pre.,~urc X XO! 
coronary blllod tlO\I: Jnd the lotal ~ripheral re.,bt'lJlCe: MAP x SO! 
aortic blood firm 
DJta arc rcp"rI~J a~ mcan(SEl'.ll. For c(lmparison of \'ariabk, an()'~ 
lime bet\\een th.:> g[()llP~, a 1\\'0 faClor analysis of mriance (",""-OVA) of 
repealed me.lwre~ \\'a~ used. When the -,.'.;oVA was significant. p<lirwis.:> 
comparison, 11<'f~' made with lhe Stuu.:>nt'.\ I test wilh the significallc~' 
level for the P \<llue_, corrected with thc Bonferroni method. F(lr 
comparison <la.", lime in ench of the bimnkalim or hyJr.dazinc trealed 
groups or lhe c'.l!lHn! group. a one faclor ",SUVA of repeated mca.'ure~ 
was employed, Ililh a po~t-hoc tesling ~trateg)' idemic,1! 10 Ihal of the 
IWO factor .... "01 ... , A 11\0 sample rank sum test (Mnnn-Whitney U) II'." 
used to te~1 Ihe differences of !he bimaknlim I' hydralazine. bimakalim 
I' conlroL anti hyJral,lzine I' conlrol nnimals with regard tn the ri~k 
region and Ihe pC'n:enlage of the risk region infarcted. 
Results 
Risk region lIml illfarc! size 
The risk region and inf<lrc( size <Ire depicted in fig 2. The risk 
regions were virtually identical in all groups. The risk area 
was intentionally kept small (10% of left ventricular wall 
volume). because in pilot studies larger risk areas were 
associated with :m unacceptably high incidence of ven-
tricular librillatinn, The percentage of the risk region in-
farcted was 60A(SEM 5,2)1j~ for controls. Starting dmg 
treatment after 45 min of occlusion did not alter infarct size 
[group A. 56.6(4.2)%J. but infusing bimakalim before 
ischaemia reduced infarct size by about 50% {group B_ 
22.4(4.5)C;'c: group C. 35.3(6.6)Cff: p<0.05j. The difference 
in infarct size between group Band C was not significant 
Ip:::: 0.1). Pretreatment with hydralazine did not affect infarct 
size [59.4(4.3n: NSJ. which was therefore significantly 
differelll as t'ompared with that after bimakalim treatment in 
groups Band C. 
HaemodYII{lll1ic\ {l1Il/wall fimclioll 
Haemodynamic and wall thickness data are summarised in 
Ihe table. The control pigs remained haemodynamicnlly 
stable throughout the occlusion and reperfusion period and 
did not vary :-.ignificantly frolll ba~eline with regard 10 heart 
rate. mean ilflcrial pressure. or duuble product: only during 
the hyperaemic response (reperfusion at 3 min) was heart 
rate significantly increased. while mean <lrterial pressure and 
double product decreased. 
Infusion of himakalim at 45 min of total coronary 
occlusion (group A) affected hacmodynumics when com-
paring the time poinls 30 min of total coronary occlusion 
• Control 
:::J Bimakalim 
, Group A 
o Bimakalim 
, Group B 
~ Bimakalim Group C § Hydralazine 
, 
(% left ventricle) 
Fig//re 2 Art'll a/ ri~k (MR) eXprent'd (I.~ percent 0/ the left 
\'elltricle (LV) (IIld myocardial ill/orclsize expressed as pacelli 0/ 
AAR II'itll and wi/hout bimokalim trea/ment. CO/III1/IIS are lIlellll~, 
han =: SEM. II'" 7 ill all group.I. Trt'llllllt'/ll lI'ilh bill/aka/illl 
xiXllijinllllly rel/lln'lI ill/arc! si~e I'rorided l!Jal il mu .~llIrt('d prillr 
10 COrOllary oCelll_i-jllll. 
{before bimakalim treatment} with 60 min of occlusion (15 
min of bhmkulim Ireatment): heart rate increascd (from 
115(3) to 127(6) beats·min- ' , p<0.05] and mean :Irtcriui 
pressure decreased [rrom 84(6) to 60(6) mm fig. p<O.05]. 
while regional wall function (Clod WT) slightly improved, 
from -4.8{1.6)<;t 10 +2.4(2.1). p<0,05. 
The effects on haemodynamics and wall function of 
bimakalim infused prior to the onset of ischaemi:l (group C) 
in comparison with the hydralazine group are depicted as 
percent change from baseline in fig 3, In the two groups 
pretreatment non-significantly increased heart rate and 
significantly lowered mean arterial pressure (p<O.OI). 
Although both bimakalim and hydralazine signific<lntly 
decreased coronary vascular resistance (bimak<llim group C. 
from 177(27) to 101(18) dyn,s'cm-5 before occlusion; hy. 
dralazine. from 189(18) to 126(14) dyn·s·cm-5 before oc-
clusion; p < 0,01 J, only bimakalim increased myocardial 
blood flow [group B. from 36(9) 10 40(8) ml·min .}; group C, 
from 37(5) to 44(9) mi·min-1). Before Ihe onset of the 60 min 
coronary occlusion %.6. WT was not signilkantly different in 
the bimakalim or the hydralazine treated regions compared 
with baseline values. Neither bimak:llim nor hydralazine 
significantly altered cardiac output or maximum left ven-
tricular dP/dt. 
In a subset of 20 pigs the time elapsed until bulging 
(%dWT<07r-) was measurable in the first minute <lfter 
coron<lry occlusion. In 15 cases a wall function analysis was 
not possible due to premature ventricular beats, The un· 
treated group consisted of five animals in the q:lIltrol group 
and four in the bimakalim group A. while the bimakalilll 
!rented group consisted of seven pigs from the bimakalim 
groups Band C. In the hydralazine grollp four animals were 
Hllelllor/Ylllllllic rariahles. regional lrall jimcliml (percelll J \\'(//1 
Ihickenillg). alld global canliac perjl/nil/IIICt' mrhlble~ IlSseHetl!ll 
hu.\elille. direclly ht10re lite 60 mill ("omllary Ded!lsiml (Pre· 
oOTeD}. tIl nO mill of occlusioll (60TCO). 1113 lIIill f!{n'peTjinjl!ll 
fRt'p 3'). rlmlllllhe ("JIll oj fIle protocol IRel) 120'). 
Btl.ldilll' Prl'·607CO 60TCO Nt·/} J" HI'fI 12U' 
Heart rale (bea/5·mill· l ) 
COnlrol 114(3) 1I4(3) 107(7) 111m m(8) 
Group A J 160) 116(3) 127(6J~ 13)(6)* 159(9)~ 
Group B t06(7) m(7) 12-1l7)~ ))2(5)" 143(8)" 
Group C 102111 ) I1J(8) 116(9) 11sm 127m) 
Hydra 1000R) 109(9) 12001) 105(13) 119(8) 
Comlo] 87(6) 
Ml'lJTi urleriu/ P":55/If" /lIIm Hg} 
87(6) 7](4) 60(4) 71(6) 
Group A 91(6) 91(6) 6O(6)t 61(7) 51(.'i1~ 
Group B t;(0) 58(4)* 5---I(5)~ 59(6) 52(3)* 
Gf\lUpC 91(1) 61(4)* 71(6) 62(5) 70(3) 
Hydra 92(4) 6--t(6)* 68(8) 67(7) 74(9) 
Comrol 26.10.)) 
1\111/ jum-liol! r<Jjll'TJ 
26.2().) -4.H1.6) -5.7(J.QJ -4.80.5) 
Group A 27.7(3.2) 27.7(3,2) 2AI2.lJ -1.9(2.1) 4.5(1.2) 
Group B 23.1(3.5) 23.9(4,4) ----O,7(IA) -2AILS} 6.5(2A) 
Group C 2J.4{1.8) 23.6{2.2) -3.8{2,4) -4.6(4.5) -2.9(2.1) 
Hydra 23.(){4.5) 24.2{5.0) -2.6(_16) -14.1{5.9) -8.6(4.9) 
LV dP/dI~, 
Control J423(122) 1423(122) 1149(1\1) 959(30) 102]{59) 
Group A 2151(286) 2151(286) 1656{l47)* 16-18(188)' 2456(372)t 
Group B )503(138) ))32(138) 141(){86}* 1484(109)' 1610(101)' 
GroupC 1837{258) 1889(337) 1845(348) 1378{202)* 1782(288)+ 
Hydm 169--1(117) 1762(80) 1714(135)* 1659(147)* 1622I2OY)' 
C",,/ifl(" Oil/PIlI fm/·mill'·ID I.g ') 
COlllrol 967(62) 967(62) 855(59) 76-1(75) 739(62) 
Group A 900(112) <JOO(112) 858(121) 851{123) 930(115) 
Group B 928(81) 877(74) 93](91) 877(43) 803(63) 
Group C 851(70) 846(82) 758(72) 690(43) 684(83) 
Hydrd 852(11 ]) 953(]1I) 869(95) ~74(9--1) 70-1(103) 
TCO;: IOtal eurun3f)' o\:du~ion; Rep;: repafu~iGn: Hytlrd;: hyuratazin .... 
*p < (J.05. tp < OJ)) \. cun!rok 
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Figllre 3 lleart raIl' (HRJ. IIU'CIII arterial fln'_HI/r!' (MAP), al/d 
regilllla/walf filll%J/ (<;f J \Vfj Ill/rillg lite e.ljlerilllt'lIIa! llTO/ocol ill 
the hydml(l;:illt' (11:= 7) al/d IIII' bill/ukllfim !!,WII(l C {II = 1}. Tlte!"e 
!H'rt' /1/} s(~I1(tinlllt d{fj"erent"{'s betH"ern the groups Ilmmglwl/l ,ht' 
£'·lfIcrillU'lII. 
included in the analysis. There was a tendency towards. a 
slowed myocardial depression in the pigs treated with 
hydralazine (20.3C~.O) sl or bimakalim l22.6(2.5) sl com~ 
pared with untreated animals. f IS.2( 1.7) sl. 
Myocardial oxygell COllSlfIlIprioll (Al\iO~' 
Regional MV01 was assessed at baseline and before Ihe 60 
min coronary occlusion. Treatment before ischaemia 
significantly decreased MVO~ by 36.5'7c, in the bi01akali01 
group B (from 2.60(0.32) to 1.65(0.36) ml.min-I.IOO g_l. 
p<0.05], by 27.1% in the bimakalim group C [from 
2.65(0.29) to 1.93(0.31) m\·01in-I·IOO g-I. p < 0.05}, and by 
14.6% in the hydralazine group [from 2.32(0.23) to 
1.98(0.09) mi·min-I·IOO g-I. p <0.051. ~'tV02 measured prior 
to 60 min of ischaemia was plotted against subsequent 
infarct size. No significant positive correlation was found 
(y=: 1.29+0.02x; r=0.37; NS). Regional MVO~ was 
virtually identical in the bimakalim or hydralazine treated 
groups prior to the onset of bchuemiu. although subsequent 
infarct size wa" significantly larger in hydralazine treated 
animal:-. compared with himakulim pretreated pigs (fig 4). 
Laclate ('x/raelioll 
The percent lactate extraction was a"scssed at baseline. 
dming the peak of reactive hyperaemia (approximately 3 min 
of reperfusion). and at the end of the protocol. There were 
no significant difference" belwebn groups. although the mean 
negative percen! luetate extraction during reactivc hyper-
aemia was less than 40% of the controls [-157(56)%1 if 
Ihe animals were pretreated with bimakalim [group B: 
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-56(26)Ck: group C: -59(16)%1. Pretreatment with hydrala-
zine was not associuted with such a trend [-I27C~6)c!c]. 
Discussion 
The objective of this study was the assessmcnt of the effect 
of bimakalim. an activator of ATP sensitive potassium 
channels. on ischaemic tolerance in pig hearts. Bimakalim 
reduced infarct size by approximately one half provided that 
its infusion was started prior to the cown:ny artery 
occlusion. Bimakalim infusion towards the end of the 
occlusion period and continued into Ihe reperfusion period 
was ineffective. Our finding" are in line with rewlts 
published by Lamping el al.l~ These investigators "howed 
that nicorandil. in doses thai produced a 20-25 mm Hg 
decrease in mean arterial pressure. significantly rt'!duced 
myocardial infarct size (from 34% to 18%) in dogs subjected 
to two hours of coronary artery occlusion followed by 30 
minutes of reperfusion. Grover el al~ obtained similar results 
with cromakalim and a high dose of pinacidil injected into 
the coronary circulation. In the absence of peripheral 
haemodynamic effects. a marked reduction in infarct size 
was observed in anaesthetised dogs subjected to 90 minutes 
of left circumflex coronary artery occlusion follm\'ed by live 
hours of reperfusion. Similarly. Auchampach el al. 11 using 
anaesthetised dogs, found a 40-S0t7c decrease in myocardial 
infarct size for RP 52891 after 90 minutes of left cin:umllex 
t:oronary artery occlusion followed by five hours of 
reperfusion. In the latter two studies the protective effect 
ot:curred independently of changes in peripheral huelllo-
dynamics. area al risk, or collatt'!ral blood Row. suggesting 
that pota"siulll channel activators have a direct erIC..:t on the 
hcart. 
In order to evaluate whether the differences in infarct size 
observed in our sllldy are reluted to drug induced dmnges of 
the well known determinants of infarct size,!X namely size of 
risk region.!~ haeTllodynamic variables.':') and coliateral blood 
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flow.~1 the vasodilator hydralazine~~ was used to induce 
cardiovascular changes similar to tho~e of bimakalim. 
Apparently. the cardioprotectivc effect of bimakalim cannot 
be explained in this way, for the following reasons. (I) The 
risk regions of all groups were virtually identical. (2) 
Bimakalim and hydralazine were givcn in cquihypotensive 
doses; neither dmg showed any significant difference with 
regard to regional wall function. regional oxygen consump· 
tion. hc;nt rate. left ventricular dP/dtru,. and cardiac output. 
either at the onset of ischaemia or during the experimental 
protocol (fig 3). Nevertheless. bimakalim was capable of 
reducing infarct size by about 50%. while hydralazine was 
totally ineffective. Therefore unloading of the heart is unlikely 
to account for the caniioprotective effect of bimakalim 
treatment. (3) It has been shown that pig hearts lack pre· 
existing collateral vessels,s in contrast to dogs. excluding such 
vessels as a target of the action of bimakalim. This conclusion 
carries considerable weight. since previous studies in dogs had 
revealed a rather selective dilatation of coronary collateral 
vessels by potassium channel activators.2-' 
It is well known that the plateau phase of the cardiac 
action potential shortens markedly during metabolic 
depression elicited by ischaemia.~~ The more rapid re~ 
polarisation of the action potential could be due to a decrease 
in inward current. or an increase in outward current, or a 
combination of these changes. Voltage clamp studies imply 
that the primary alteration in membrane currents during 
ischaemia is the development of a Yery large time 
independent outward K' conductance. resulting from the 
activation of ATP sensitive potassium channelsY NOllla~" 
postulated that ATP sensitive potassium channel opening and 
a shortening of the action potential with the ~lIbsequent rapid 
decline in lllyocardial function may preserve cellular ATP 
and delay irrever:.ible ischaemic injury. 
in our study the total dose of bimakalim (4 f.1g·kg'!) given 
before the onset of ischaemia was not negatively inotropic 
in the normoxic myocardium. which precludes a saving of 
high energy phosphates prior to the 60 minute coronary 
occlusion. if preservation of high energy phmphates through 
a decrease in myocardial contractility plays a role. it has to 
OCcur immediately after the onset of ischaemia. 
To preserve energy in early phase of ischaemia. ATP 
sensitive potassium channel openers must shut down 
contractile function more rapidly than would occur with 
ischaemia alone. There is evidence that under hypoxic 
conditions lower doses of these drugs are sufficient to open 
ATP sensitive potassium channels. with a subsequent 
decrease in contractility.n This would allow. for example. 
bimakalim to become more pOient in ischaemia. This 
sensitisation of the myocardium to potassium channel 
openers may be related to a decrease in ATP concentration 
in a subsarcolemmal compartment, that is. in close vicinity 
of the ATP sensitive potassium channels.23 If one mechanism 
for the cardioprotective action of potassium channel openers 
is sparing of high energy phosphates because of rapid cardiac 
arrest, one should be able to demonstrate with these drugs 
an acceleration in the decline of mechanical activity as soon 
as ischaemia starts to develop. In fact, Mitani el al29 
observed in globally ischaemic rat hearts that during 
ischaemia nicor:mdil decreases the time to mechanical arrest 
by 21%. while glibenclamide increased it by 42%.lIowever. 
in our pig model we did not observe changes in mechanical 
activity during the first minute of ischemia; regional wall 
function did not !ihow an accelerated decline in a subset of 
bimakalim treated pigs. Nevertheless. binwkalim treatment 
!iignificantly reduced inforct size. 
In pig!i pretreated with bimakalim the lactate washout 
·during the fir!it minutes of reperfusion after 60 minutes of 
coronary artery occlusion was about 50~f Je.\s as compared 
with controls or hydralazine treated animals. 'Ill is could give 
rise to the assumption that under ischaemic conditions 
opening of ATP sensitive potassium channels triggers a 
process that slows down glycolysis and in this way retards 
the development of acidosis. However, the accuracy of our 
lactate measurements was limited because the cannulated 
epicardial vein drained infarcted, salvaged. and non· 
ischaemic rcgions and this might be responsible for the large 
scatter of the lactate data. Despite this scatter. the difference 
in" lactate washout between bimakalim and hydralazine 
treated pigs almost reached statistical significance (p = 0.06). 
There is evidence in another model of cardioproleclion that 
the rate of glycolysis plays an important role. Murry and 
coworkers.") showed in a canine model of coronary artery 
occlusion and reperfusion ("preconditioning") that the rates 
of glycogen breakdown and ATP use during ischaemia were 
significantly reduced in the cardioprotected hearts. Recently. 
Wolfe el (lei found in a rat model of preconditioning that a 
reduced rate of glycolysis and attenuation of intracellular 
acidosis during ischaemia appear to be important factors in 
delaying irreversible injury and reducing infarct size. The 
importance of attenuating acidosis is confirmed by results of 
Kida and coworkers;'l \VllO showed that preservation of pH 
contributes to the infarct size reducing effect of ischaemic 
preconditioning in pigs. We recently presented evidence that 
myocardial preconditioning in the pig heart is mediated by 
opening of ATP sensitive potassium ch,mnels and can be 
blocked by glibenclamide;'3 Similar results were obtained by 
Gross and Auchampach in a canine model. lu All these 
experimental findings suggest that dmg induced opening of 
ATP sensitive potassium channels may set in motion a 
process that ultimately leads to myocardial protection and is 
therefore of significant therapeutic relevance. 
Conclusion 
Bimakalim. an activator of ATP sensitive potassium 
channels. reduced infarct size in anaesthetised pigs with 
acute coronary artery occlusion. provided that the dmg was 
given prior to the onset of cardiac ischaemia. There is 
evidence. albeit indirect. that haemodynamic or coronary 
vascular factors are not responsible for the cardioprolective 
effect of bimakalim. We therefore conclude that the 
potassium channel activator induces ischaemic tolerance in 
pig myocardium through a direct effect nn cardiac cells. 
most likely through opening of ATP sensitive potassium 
channels. 
Key teons: infarl:t size; bimakalim; hydralazine: ATP sensitive 
potassium channels; myocardial o.\ygen con.~umption; myocardial 
lactate extraction. 
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In swine myocardium the infarct size reduction induced by U-89232 
is glibencIamide-sensitive. Evidence that U-89232 is a cardioselective 
opener of ATP-sensitive potassium channels. 
Sven Rohmann, Claus Fuchs, Pierre Schelling 
Objective: We determined if U-89232, a derivative of the ATP-sensitive 
potassium (KATP) charmel opener cromakalim, is cardioselective and whether 
its action on the myocardium is still sensitive to glibenclamide. Methods: 
Experiments were performed in open chest pigs subjected to a 60 min 
occlusion ofthe left anterior descending coronary artery (LADCA) and to 2 h 
of reperfusion. Four groups of animals were studied (n = 6 each). Animals 
received either U-89232 3mg/kg Lv. over IS min (U) or glibenclamide, a 
selective KA'IP channel blocker, Img/kg Lv. over IS min (GLJ) prior to the 
LADCA occlusion. In the GLJ+U group, first glibenclamide (Imglkg/1Smin) 
and then U-89232 Clmglkg/1Smin) were infused prior to the 60 min of 
ischemia. Saline treated ·animals served as controls (CON). Hemodynamic 
parameters were continuously' monitored. Regional contractile wall function 
was quantified with ultrasonic crystals aligned to measure wall thickening. At 
the end of the protocol, infarct size (IS, as percent of risk region) was 
determined by incubating the myocardium with p-nitrobluetetrazolium. 
Results: \Vith comparable myocardium at risk, infusion ofU·89232 prior to 
60 min of LA DCA occlusion significantly reduced infarct size (IS: 18.S±3.7%, 
p<O.OOI vs. 63.2±3.3% for the controls), while glibenclamide had no effect on 
infarct size (IS: 69.S±4.4%). The administration of glibenclamide prior to U-
89232 infusion blocked the infarct size reducing effect of U-89232 (IS: 
61.2±9.1, n.s. vs controls and p<O.OOI vs. U). Infusion ofU-89232 had no 
effect on hemodynamic parameters or on regional wall function. Conclusions: 
At least in a pig model, U·89232 appears to be a cardioselective KATP channel 
opener, since in the absence of hemodynamic alterations it exhibits a profound 
cardioprotective effect, which is fully reversible by blocking KA'IP channels. 
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Numerous studies have showIl that structurally diverse openers of ATP sensitive potassium chrumels (KAIP), namely e.g. nicorandiJi. pinacidiF, cromakalim3, aprikalim\ ~ and bimakalim5, can protect ischemic myocardial tissue. The fact that structurally 
unrelated KATP channel openers protect with a similar profile indicates a common mechanism 
which may involve an interaction with the KATP charmcl6 7. Further confirmation of this 
mechanism was shown by the reversal ofthe cardioprotective effects afthe KATP chatmcl openers 
by selective blockers of this channels 9, such as glibenclamide 10, These data provide evidence that 
K,n}' channel opening senres as an endogenous protective mechanism and several studies 
showing a potential protective role for KATI' channels in ischemic preconditioning further support 
this possibility" 12 13 • However, in some clinical situations KATP charmel openers, may not be 
ideal cardioprotective drugs since their direct vasodilatory properties l4 could reduce cardiac 
output and thereby coronary perfusion pressure, although it has been reported in anesthetized 
dogs that aprikalinl~ as well as bimakalim1s are able to induce cardioprotection in doses, which 
have no effect on blood pressure and heart rate. 
Most recently, there have been reports about cromakalim analogs which are relatively devoid of 
peripheral vasodilator activity even in high doses, but afford a pronounced cardioprotectionl6 17. 
The more "cardioselective" opening of KATP channels may not only improve the therapeutic 
window, in which KATP channel openers can effectively be used to treat myocardial infarction 
without potentially inducing hypotension and subsequent reflex tachycardial8, but also suggests 
that channel subtypes may exist. 
While the protection induced by the cromakalim analog BMS-180448 can be reversed by 
glibenclamide19, the infarct size reducing effect of another cromakalim derivative U-89232 was 
reported not to be glibenclamide sensitive20• These data, however, would question whether KATP 
charmel opening is still the mecharlism by wllich the cardioselective cromakalim analogs induce 
the reported cardioprotection. 
It was the aim of the present study to evaluate the hemodynamic and cardioprotective properties 
of U-89232 in a pig model, in which a peripheral vasodilatory active cromakalim derivative, 
bimakalim, had been characterized21 and to test whether the reported cardioprotectioll is sensitive 
to glibenclamide. 
Methods 
The investigation conforms with the Guide for the Care and Use of Laboratory Animals 
published by the US National Institutes of Health (NIH publication No 85-23. revised 1985). 
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Experimental Design: 
All 24 pigs underwent a 60 min left anterior descending coronary artery (LADCA) occlusion 
followed by 120 min ofreperfusion. The animals were randomly assigned to one offaur groups. 
They received either U-89232 3 mgikg i.v. over 15 min (U) or glibenclamide Img/kg i.v. over 
15 min (GLl) prior to the LADCA occlusion. In the GLl+U group first glibenclamide 
(Img/kg/lSmin) and then U-89232 (3mg/kg/ISmin) were infused prior to the 60 min of 
ischemia. Vehicle treated animals served as controls (CON). The design is depicted in Figure 1. 
Experimental Preparation: 
Twenty-four mixed breed Landrace-type domestic pigs of either sex weighing between 24 and 
31 kg were premedicated with ketamlne-HCI (lOmglkg Lm.) 15 min prior to anesthesia with Lv. 
bolus injection of sodium pentobarbital (30 mg/kg). Following tracheotomy pigs were mechani-
cally ventilated with an animal respirator (Rhema, HofheimlFRG) on nitrous oxide 
supplemented with oxygen at a ratio of2: 1. In order to guide adjustment of ventilator settings 
arterial blood gases were measured repeatedly. Anesthesia was maintained by continous infusion 
of sodium pentobarbital (3mg/kg/h). Arterial blood was sampled through a catheter placed in the 
right femoral artery, while the right brachial artery was cannulated with a polyethylene catheter, 
which was advanced to the ascending aorta for continuous recording of arterial pressure. An 8 
French Millar micromanometer was advanced via the carotid artery into the left ventricle for 
continuous measurement of left ventricular pressure. The heart was exposed through a midline 
thoracotomy and suspended in a pericardial cradle. Distally of its second branch the (LADCA) 
was carefully dissected free over a length of 4 mm and a loose ligature was placed around the 
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Figure I. Design orthe study. TCQ= lolal coronary artery occlusion. 
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vessel which could be occluded with a small vascular clip. Electromagnetic flow probes (Flo-
Probe, Spectramed Inc., Oxnard, California 93030, USA) were situated on the ascending aorta 
and the LADCA proximal to the occlusion site. A Teflon catheter (outer diameter 0.8 mm) was 
placed into the epicardial vein draining the area at risk. Rectal temperature was monitored 
throughout the experiment and the chest cavity was covered with a plastic sheet and kept warm 
with a heat lamp to keep body temperature between 37'C and 38'C. Myocardial function in the 
ischaemic area was measured with 5 mHz ultrasonic crystals aligned transmurally to measure 
wall thickness. A brief« 10 second) occlusion was performed to identify the ischaemic region 
and the crystal pair was located centrally in the ischaemic region. The inner crystal was advanced 
to the endocardium tangentially through a stab wound in the epicardium. The epicardial crystal, 
attached to a Dacron patch, was positioned on the epicardium with the aid of an oscilloscope, and 
secured with three sutures. After a stabilisation period of 30 min after surgery the experimental 
protocol was started. 
Risk Regloll and Illfarct Size: 
Following a repernlsion period oftwo hours the LADCA was reoccluded and 10 ml of 10% fluo-
rescein dye were injected into the left atrium. After one to two min the pig was killed by 
electrical fibrillation with a 9-V battery and the heat1 excised. \Varm 2% agarose was injected 
into the ventricle via the aortic root and the heart was kept on ice. After the agarose had 
congealed, the right ventricle was removed and the left ventricle was sliced into four to six rings 
perpendicular to the LADCA. Subsequently, the rings were weighed and the risk region traced 
onto an acetate sheet under blacklight, which sharply defined the borders of the risk area not 
perfused with fluorescein. Incubation for 30 min in 1.25% paranitrobluetetrazolium in phosphate 
buffer (PH 7.1) at 37'C delineated noninfarcted tissue (deep blue) and infarcted tissue (pale). The 
size of the area at risk and the infarcted region were detennined by planimetry. The % risk region 
(area at risk/ area ofring) was calculated for the top and bottom of each ring and the mean value 
for each ring was multiplied by the weight. The weights of regions were summed and divided 
by the weight of the left ventricle to yield the % ofthe left ventricle at risk (%RR) and % of the 
left ventricular risk region infarcted (% IS). 
Admillistration of U-89232 and glibenclamide: 
Animals in the treatment groups received U-89232 dissolved in isotonic saline, while the pigs 
in the control group received isotonic saline only. Prior to each experiment the compound was 
dissolved and mixed in 37°C wann saline. U-89232 (3mglkg) was administered as a continuous 
infusion over 15 min via a femoral vein. Glibenclamide (l mg/kg) was dissolved in 1.2 
propandiol and was infused intravenously over 15 minutes. 
Table 1. Hemodynamics, coronary blood flow, and regional contractile wall function assessed 
at baseline are presented in column I. Changes from baseline directly before the 60 min LADCA 
occlusion (Pre-TCO), 60 min of LA DCA occlusion (TCO), at reactive hyperemia (about 3 min 
ofreperfusion; RH), and at the end of the protocol (120' REP) are listed. 
Baseline Pre-TCO 60' TCO RH 15'REP 120' REP 
Values A% .6.% .6.% A% A% 
Hearl rate (heats / mill 
Control 111±5 -1.0 ± 1.2 1.1±5.2 1.4 ± 6.5 5.7± 5.4 13.4 ± 12.3 
U 113±9 -3.7 ± 2.4 -6.2 ± 4.6 5.0 ± 9.3 -6.4 ± 9.6 13.0±7.1 
Gli 108 ± 11 -4.9 ±3.7 -2.3 ± 7.9 6.5 ± 15.5 9.1 ± 15.2 19.2 ± 14.0 
GIi+U 100±8 6.0 ± 10.6 6.3 ± 8.4 13.5 ± 9.4 10.3 ± 7.0 25.9 ± 11.3 
Meall arlerial pressure (IIImHg) 
Control 92±6 -3.9 ±2.6 -19.3 ± 6.5 -30.3 ± 6.2 -24.7 ± 7.2 -14.7±3.1 
U 96±7 8.7±2.7 -11.8 ± 4.7 -28.8 ± 8.7 -20.0 ± 9.3 -7.5 ±7.1 
Gli 98±6 20.7 ± 2.2 2.3 ± 6.4* -12.9 ± 4.6 -19.8 ± 8.7 -15.5 ± 6.9 
Gli+U 102±4 1.2± 5.3 -8.5 ± 7.6 -21.1± 11.9 -16.1± 8.6 -13.4 ± 8.8 
Double product [(mIllHg.~ bpm) /100) 
Control 120 ± 11 -4.3 ±3.0 -21.3 ± 7.5 -31.3 ± 5.3 -21.4 ± 9.9 -0.1 ± 10.8 
U 117±8 5.3 ± 4.6 -12.0 ± 8.9 -20.0 ± 14.4 -26.5 ± 9.1 8.8 ± 9.5 
Gli 120 ± 12 16.7 ± 4.7 0.6 ± 12.0 -7.6 ± 12.0 -12.7 ± 11.6 -2.0 ± 10.3 
GIi+U 117±7 8.8 ± 12.0 0.4 ± 11.8 -7.8 ± 16.0 -5.2 ± 10.7 6.1± 21.6 
LV dP / dl~ (mmHg / s) 
Control 1720 ± 157 -0.6 ± 1.4 -15.6 ± 7.2 -26.2 ± 12.7 -20 ± 9.1 -17.9±4.3 
U 1698 ± 144 2.6±3.2 -22.2 ±5.7 -41.4 ± 5.1 -35.1±7.3 -17.2 ± 9.1 
Gli 1862 ± 132 -4.4 ±2.8 -13.6 ± 10.5 -27.9 ±. 8.3 -28.4 ± 8.2 -26.4 ± 9.0 
Gli +U 1625 ± 104 -8.9 ± 12.2 -12.9 ± 12.6 -30.5 ± 18.7 -16.9 ± 18.1 -23.8 ± 9.8 
Wall function ("1'6.1'1 wall thickening) 
Control 32±3 -0.9 ± 0.9 -120.8 ± 5.3 -122.9 ± 8.9 -123.1 ± 8.2 -122.4 ± 3.0 
U 29±7 -2.6 ±3.0 -105.0 ± 8.0 -125.3 ± 17.5 -142.2 ± 14.2 -127.8 ± 14.0 
Gli 27±3 4.0 ± 13.1 -132.4 ± 16.6 -146.8 ± 13.3 -116.6 ± 6.7 -125.5 ± 6.8 
Gli+U 30 ±5 -0.9 ± 8.5 -104.7 ± 10.2 -132.3 ± 21.1 -134.3 ± 18.7 -132.7 ± 14.4 
CBF (ml / mill) 
Control 36 ±4 -2.9 ±3.2 -52.7 ± 6.2 17.4 ± 16.5 0.8 ±23.0 5.6 ± 15.6 
U 47±9 5.2±6.1 -45.2 ± 8.0 6.9 ± 10.8 6.4 ± 15.5 -2.5 ±21.5 
Gil 32±4 -1.7 ± 4.1 -55.3 ± 5.0 45.3 ±20.0 6.5 ± 14.1 -9.3 ± 13.4 
Gli + U 42±5 -10.1 ± 12.5 -43.4 ±8.4 22.1 ± 17.4 12.1±22.6 0.1 ± 19.3 
CVRxJ(/ (dyu x SXCIII'~) 
Control 183 ± 24 -1.5 ±3.6 85.1 ±39.1* -40 ± 4.4 -12 ± 17.1 -11.9 ± 10.0 
U 153 ± 26 4.9 ± 6.0 76.7 ± 35.6' -35.6 ± 4.6 -26.3 ± 4.8 6.6 ± 16.8 
Gli 225 ± 38 25.0 ± 4.3 127.3 ± 28.9' -36.7 ± 7.8 -22.7 ± 7.5 -2.9 ± 9.2 
Gli + U 175 ±30 19.7 ± 15.0 79.7 ± 41.2' -36.0 ± 5.5 -18.4 ± 13.1 0.5 ± 8.0 
COl (1111/ lIIi" / 10kg) 
Conh'ol 987 ± 81 -1.2 ± 1.2 -6.3 ± 1.6 -10.4 ± 7.6 -3.6 ± 5.6 -17.0 ± 4.6 
U 1020 ± 59 1.6 ±3.6 -13.7 ± 6.0 -35.8 ± 7.2 -28.4 ± 9.4 -17.4 ± 11.3 
Gli 916 ± 19 -8.2 ± 8.7 -24.7 ±3.6· -37.1 ± 4.4* -38.0 ±2.9"" -30.3 ± 8.7 
Gli + U 990±71 -3.8 ± 8.8 -11.9 ± 6.0 -31.0 ± 8.6 -16.2 ± 7.4 -16.6 ± 6.7 
TPRx1t1 (dyu.~sxcn{~) 
Control 2.9 ± 0.3 - 2.8 ± 2.3 -13.9 ± 6.7 -20.7 ± 7.4 -21.3 ± 8.0 4.7 ± 8.7 
U 3.3 ± 0.4 7.6 ± 4.8 5.1± 11.2 13.9 ± 13.7 15.0 ± 13.6' 22.3 ± 19.8 
Gli 3.5 ± 0.3 38.0 ± 16.4 35.7 ± 4.3' 39.5 ± 5.9"" 28.2 ± 10.4' 28.2 ± 15.4 
GIi+U 3.1 ± 0.3 9.0 ± 12.0 4.7 ± 8.42 13.0 ±7.2 0.7±7.3 12.8 ± 11.7 
*= p<O.05 compared with baseline. Abbr.: MAP = mean arterial blood pressure, LV = left ventricular 
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Data analysis: 
Continuous recording of hemodynamic and wall thickness data was made on a paper recorder 
(Gould) and on a computer-aided registration system (IFD, Mescher, MUlheim/Ruhr, FRG). 
Recordings at timcpoints of interest were made at a paper speed of IOOmm/sec, and the wall 
thickness data were collected from the recordings. \Vall thickness variables were averaged over 
10 cycles at each timepoint and included end diastolic wall thickness (EDWT, defined as the 
point when left ventricular dP/dt started its rapid upstroke after crossing the zeroline), and end 
systolic wall thickness (ESWT, defined as the point of maximal wall thickness within 20 IllS 
before peak negative left ventricular dP/dt). These data were used to calculate wall thickening 
(%deIta WT) with the following formula: ((ESWT-EDWT) / EDWT) x 100. Other variables 
included peak left ventricular systolic pressure (L VSP, mmHg), mean arterial pressure (MAP, 
nnnHg), and heart rate (HR, beats/min). The double product (DP) was calculated by heart rate 
x peak systolic pressure. Flow-ProbesThI (Spectramed Inc.) were used for measurement of aortic 
and coronary blood flows. The zero baseline (zero value and zero balance) was electronically 
calibrated by the IFD computer system, which allows non-occlusive zero adjustments. The 
coronary vascular resistance (dyn x sec x cm·5) was calculated as diastolic aortic blood pressure 
x 80 I mean coronary blood flow; analogously, the total peripherial resistance was calculated as 
MAP x 80/ mean aortic blood flow. 
Statistics: 
For comparison of variables across time between the groups, a two factor analysis of variance 
(ANOVA) of repeated measures was used. \Vhen the ANOVA was significant, pairwise compari-
sons were made with the Student's t-test with the significance level for the p values corrected 
with the BonfelTOIllmethod. For comparison across time in the control group, a one factor ANO-
V A of repeated measures was employed, with a post-hoc testing strategy identical to that of the 
two factor ANOY A. A two sample rank sum test (Mann-Whitney-U) was used to test the 
differences between two groups with regard to the risk region and the % of the risk region in-
farcted. Data are reported as mean±SEM. 
Results 
During the protocol, no more than a single shock to defibrillate the pig heart was given. 
Ventricular fibrillations, which required electrical defibrillation, were observed in one pig in the 
control group, in none of the alllmais in the U-89232 group, in one pig in the glibenclamide 
group and in one in the Gli+U group. In consequence, no pig had to be excluded from data 
analysis. 
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Figure 2. Plot of the mean±SEM of the myocardial infarct size values expressed as percent oftne risk region (RR). 
All groups n = 6. 
Risk Regioll and Infarct Size: 
The risk regions (expressed as % of the left ventricle) were virtually identical in all groups 
(Control, 12.0±2.1%; GLI, 13.7±2.3%; U, 11.9±1.8%; GLI+U, 12.5±1.2%). The risk area was 
intentionally kept small (10% - 15% of left ventricular wall volume), because in pilot studies 
larger risk areas were associated with a high incidence of ventricular fibrillation. 
The percentage of the risk region infarcted was 63.2±3.3% for the controls. Infbsion ofU-89232 
prior to 60 min of LA DCA occlusion significantly reduced infarct size (l8.5±3. 7%, p<O.OO I ys. 
controls), while glibenclamide had no effect on infarct size (69.5±4.4%). The administration of 
glibenclamide prior to U-89232 infusion blocked the infarct size reducing effect of U-89232 
(61.2±9.1, n.s. ys controls and p<O.OO I ys. U). 
Hemodynamics and wall junction: The control pigs remained hemodynamically stable 
throughout the occlusion and reperfusion period and did not vary significantly from baseline with 
regard to heart rate, mean arterial pressure or double product. 
Infusion of U-89232 did not significantly alter mean arterial pressure, double product, regional 
wall function or any other measured hemodynamic parameter (table 1). Glibenclamide 
significantly increased coronary vascular resistance, tended to rise mean arterial blood pressure, 
but did not significantly affect regional wall function (table I). 
Discussion 
Our results indicate that U-89232 is a cardioselective KATP-chatUlel opener, since its protective 
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actions are glibenclamide-sensitive and appear in the absence of hemodynamic changes. This 
would put U-89232 in line with other more cardioselective cromakalim analogs, such as BMS-
180448. 
In our pig model U-89232 reduced infarct size by 70%, which is in the range reported for other 
KATP-channel openers48, e.g. bimakalim, another cromakalim derivative, reduces in the same pig 
model infarct size by 50% - 70%21, In addition, the noted effect on infarct size is very much 
consistent with the observations made by Norman et al.22 or Toombs et al~3 ; in anesthetized 
rabbits with comparable myocardium at risk U-89232 reduced infhrct size significantly by about 
50% . Furthermore, in line with their rabbit results, we observed no alterations of any of the 
measured hemodynamic parameters by U-89232 while using a dosage, which is highly 
significantly cardioprotective. Thereby UR89232 fullfills some important criteria, necessary to 
achieve the claim "cardioselective"24. 
The protective effect of U-89232, however, observed in rabbits was not influenced by 
glibenclamide2022. This would rule out that the protective effects ofUR89232 on the myocardium 
are mediated by activation of KATPRchannels, since blocking these channels by glibenclamide 
abolishs the protective effect, as it has been shown with other KATPRchmmel opener studied89 13. 
In our pig model, glibenclamide (I mglkgll5min), in line with previously published reports", 
affected coronary vasculature, but not infarct size. The same dose of glibenclamide, which has 
previously been reported to block the effects ofbimakalim13, has been used in this study, too. 
In contrast to the results obtained in rabbits20 22, in pigs glibenclamide was able to completely 
antagonize the infarct size reducing effect of UR89232, thereby favouring a KATPRchmmel 
involving mechanism. The discrepancy between the observations might be attributable either to 
the animal model or to the dosage ofU-89232 used. 
Several reports state that in rats26 27 and rabbits28 glibenclamide itself is able to increase infarct 
size, thereby biasing direct comparisons between control and treated animals29. This may raise 
SOIlle doubts whether rat or rabbit models are the best suited to evaluate the protective potential 
of KATPwchamlel openers, since only in pigs and dogs their effects MP- K -channels are 
unequivocalli~o. However, Toombs et Nl. could demonstrate that in their rabbit model 
glibenclamide had no such effect, since using glibenclamide they could completely block the 
protective effect of ischemic preconditioning, an endogenous protective mechanism that may 
involve activation of KATP-chamlels. Furthermore, they were able to completely block the 
protective effects of cromakalim, while in the same model the same dose of glibenclamide did 
not affect Uw89232's protection20• 
As the more cardioselective KATP channel openers do not allow to titrate doses by their impact 
on blood pressure, the only way to find an effective dose is to measure infarct size. In rabbits 
Toombs et a1. 20 infused 20,uglkgl30min to observe an infarct size reduction by maximatly 50%, 
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which is close to the dose range reported for other KAIP channel openers2. In contrast, in the pig 
U-89232 exhibited a marked reduction of infarct size (70%) at a dose of 3 mgikg/15min and, 
furthermore, in some pilot dose finding experiments we observed no reduction in infarct size at 
a dose below Img/kg/15min. Whether this reflects species differences between rabbits and pigs 
with regard to U-89232's binding affinity to cardiac KAll' chamlels is speculative. 
Toombs et al." concluded from the bulk of evidence they have obtained in the rabbit, that the 
mechanism of action of U-89232 is most likely due to the ability to affect cardiac 
electrophysiology, since U-89232 decreased the myocardial action potential duration (APD)16 ". 
TIllS electrophysiological feature is very commonly observed with high doses of KATP channel 
openers32 33 and is supposed to be sensitive to KATP channel blockersH 35. 
The relevance of APD shortening in the cascade leading to cardioprotection, however, is 
questionable. Yao and Grossl 5 showed that it is possible to find an intracorollary dose of 
bimakalim which reduced infarct size, but had no effect on epicardial monophasic APD. This 
suggests that significant APD shortening is not necessary for cardioprotection to occur. In line 
with these findings, Grover et al. 18 reported that the cardioprotective effect of another 
cardioselective cromakalim derivative, BMS~ 180448, is independent of APD shortening. 
Whether the mechanism of action ofU-89232 or the affinity ofU-89232 towards KAll' channels 
is different between species can not be excluded or confirmed by our study, but at least in the 
swine myocardium the protective mechanism appears to involve KATP-channels 
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Involvement of ATP"sensitive potassium channels 
in preconditioning protection* 
S. Rohmann, H. \Veygandt, P. Schelling, L. Kie Soei l , P. D. Verdouw l and I. Lues 
E. Merck, Department of Preclinical Cardiovascular Research, Darmstadt, Germany and 
I Laboratory for Experimental Cardiology, Thoraxcenter, Erasmus University Rotterdam, The 
Netherlands 
SllllllllW)': Single or multiple brief periods of ischemia (preconditioning, PC) have been shown to 
protect the myocardium from infarction during a subsequent more prolonged ischemic insult. To test 
the hypothesis that opening of ATP-sensitive potassium channels (KATP) is involved in this mecha-
nism, either bimakalim, a KATP channel opener, or glibenclamide, a K ATP channel blocker, were adminis~ 
tered to mimic or to block preconditioning protection in barbital-anesthetized pigs. PC wa,> elicited by a 
single period of 10 min left anterior descending coronary artery (LADCA) occlusion followed by 15 min 
of reperfusion before the LADCA was reoccluded for 60 min. Instead of PC, bimakalim infusion was 
started 15 min before the 60 min LADCA occlusion (TCO) and stopped with the onset of ischemia. 
GJibencJamide was administered either for 10 min prior to the PC protocol, before bimakalim infu-
sion, or before TCO. Regional wall function was quantified with ultmsonic crystals aligncd to measure 
Willi thickening (%.1. WT). At the end of the protocol, infarct size was determined by incubating m)'ocar~ 
dium with p-nitrobluetetrazolium. 
In seven preconditioned pigs, infarct size was 9.9 ± 5.1% of the risk region compared with 
65.9 ± 6.0% in the seven control pigs subjected to 60 min of ischemia only (1'<0.001). In seven pigs 
treated with bimakalim, infarct size was reduced to 35.3 ± 6.6 (p<0.05 \'s. controls). Blocking ATP-sen-
sitive potassium channels with glibcnclamide prior to PC abolished its protective effect (infarct size. 
62.2 ± 4.5%; p<O.ool vs. PC alone). Glibenclamide also antagonized the protective effect of bimakalim 
(infarct size, 55.2 ± 4.0%), but did not affect infarct size, when solely administered prior to the prolonged 
ischcmic period (62.2 ± 4.3%). We conclude that in swine myocardium KATP channels are involved in the 
protective effect of ischemic preconditioning, since glibenclamide completely abolished the protective 
effect of preconditioning. while bimakalim could - at least in part - mimic it. 
Key words: Preconditioning - stunning - infarct size - ATP-sensitive potassium channels - gliben-
c1amide 
Introduction 
Pretreating myocardium with brief periods of coronary artery occlusion and reperfu~ 
sion increases myocardial tolerance to a subsequent prolonged episode of ischemia, a 
phenomenon, which has been termed "ischemic preconditioning" (19), Ischemically pre-
conditioned myocardium greatly slows the rate of myocardial necrosis during a subse-
quent coronary occlusion (14), reduces the incidence of rcperfusion an-hythmias (10, 27), 
and decreases autonomic de nervation (35). Protection by preconditioning the myocar-
dium with a sublethal period of ischemia is manifest in every species examined to 
* Dedicated to Prof. Dr. H.-J. Langmann on the occassion of his 70th birthday. 
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date, including man (34). Recent studies indicate that occupancy of AI-type adenosine 
receptors and lor the activation of ATP-sensitive potassium channels might be the trigger 
for the preconditioning response. Lill et al. (15) have reported that the protection against 
infarction that is afforded by preconditioning is mediated by AI adenosine receptors. 
Kirsch and coworkers (11) provided evidence that ATP-sensitive potassium channels 
are functionally coupled via OJ proteins to A [ receptors. Accordingly, Gross and Aucham-
pach (6) reported that in dogs the ATP-sensitive potassium channel blocker glibencla-
mide blocked the protective effect of preconditioning, while the ATP-sensitive potassium 
channel opener RP 52891 could mimic it. 
However, the importance of KATP channel involvement in preconditioning's protection 
became highly controversial since Thornton and Downey were unable to block ischemic 
preconditioning protection against infarction with glibenclamide in rabbit hearts (28). 
Glibenclamide also failed to alter preconditioning in their second low collateral blood 
flow model, the rat heart (16). In addition, the results of Kitzen et al. (12) in a canine 
model indicate that potassium channel openers can fail to protect myocardium from 
ischemia-reperfusion injury. 
Prompted by studies performed in seemingly identical rabbit models which have 
yielded opposing results (28, 29), a second element was added to the controversy. Down-
ey (4) raises the point that involvement of KATP channels in preconditioning may be 
sensitive to the type of anesthetic used. He indicates from prepUblication data that glib-
enclamide blocks preconditioning under ketamine-xylazine anesthesia, but fails to show 
similar blockade when pentobarbitone is used. 
To address the above-mentioned points, we have chosen a porcine model of ischemia 
and reperfusion, from which it is known that I) preconditioning cardioprotection is in-
ducible in the presence of pentobarbitone anesthesia (26) and 2) preexisting collateral 
blood flow is low (26), allowing comparisons with other low collateral blood flow mod-
els such as rabbits and rats. Thus, the aim of the study was to evaluate in this porcine 
model whether bimakalim, an opener of KATP channels, is able to mimic preconditioning 
and whether glibenclamide is able to block the cardioprotective effects of both ischemic 
preconditioning and bimakalim. 
Methods 
The investigation conforms with the Guide for the Care and Use of Laboratory Ani-
mals published by the US National [nstitutes of Health (NIH publication No 85-23, re-
vised 1985). 
Experimental desigll 
Fifty-six pigs were assigned to one of six groups; controls (n = 9), preconditioning 
(PC. n = 9), treatment with Bimakalim (BIM. n = 9, the results of the animals in this 
group have been described before (24», and treatment with glibenclamide prior to 
the preconditioning protocol (Gli + PC; n = 10), to the application of bimakalim (Gii 
+B[M, n = 9), or before the onset of 60 min of ischemia (GIi, n = 10). The experimental 
design of the six groups is depicted in Fig. I. All animals were subjected to a 60 min 
LA DCA occlusion followed by 120 min of reperfusion. Vehicle-treated animals served as 
controls. Preconditioning was elicited by a single cycle of 10 min LADCA occlusion 
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followed by 15 min of reperfusioll. Bimakalim (Bim; 4j..tg/kg/fS min) was administered 
for 15 min before the onset of 60 min of ischemia. Glibenclamide (I mg/kg/lO min) was 
infused over 10 min either before the onset of 60 min LADCA occlusion (Gli), or before 
starting the bimakalim treatment (Oli + Bim), or before the preconditioning period 
(Gli + PC). 
l:.:rperimelltal preparation 
Fifty-six mixed breed Landracc-type domestic pigs of either sex between 25 and 29 kg 
were premedicated with ketamine-HCI (500 mg Lm.) 15 min prior to anesthesia with i.v. 
chloralose (100 mg/kg). Following tracheotomy pigs were mechanically ventilated with a 
Rhema animal respirator (HofhcimIFRG) on nitrous oxide supplemented with oxygen at 
a ratio of 2: I. In order to guide adjustment of ventilator settings arterial blood gases were 
ineasured repeatedly. Anesthesia was maintained by continuous infusion of pentobarbital 
at 3 mg/kg/h through a catheter in the right jugular vein. Arterial blood was sampled 
through a catheter placed in the right femoral artery, while the right brachial artery 
was cannulated with a polyethylene catheter, which was advanced to the ascending aorta 
for continuous recording of arterial pressure. A 8 French Millar micromanometer was 
advanced via the carotid artery into the left ventricle for continuous measurement of 
left ventricular pressure. The heart was exposed through a midline thoracotomy and 
suspended in a pericardial cradle. The proximal part of the second branch of the left 
anterior descending coronary artery (LADCA) was carefully dissected free over a length 
of 4 mm and a loose ligature was placed around the vessel which could be occluded with a 
small vascular clip. Electromagnetic flow probes were situated on the ascending aorta 
and the LADCA proximal to the occlusion site. A Teflon catheter (outer diameter 0.8 mm) 
was placed into the epicardial vein draining the area at risk. Rectal temperature was 
monitored throughout the experiment and the chest cavity was covered with a plastic 
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Fig. I. Design of the study (Him = bimukulim, TCO = total coronary artery occlusion). 
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sheet anci kept warm with a heat lamp to keep body temperature between 37 and 3S-C. 
Myocardial function in the ischemic area was measured with 5 MHz ultrasonic crystals 
aligned transmurally to measure wall thickness. A brief « 10 s) occlusion was per-
formed to identify the ischemic region and the crystal pair was located centrally in 
the ischemic region. The inner crystal was advanced to the endocardium tangentially 
through a stab wound in the epicardium. The epicardial crystal, attached to a Dacron 
patch, was positioned on the epicardium with the aid of an oscilloscope, and secured 
with three sutures. After a stabilization period of 30 min after surgery the experimental 
protocol was started. 
Risk region and infarct size 
Following a reperfusion period of2 h the LADCAwas reoccluded and IO ml of 10% 
fluorescein dye were injected into the left atrium .. After I to 2 min the pig was killed by 
electrical fibrillation with a 9-V battery and the heart excised. \Varm 2% agarose was 
injected into the ventricle via the aortic root and the heart was kept on ice. After the 
agarose had congealed, the right ventricle was removed and the left ventricle was sliced 
into four to six rings perpendicular to the LADCA. Subsequently. the rings were weighed 
and the risk region traced onto an acetate sheet under black light, which sharply defined 
the borders of the risk area not perfused with fluorescein. Incubation for 30 min in t .25% 
paranitrobluetetrazolium in phosphate buffer (pH 7.1) at 37°C delineated noninfarcted 
tissue (deep blue) and infarcted tissue (pale). Rings were then photographed with Polar-
oid MP-4 camera and acetate tracings of the ring and infarcted region were determined by 
planimetry. The percent risk region (area at risk / area of ring) was calculated for the top 
and bottom of each ring and the mean value for each ring was multiplied by the weight. 
The weights of regions were summed and divided by the weight of the left ventricle to 
yield the percent of the left ventricle at risk (%AAR) and percent of infarction in the left 
ventricular area at risk. 
Lactate e.r1ractiol/ 
Lactate production has been a reliable index for the presence of anaerobic glycolysis 
(5), and percentage lactate extraction has been shown to correlate well with tissue gra-
dients of lactate (17). At baseline. at the peak reactive hyperemia (about 3 min of final 
reperfusion), and at 120 min of reperfusion arterial and coronary venous blood samples 
were simultaneously obtained for measuring lactate concentration. Since anterior inter-
ventricular vein blood flow cOlTesponds to LADCA influx (3), this method allowed de-
termination of changes in myocardial lactate extraction in the region perfused by the 
LADCA. Lactate values were calculated in the following fashion: 
% lactate extraction = [(arterial minus venous lactate)/arterial lactate] x 100. 
Admillistratioll of dmgs 
Animals in the treatment group received bimakalim dissolved in 1,2-propandiol 
(D.OSCfc') and isotonic saline, while the pigs in the control group received an equal volume 
of the vehicle at con'esponding time points. Bimakalim was supplied as sterile, nonpyro-
genic freeze-dried solid. Prior to each experiment bimakalim was dissolved and mixed in 
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a 38° C warm sodium chloride solution for injection (0.9%). The bimakalim solution was 
administered at a rate of 3j..lg/kg over 5 min followed by a continuous infusion of l~tglkg 
over 10 min via one femoral vein. 
Glibenclamide was purchased from Sigma (St. Louis, Missouri, USA) and dissolved as 
well as administered in an identical fashion as described above for bimakalim. 
Data analysis 
Continuolls recording of hemodynamic and wall thickness data was made on a recor-
der and on a computer-aided registration system (IFD, Mescher, MiilheimlRuhr, FRO), 
Recordings at timepoints of interest were made at a paper speed of 100 mm/s, and the waH 
thickness data were collected from the recordings. Wall thickness variables were aver-
aged over 10 cycles at each timepoint and included end diastolic wall thickness (EDWT, 
~defined as the point when left ventricular dP/dt started its rapid upstroke after crossing the 
zeroline), and end systolic wall thickness (ESWT, defined as the point of maximal wall 
thickness within 20 ms before peak negative left ventricular dP/dt). These data were used 
to calculate the extent of wall thickening (% 11 WT) with the following formnla: «ESWT-
EDWT) I EDWTj* 100. Other variables include peak systolic pressure (PSP, mmHg) 
from the Millar, mean arterial pressure (MAP, mmHg), and heart rate (HR, beats/min-
ute). The double product (DP) was calculated by multiplying PSP x HR. The coronary 
resistance (in dyn) was calculated as follows: Diastolic blood pressure x 80 I coronary 
blood flow; analogous, the total peripherial resistence: MAP x 80/ aortic blood flow. 
Results 
1\vo control, two preconditioned, two BIM, and two GLI + HIM treated pigs. as well 
as three GLI,.and three GLI + Precon animals were excluded from the study because of 
intractable fibrillation. Thus, 42 pigs completed the protocol and were used in data ana-
lysis. 
Risk region and infarc, size 
The infarct size expressed as a percentage ofrisk region is presented in Fig. 2. The risk 
regions were virtually identical (Control, 12.4 ± 2.4; GU, 13.4 ± 1.8%, BIM, 
11.5 ± 2.5%; GU + BIM, 11.9 ± 1.5%; Precon, 11.6 ± 1.8%; GLl + Precon,13.4 ± 
1.6%). The risk area was kept intentionally small, because in pilot studies large risk 
areas (> 20% of the left ventricle) were associated with an unacceptably high incidence 
of ventricular fibrillations. The percent of the risk region infarcted was 65.9 ± 6.0% .for 
controls vs. 9.9 ± 5.1 % for preconditioned pigs (p < 0.001). Bimakalim treatment re-
duced infarct size (35.3 ± 6.6%; p < 0.05 "s. control), but significantly less than is-
chemic preconditioning. There was no significant difference between the three 
glibenclamide groups (GLl, 58.7 ± 5.9%; GLl + BIM, 55.2 ± 4.0%; GLl + Precon, 
62.2 ± 4.5%; n.s.) and the control group. 
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Fig. 2. Myocardial infarct size expressed as percent of the left ventricular area at risk (AAR), results are 
mean ± SEM. All groups n = 7. 
Hemodynamics alld wall fimctioll 
Hemodynamic data are summarized in Table 1. Baseline values were not different for 
the different groups. Bimakalim trcatment decreased mean arterial pressure and increased 
left ventricular dP/cltmax. while ischemic preconditioning did not significantly alter he-
modynamic parameters. Glibenclamide treatment tended to increase mean arterial pres-
sure independent of whether pigs underwent preconditioning, bimakalim treatment, or 
just infusion of vehicle. Cardiac output was neither different from baseline values nor 
between groups at the onset of the 60 min LADCA occlusion. 
Before the onset of the 60 min LA DCA occlusion regional wall function was signifi-
cantly reduced by about 50% in preconditioned pigs compared with control or bimakalim 
treated animals. Treatment with glibenclamide further reduced regional wall function 
following the ischemic preconditioning stimulus (-86%;p < 0.05 vs. PC), while glib-
enclamide administration alone or in combination with bimakalim did not affect wall 
function (see Table 2). After 60 min of LA DCA occlusion, wall function remained de-
pressed to the same extent in all groups. 
Corollary blood floll' 
Coronary blood flow (CBF) and coronary vascular resistance (CYR) values are sum-
marized in" Table 3. 
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Table I. Hemodynamics and global cardiac performance parameters. (n = 7 for all groups; * = p < 0.05 
compared with corresponding lime value in the control group; # = P < 0.05 compared with corresponding 
time value in the group not treated with glibencimnide, Pre Teo = before onset of 60 min LADCA 
occlusion (TCO), RH = reactive hyperemia (3 min of reperfusion), Rep = reperfusion.). 
Heart Rate [beals/min] 
Baseline Pre TCO 60' TCO RH 120' Rep 
Control 112± 4 115±5 107 ± 7 11O± 7 127 ± 10 
Gli 108± 9 103 ± 9 102± 3 110 ± 6 124± 4 
Bim 102 ± II 113 ± 8 116± 9 118± 7 127 ± 13 
GIi+Bim 106± 8 116 ±5 108± 7 134± 6* 134 ± 10 
PC 112± 7 114±6 112± 8 124 ± 8* III ± 13 
Gli+PC III± 8 97 ± 6# 108 ± 10 143 ± 20* 115 ± 6 
tvtAPlmmHg] 
Baseline Pre TCO 60' TCO RH 120' Rep 
~Control 93 ± 7 91 ±6 67 ±4 62 ± 2 77 ± 8 
Gli 99± 5 109 ± 7*# 102 ± 7*# 85 ± 7*# 87 ± 8 
Bim 92 ± 2 61 ± 4* 71 ±6 62 ±5 70 ± 3 
GIi+Bim 94 ±4 78 ± 7*# 81 ± 5* 73 ± 3# 70± 6 
PC 95 ±9 86±9 80 ± 6* 61 ±6 75 ± 10 
GIi+PC 104±4 106 ± 7# 94 ± 5*# 69 ± 6 93 ± 6# 
Double Product j(mmHg*bpm)II00J 
Baseline Pre TCO 60' TCO RH 120' Rep 
Control 118± 9 IIS± 9 98± 7 SI ± 6 116± 15 
Gli 121 ± 9 15S ± 29*# 116 ± 7# 107± 12# 122± II 
Bim 103± 6 86± 7* 95± 7 87 ± 7 106± II 
GIi+Bim 112± 6 109±11# III ± II 112± 7# 115 ± 16 
PC 135 ± 15 114 ± 10 107 ± 10 91 ± 5 102 ± 18 
GIi+PC 136± 15 130± 14 116 ± II 108 ± 14 124 ± 10 
LV dP/dtm.l\ {mmHglsec] 
Baseline Pre TCO 60' TCO RH 120' Rep 
Control 1224± 115 1116± 108 1078 ± 83 874 ± 53 1029 ± 65 
Gli 1335 ± 135 1522 ± 136*# 1558± 74*# 1272± 85*# 1460 ± 159*# 
Bim 1373 ± 258 1889 ± 337* 1845 ± 348* 1378 ± 202* 1382 ± 288* 
GIi+Bim 1341 ± 44 1601 ± 48* 1731 ± 116* 1550± 95* 1317 ± 70* 
PC 1369 ± 84 1374 ± 132*# 1669± 112* 1199 ± 147* 1397 ± 181* 
GIi+PC 1322 ± 66 1447 ± 90* 1238 ± 90*# 900± 95 lOIS ± 152 
Cardiac Output Iml/minlJO kg] 
Baseline Pre TCO 60' TCO RH 120' Rep 
Control 963 ± 63 865 ± 80 741 ± 76 751 ± 56 755 ± 63 
Gli 844 ± 35 767 ± 66 623 ± 28*# 509 ± 28*# 596± 68*# 
Bim 851 ± 70 846 ± 82 785 ± 72 690 ± 43 684 ± 83 
GIi+Bim 829± 53 784± 45 765 ± 44 676 ± 40 691 ± 41 
PC 1024 ± 154 1080 ± 157 848 ± 128 698 ± 80 823± 115 
Gli+PC 845 ± 91 835 ± 67 624 ± 96 435 ± 90*# 689 ± III 
In preconditioned animals after 10 min of LADCA occlusion and 15 min of reperfu-
sion CBF was signiticantly reduced (I' <0.05 vs, control). paralleled by a signitlcant 
increase in CVR (+32%), Althollgh gJibencJamide infusion prior to preconditioning 
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Table 2. Wall function (as %8 wall thickening) in the LADCA region (n = 7 for all groups; * = p < 0.05 
compared with corresponding time value in the control group; # = P < 0.05 compared with corresponding 
time valuc in the group nol treated with gJibenciamide), 
% !1WT 
Baseline Pre TeO 60' TCO RH 120' Rep 
Control 25 ± 3 24±3 - 8±3 -10±2 -7±3 
Gli 26± 3 28 ± 5 - 8±2 -11 ± 2 -8±2 
Dim 23 ±2 24 ±2 - 4±2 - 5 ±5 -3±2 
GIi+Bim 23 ±2 21 ±2 -10 ± 2# -14±5 -6±2 
PC 27 ± 3 14 ±6* - 6±7 5±5 -2±6 
Gli+PC 23 ± 3 3 ± 3'# - 2±4 - 8±2 -5± 1 
Table 3. Coronary blood flow (CBF) and coronary vascular resistance (CVR) at five time points during 
the experimental protocol (n = 7 for all groups; * = p < 0.05 compared with corresponding time value in 
the control group; # = P < 0.05 compared with corresponding time value in the group not treated with 
gUbcnclamide). 
CBF [mUmin] 
Baseline Pre Teo 60' TCO RH 120' Rep 
Control 32 ± 3 35 ±4 17 ± 3 53 ±6 29±7 
Gli 33 ± 3 31 ±2 14±2 46±2 29 ±3 
Bim 37 ± 5 44 ±6 15 ±3 51 ±7 45 ± 8 
Gli+Bim 39 ±5 42±7 13 ±4 63±8 44±4 
PC 35 ± 2 22 ± 3 16±2 40±2' 23 ±3 
Gli+PC 38 ±5 31 ±6# 16±6 51 ±6# 32±4# 
CVR [dyn*sec*cm -5J 
Baseline Pre TCO 60' TCO RH 120' Rep 
Control 208 ± 24 206 ± 24 299 ± 61 138 ± 20 210 ± 47 
Gli 221 ± 28 276±31*# 423 ± 67 115 ± 14 219 ± 37 
Bim 197 ± 27 101 ±18* 189 ± 23* 100 ± 10' 87 ± 9* 
GIi+Bim 183 ± 25 135 ± 20* 277 ± 41# 92 ± 13* 112 ± 9*# 
PC 229 ± 44 303 ± 69* 350 ± 58 138 ± 18 239 ± 47 
Gli+PC 182 ± 26 249 ± 43 288 ± 74 76 ± 9*# 186 ± 35 
period resulted in nearly akinesis in the LADCA region before the onset of the 60 min 
LADCA occlusion, it did not significantly decrease CBF. 
Bimakalim treatment did not alter CBr to the subsequent ischemic region, but signif-
icantly reduced CYR by 49%. Pretreatment with glibenclamide at the given dose only 
partially antagonized the bimakalim-induced vascular effects before the onset of 60 min 
of LADCA occlusion, e.g. CYR still declined by 26%, 
Glibenclamide treatment alone resulted in a little less pronounced hyperemic response 
(3 min of reperfusion) after 60 min of ischemia compared with control animals, but in 
combination with preconditioning of bimakalim CBF was increased. 
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Table 4. Venous blood glucose levels. 
Glucose {ml .... lILJ 
Baseline Pre Teo 60' TCO RH 120' Rep 
Control 4.7 ± 0.5 4.7 ± 0.5 4.1 ±O.S 3.7 ± 0.4 3.9 ± 0.5 
Gli 4.8 ± 0.4 4.4 ± 0.4 4.5 ± 0.4 4.1 ±0.4 3.7 ± 0.4 
Bim 4.6 ± 0.2 4.7 ±0.2 5.3 ±0.2 4.9 ± 0.2 5.3 ± 0.3 
Gli+Bim 4.6 ± 0.6 4.3 ± 0.7 4.7± 1.1 4.3 ±0.9 3.6 ± 0.9 
PC 3.9 ±0.4 3.9 ± 0.4 3.8 ± 0.4 3.3 ± 0.3 3.9 ± 0.4 
GIi+PC 3.9 ± 0.5 3.7 ± 0.8 3.7±0.7 3.4 ± 0.7 2.7 ± 0.7 
Lactate alld glucose analysis 
The venous glucose concentrations are listed in Table 4. There were no significant 
differences by the ANOVA between glibenclamide treated animals and corresponding 
time values in the control, preconditioned, or bimakalim treated groups. 
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Fig. 3. Percent laclale extraction (mean ± sm.'I) in the LADCA region at baseline. during reactive hy-
peremia (3 min of r('perfusion). and allhe end of the protocol (120 min of reperfusion). All groups n = 7. 
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The extent of lactate wash-ollt after 60 min of LADCA occlusion was different be-
tween groups (see Fig. 3). While all glibenciamide treated hearts showed no significant 
different lactate wash-out, it was reduced by about 60% when pretreated with bimakalim. 
In preconditioned animals an even morc reduced lactate wash-out was observed after the 
60 min of ischemia (I' < 0.00 I vs. control; p< 0.05 vs. bimakalim treatment), which was 
fully reversible by the pretreatment with glibenclamide. 
Discussion 
The objective of this study was to evaluate in pigs the hypothesis that activation of 
ATP-scnsitive potassium channels (KATP) is involved in the phenomenon of ischemic 
preconditioning. The opener of KATP channels, bimakalim, was able to reduce infarct 
size about 50%, albeit not to the same extent as ischemic preconditioning (80%), while 
the KATPchannel blocker, glibenciamide, could fully prevent both the protective effects of 
bimakalim and ischemic preconditioning. Thereby, this study extends the hypothesis of 
KATP channel involvement in preconditioning to a large animal model which lacks sig-
nificant collateral blood flow and confirms results previously obtained in the dog and 
some rabbit studies. 
ATP-sellsitil'e potassium channels ill illfarct size limitation 
Pig hearts, when subjected to a JO-min ischemic episode of the LADCA region fol-
lowed by 15 min of reperfusion, acquired not only regional dyskinesis, but also protection 
against a further episode of ischemia. Myocardium preconditioned in this fashion had 
much less necrosis than myocardium that has not previously been made ischemic, de-
spite the additional 10 min of ischemia in the preconditioned pigs. This is in line with 
results obtained in dogs showing that a single occlusion seems to be equally effective as 
six or 12 5-min occlusive episodes (14). Consistently, in our study in pigs a single, pre-
conditioning period of 10 min of ischemia followed by 15 min of reperfusion was as 
protective as the previously reported two cycles of 10 min of ischemia and 30 min of 
reperfusion (26). These observations imply that ischemic preconditioning is consistent 
with an "all or nothing" response (13), which may correlate with an on or off switching of 
KATP channels. 
Similar to preconditioning with ischemia, bimakalim treatment was associated with a 
significant decrease in infarct size. This confirms in pigs the results of Grover et al. (7) 
and Auchampach et al. (29) that KATP channel openers are able to signiticantly reduce 
infarct size. In both dog models the protective effect occurred independent of any changes 
in peripheral hemodynamics, area at risk, or collateral blood flow, suggesting that po~ 
tassium channel agonists have a direct cardioprotective effect. 
The results from Murry and coworkers (20) provide evidence that it reduced accumu-
lation of glycolytic intermediates (such as lactate, H+, and NADH) may be responsible 
for the protective effect of preconditioning. Lactate accumulation has been reported to 
cause marked alterations in mitochondrial structure (1), which were significantly reduced 
in dogs preconditioned with ischemia. The combined effects of ischemic catabolites may 
act as an osmotic load to the cell, the reduction of this osmotic load may be protective by 
preventing osmotically induced rupture of cell membranes. In our study, the birnakalim 
treated pigs released only half the amount of lactate after 60 min of ischemia as did the 
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control pigs, which would support the concept that reduction in the osmotic load during 
coronary artery occlusion results in signs of reduced ischemia (9, 24). Thus, precondi-
tioned pigs showed an even more decreased lactate wash~out after the final occlusion 
(about 1/10 the amollnt of control animals). Accordingly, the infarct in preconditioned 
myocardium was only one-third the size measured in bimakaJim treated myocardium. 
Consistent with our results, Gross and Auchampach (6) found in their dog model is-
chemic preconditioning much more potent to reduce infarct size (from 28% to 6%; 
79% reduction) than the K,\Tp channel opener RP 52891 (to 13%; 54% reduction). 
The reason why short ischemia followed by reperfusion can prevent cumulative injury 
to a greater extent than drug-induced opening of KATP channels is unknown. However, 
during an interspersed reperfusion not only potentially harmful cataboJites are washed 
out, but also adenosine, which may contribute to the salutary effects of ischemic precon-
ditioning. In dogs intracoronary administration of an AI~selective adenosine agonist (R-
PIA) resulted in a 44% infarct size reduction (8). Infusion of a KATP channel blocker 
abolished the protective effect of AI-adenosine receptor stimulation in dogs (8) and 
in pigs (31), providing evidence that preconditioning may be mediated by KATP channel 
activation, which sensitivity is modulated by AI-receptor stimulation. This concept is 
supported by the observation that KATP channels are completely inhibited at much lower 
ATP levels than the intracellular ATP concentration seen at the early stage of ischemia 
(22). Therefore, the KATP channel has to be sensitized to smaller changes in the ATP-Ievel 
as a response to short ischemia. One possible explanation is that adenosine is involved; 
adenosine released during short ischemia decreases the KATP channel sensitivity via in-
teraction with a Gj protein. This may be a route by which channel activity eQuid be 
increased during brief ischemia and could explain the data supporting the adenosine 
hypothesis of preconditioning. 
Additionally, adenosine release from myocytes, KATP channel opening, as well as is-
chemic preconditioning seem to result in a slower accumulation of ischemic catabolites 
such as lactate. Reimer and Jennings's group did show that the metabolism during ische-
mia, namely rate of ATP depletion, glycogen utilization, and lactate accumulation during 
a later episode of ischemia is slowed by both, pretreatment with ischemic preconditioning 
(20) and intracoronary adenosine (30). 
Glibenclamide to prevent ill/arct size reduction 
In contrast to KATP channel activation, preventing KATP channel opening by. its blocker 
is expected to prevent the protective effect of preconditioning or bimakalim treatment 
resulting in a tolerance which is no longer different from the tolerance of animals under-
going a long period of ischemia only. Indeed, in our study glibenclamide abolished the 
infarct size-reducing effect of ischemic preconditioning as weB as of bimakalim. Impor-
tantly, treatment with a KATP channel blocker did not increase infarct size when admi-
nistered to pigs undergoing 60 min of ischemia and 120 min of reperfusion only. This is in 
contrast to the results obtained in rabbits by Thol11ton et ai. (28), but consistent with the 
data obtained in dogs (6) or in pigs (31). Furthermore, the antagonistic effects of glib-
enclamide on infarct size in the canine model of Gross and Auchampach (6) as well as in 
our swine model occured independently of differences in hemodynamics. coronary col-
lateral blood now, or size of the ischemic bed. 
Another possibility to explain the differences between the rabbit and doglpig models 
may result from a different sensitivity of pancreatic cells to glibenclamide. Glibencla-
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mide is known to increase insulin and to decrease blood glucose levels, which may affect 
preconditioning. Omar et al. (23) showed in an isolated rabbit heart model that precon-
ditioning protection occurs only in the presence of high glucose concentrations in per-
fusate during reperfusion. \Vith the I mg/kg dose of glibenclamide. no significant 
hypoglycemia (mean ~8.3%) was induced in the pig model and. presumably, as inferred 
from glucose levels, insulin was not greatly increased. However, Gross and Aucharnpach 
(6) observed a decrease by maximal 16% in the blood glucose levels when infusing 
glibenclamide (0.3 mglkg/lO min) in dogs. In the rabbit Thornton et al. (28) registered 
with all three doses of glibenclamide used (0.15 mg/kg, 0.3 mg/kg, and 3.0 mglkg) a 
significant drop in blood glucose levels, ranging from 23% to 38%. That the effect 
on blood glucose was less pronounced in pigs than reported for dogs and rabbits might 
be due to species related differences in the pancreatic cells to glibenc1amide. Addition-
ally, our pigs fasted for 24 h before they were instrumented and the blood glucose levels 
could have been lowered at baseline, which might reduce the response of pancreatic cells 
to glibellclamide, too. 
In a prelimenary study in pigs, glibenclamide, in a dose of I mg/kg, was able to prolong 
action potential duration by about 20% in non-ischemic myocardium. In this model, 
bimakalim (4J.lg/kg/15 min) shortened action potential duration by 15%-20%, which 
could be fully reversed by glibenclamide (I mglkg). We have no data yet in pigs about 
the influence of KATP channel openers on action potential duration under ischemic con-
ditions, but Yao et al. could show in a canine model that bimakalim accelerates (33) while 
glibenclamide blocks (32) the shortening of the action potential duration induced by 
ischemia. 
In our study glibenclamide worsened the postischemic contractile dysfunction after J 0 
min of LA DCA occlusion ("stunning") as compared with preconditioning alone. This is a 
new finding in pigs and is further evidence from a functional point of view that blocking 
KATP channels in the course of ischemia and reperfusion is detrimental. Furthermore, the 
results imply that there is a clear dissociation between myocardial stunning and precon-
ditioning, since one would expect the Glib + PC group to have small infarcts if these two 
phenomena were related. This is in line with results obtained in dogs (21) and rabbits (18) 
demonstrating that myocardial stunning is insufficient to cause preconditioning protec-
tion. 
Taken together, these results suggest an important involvement of the ATP-sensitive 
potassium clwnnel in the preconditioning phenomenon in swine myocardium, because 
blocking these channels by glibenclamide completely abolished the protective effect of 
ischemic preconditioning as well as of bimakalim, an opener of the KATP channels. Sub-
stituting preconditioning by bimakalim infusion did not exhibit the same profound infarct 
size-reducing effect as did preconditioning with ischemia. This suggests that the full 
protective effect of ischemic preconditioning is multifactorial, however, involving the 
opening of ATP~sensitive potassium channels. The precise mechanisms by which ische-
mically primed myocardium can protect itself remains unclear. The extent of the infarct 
size reduction induced by ischemic preconditioning exceeds any that has been produced 
with pharmacological interventions and warrants further investigation. 
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Renewal of Ischemic Preconditioning's Protection 
is possible by Activation of KATP-channels 
Sven Rohmann, Heinrich Weygandt, Loe Kie Soei!, Matthias Schranz, 
Pierre Schelling and Pieler D. Verdollw! 
Objective: Brief cycles of coronary artery occlusion that precede a 
sustained occlusion do not aggravate infarction but paradoxically increase 
the ischemic tolerance of the myocardium. Tlus protective effect is lost 
when the time between the first ischemic event and the sustained ischemic 
episode is prolonged. \Ve assessed whether bimakalim, an opener of ATP 
sensitive potassium channels (KATP) or a second preconditioning cycle can 
renew ischemic preconditioning protection. Methods! Studies were 
performed in pentobarbitone anesthetized, open chest pigs which were 
subjected to a 60 min occlusion (TCO) of the left anterior descending 
coronary artery (LADCA) followed by two hours of reperfusion (REP). Six 
groups of animals were studied. In two groups either a preconditioning cycle 
of 10 min TCO followed by 15 min REP was performed (PC 15) or 
bimakalim (Bim) was infused (4I'g/kg) over 10 min prior to the 60 min 
occlusion. In the third group REP following preconditiOlung with 10 min 
TCO was prolonged to 100 min (PCIOO). In the PC+PC group a second 
cycle of 10 min TCO followed by 15 min REP was performed 100 min 
after the first cycle, while in the PC+Bim group bimakalim was infused 
instead of the second preconditioning cycle. In the control group (n = 7) 
animals received vehicle only. At the end of the protocol, infarct size (IS, as 
% of the left ventricular risk region) was determined by the p-nitroblue-
tetrazolium method. Results: A single cycle of 10 min TCO is highly 
protective when followed by 15 min of REP (IS: 9.9±S.I% p<O.OOI vs. 
66.3±S.6% of controls), but this potection was completely lost in all animals 
if REP was prolonged to 100 min (IS: 61.6±S.2%). With a second 
preconditioning cycle renewal of the protection was only possible in 2 out of 
7 pigs (IS: 40.9±7.7% p<O.OS vs. controls and vs. PCIS). Applying the 
KATP channel opener instead, full protection was achieved in every pig (IS: 
21.6±3.S% p<O.OOI vs. control n.s. vs. PCIS). Conclusion: Protection by 
ischemic preconditioning in pigs was lost if the intermittent reperfusion 
period was prolonged to 100 min. The renewal of the protective effect is 
only possible in part by a second preconditioning cycle, most likely 
depending on the remaining myocardial adenosine pool, but can be fully 
restored by applying bimakalim. The results implicate that a KATP-chaJll1el 
opener may be clinically very useful in coronary heart disease as it is 
reliably able to re-establish the endogenous protection provided by ischemic 
preconditioning. 
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I schemic preconditioning is an endogenous protective mechanism in which brief periods of myocardial ischemia and reperfusion render the myocardium resistant to a ~. ~ subsequent more sustained ischemic insult!, This phenomenon has been shown to exist 
in most mammalian species including mau2• Although the protective effect could be 
confirmed in every species tested, there still exists controversy over the initiating event and 
subsequent subcellular mechanisms leading to cardioprotection. 
In anesthetized dogs Gross and coworkers} descibed prevention of ischemic preconditioning 
after blockade of KATP-channels with glibenclamide. They also reported that administration of 
the KAlP-channel opener EMD 52692 (bimakalim) provided tolerance to subsequent ischemia' 
5. Gross, therefore, theorized that activation of the KATI'-charmel is importantly involved in 
mediating ischemic preconditioning. \Ve61 have confirmed these data in anesthetized pigs, 
thereby excluding a role of coronary collaterals. 
Today there is little doubt that openers of ATP-sensitive potassium channels possess 
cardioprotective propertiess. They represent a new class of drugs that may offer exciting new 
therapeutic opportunities under conditions in which a reduction of consequences of an 
ischemic episode is desirable9• Possible clinical applications include various forms of angina, 
myocardial infarction with early thrombolysis and cardiac surgery. However, their clinical use 
could be limited. since it has been shown in rats, rabbits, pigs, and dogs that preconditioning 
protection can be lost when the intermittent reperfusion period between the initial 
preconditioning ischemia and the subsequent sustained ischemic episode is prolonged10 [I 1213. 
Control Reperfusion 
Time 
Baseline ·125' 
I I 
181 
PCIS 
PCIOO Reperfusion 
PC+PC Reperfusion Reperfusionl 
PC+Bim Reperfusion Reperfusion 
Bim Reperfusion 
Figure t. Design of the study. TCO= total coronary artery occlusion. 
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It was the aim of this study to confirm these rest,Its in our pig model, in which bimakalim has 
been shown to be able to mimic preconditioning's protection. Furthermore, we wanted to 
evaluate to which extent a second preconditioning event or the pharmacological activation the 
KAll' channel by bimakalim is able to re-establish the protection. 
Methods 
The investigation conforms with the Guide for the Care and Use of Laboratory Animals 
published by the US National Institutes of Health (NIH publication No 85-23, revised 1985). 
Experimental Design: 
The design is depicted in figure I. All 42 pigs underwent a 60 min left anterior descending 
coronary allery (LADCA) occlusion followed by 120 min of reperfusion. The animals were 
divided into six groups. Ischemic preconditioning was induced by 10 min of LADCA 
occlusion followed either by 15 min of reperfusion (PCI5) or by 100 min of repernlsion 
(PCIOO). In the PC+PC group 100 min after the first preconditioning ischemia a second 10 
min LADCA occlusion was performed, while in PC+Bim animals received an Lv. infusion of 
bimakalim (4 ,ug/kg/IOmin) after 100 min of repernlsion instead of the second 
preconditioning occlusion of the PC+PC group. Furthermore, to demonstrate that an effective 
dose of bimakalim able to limit infarct size was used, bimakalim was infused (4 ,ug/kg/15min 
Lv.) prior to the 60 min LADCA occlusion. Vehicle treated animals served as controls (CON). 
The results of two groups, BIM and pel5, have been used already in another publication7, but 
since all experiments were performed at the same time and in the same laboratory they were 
included in this shldy. 
Experimelltal Preparatioll: 
Fourty-two mixed breed Landrace-type domestic pigs of either sex weighing between 23 and 
29 kg were premedicated with ketamine-HCI (IOmg/kg Lm.) 15 min prior to anesthesia with 
Lv. bolus h*ction of sodium pentobarbital (30 mg/kg). Following tracheotomy pigs were 
mechanically ventilated with an animal respirator (Rhema, Hofheim/FRG) on nitrous oxide 
supplemented with oxygen at a ratio of2:1. In order to guide adjustment of ventilator settings 
arterial blood gases were measured repeatedly. Anesthesia was maintained by cOlltinolls 
innlsion of sodium pentobarbital (3mg/kgn,). Arterial blood was sampled through a catheter 
placed in the right femoral artery, while the right brachial artery was cannulated with a 
polyethylene catheter, which was advanced to the ascending aorta for continuous recording of 
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arterial pressure. An 8 French Millar micromanometer was advanced via the carotid artery into 
the left ventricle for continuous measurement of left ventricular pressure. The heart was 
exposed through a midline thoracotomy and suspended in a pericardial cradle, Distally of its 
second branch the (LADCA) was carefully dissected free over a length of 4 mm and a loose 
ligature was placed around the vessel which could be occluded with a small vascular clip, Elec-
tromagnetic flow probes were situated on the ascending aorta and the LADCA proximal to the 
Table 1 Hemodynamics assessed at baseline, directly before the 60 min LADCA occlusion (Pre-TCO), 60 min of 
LADCA occlusion (TeO), at reactive hyperemia (about 3 min ofreperfusion; RH), and at the end ofthe protocol (120' 
REP), 
Heart Rate (beats/min) 
Baseline PreTeO 60'TCO RH t20'Rep 
Control 102±3 t03±4 III ±4 114±4 128 ± to 
PC1~ 112±7 114 ±6 112±8 124±8 1I1±13 
PC100 96±7 98 ± 10 toI ± II 117±8 120± 13 
PC+PC 99± 5 99±4 109±4 120±3 121 ±6 
PC+Bim 97±9 105±6 121 ± 15 120 ± 13 122±9 
Bim 102± II 113 ± 8 116± 9 118 ± 7 127 ± 13 
Mean Arterial Pressure [mmHg] 
Baseline PreTeO 60'TCO RH f20'Rep 
Control 95±6 93 ±6 70±3 63±2 80±7 
PCIS 95 ±9 86±9 80±6 61 ±6 75 ±1O 
PC[oo 104 ±4 96±6 93 ±7* 80±8* 92 ±7 
PC+PC 99±6 97±6 91 ±4* 71 ±4* 88±4 
PC+Bim 103±7 70±4* 76±4 64 ±5 78±4 
Dim 92±2 61 ±4* 71 ±6 62 ±5 70±3 
Double Product (mmHg"'bpm)/lOO) 
Baseline PreTeO 60'TCO RH t20'Rep 
Control 117± 7 112±8 95±4 85±3 120 ±13 
PCIS 135±15 114± 10 107 ±1O 91 ±5 102 ±18 
PC100 116 ± 10 102 ± 14 112±14 110 ±8* 130±16 
PC+PC 106±7 112±6 116±6 100 ±4* 126 ±IO 
PC+Bim 113±8 94 ±6* 112±13 93±6 1l8±I1 
Bim 103±6 86± 7* 95 ±7 87±7 106±11 
LVdP/dtlllu (mmHg/sec) 
Baseline PreTCO 60'TCO RH l20'Rep 
Control 1435 ±1I4 1367 ±I04 1076 ±84 869 ±53 1018±64 
PCIS 1369±84 1374±132 1669 ±1I2* 1199 ±147* 1397 ±l81 * 
PC!OO 1565±187 1520 ±167 1469 ±146* 1168 ±207* 1357 ±161 * 
PC+PC 1564 ±95 1463 ±8J 1244 ±62* 991 ±67 1430 ±109* 
PC+Bim 1365±74 1529 ±98 1394 ±84* 1162 ±1I6* 1471 ±Ill* 
Bim 1373 ±258 1889 ±337 1845 ±348* 1378 ±202* 1382 ±288* 
Cardiac Output [ml/min/to kg) 
Baseline PreTCO 60'TCO RH t20'Rep 
Control 969 ± 66 923± 64 839 ± 76 691 ± 53 771 ± 77 
PCIS 1024± 154 1080± 157 848 ± 128 698 ± 80 823±115 
PC[OO 1078 ± 40 992 ± 106 890± 89 748 ± 126 776 ± 135 
PC+PC 950± 35 896 ± 32 818±40 558 ± 48* 795± 67 
PC+Bim 1065± 62 1087 ± 49* 1114±56* 883 ± 124* 1093 ± 112* 
Bim 851 ± 70 864 ±82 785± 72 690 ± 43 684 ± 83 
*= p<O.05 compared with control animals at the same timepoint. (Abbr.: MAP = mean arterial blood pressure, LV 
= left ventricular) 
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occlusion site. A Teflon catheter (outer diameter 0.8 mm) was placed into the epicardial vein 
draining the area at risk. Rectal temperature was monitored throughout the experiment and the 
chest cavity was covered with a plastic sheet and kept warm with a heat lamp to keep body 
temperature between 37°C and 38°C. Myocardial function in the ischaemic area was measured 
with 5 mHz ultrasonic crystals aligned transmurally to measure wall thickness. A brief « 1 0 
second) occlusion was perfomled to identifY the ischaemic region and the crystal pair was 
located centrally in the ischaemic region. The iuner crystal was advanced to the endocardium 
tangentially through a stab wound in the epicardium. The epicardial crystal, attached to a 
Dacron patch, was positioned on the epicardium with the aid of an oscilloscope, and secured 
with three sutures. After a stabilisation period of 30 min after surgery the experimental 
protocol was started. 
Risk Region and flgare/ Size: 
Following a reperfusion period of two hours the LADCA was reoccluded and 10 ml of 10% 
fluorescein dye were injected into the left atrium. After one to two min the pig was killed by 
electrical fibrillation with a 9M V battery and the heart excised. \Varm 2% agarose was injected 
into the ventricle via the aortic root and the heart was kept on ice. After the agarose had 
congealed, the right ventricle was removed and the left ventricle was sliced into four to six 
rings perpendicular to the LADCA. Subsequently, the rings were weighed and the risk region 
traced onto an acetate sheet under blacklight, which sharply defined the borders of the risk area 
Table 2. Coronary blood flow (CBF) and calculated coronary vascular resistance (CVR) during the protocol. 
CDF lOll/min] 
Baseline PreTCO 60'TCO RH f20'Rep 
Control 36±3 37±3 i7±3 48±6 31 ±6 
PC IS 35 ±2 22±3* 16±2 40±2 23 ± 3 
PC100 40±4 36±3 20±2 58± II 41 ±3 
PC+PC 37 ± I 33±2 22±2 49± 3 37±2 
PC+'Bim 39±2 35±3 21 ± 3 55 ±7 57± 7* 
Bim 37 ±5 44±6 i5 ±3 51 ± 7 45 ±8 
CVR Idyn""sec*cmosJ 
Baseline PreTCO 60'TCO RH nO'Rell 
Control 201 ± 24 198±22 306± 66 135±21 206 ±48 
PC,s 229±44 303 ± 69* 350 ± 58 138 ± is 239± 47 pe loo 165±20 171 ± 17* 240 ± 26 101 ± 14 i48 ± 10* 
PC+PC 182± II 197 ± 19 307 ± 54 101 ± 9* 158± 6* 
PC+Bim 179± II 129 ± i2* 207 ± 28* 97± 10 93±1l* 
Bim 197 ± 27 101 ± 18* 189 ± 23* 100 ± 10* 87±9* 
*- p<O.05 compared with control animals at the same timepoint, time points (see table I). 
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Table 3. Regional wall function (%WT = % delta wall thickening) in the LADCA area subsequently made ischemic 
for 60 min. 
Baseline PreTCO 60'TCO R11 120'Rep 
Control 28± 3 25±3 -6±3 -II ±2 -9±3 
pelS 27± 3 14±6* -6±7 - 5 ± 5 - 2± 6 
PC100 32±3 23±5 - 5±2 - 9±3 -8±2 
PC+PC 33±3 14± 3* - 5 ±2 - 8±3 - 6± I 
PC+Bim 33±4 24± 3 -6±2 - 12±3 
- 4 ±4 
Bim 23±2 24 ±2 -4±2 - 5±5 - 3 ±2 
, p<O.05 compared with control animals at the same timepoinl, time points (see table 1). 
not perfused with fluorescein. Incubation for 30 min in 1.25% paranitrobluetetrazolium in 
phosphate buffer (PH 7.1) at 37'C delineated noninfarcted tissue (deep blue) and infarcted 
tissue (pale). The size of the area at risk and the infarcted region were determined by planime-
try, The % risk region (area at risk / area of ring) was calculated for the top and bottom of 
each ring and the mean value for each ring was multiplied by the weight. The weights of 
regions Were summed and divided by the weight of the left ventricle to yield the % of the left 
ventricle at risk (%RR) and % of the left ventricular risk region infarcted (%IS), 
Administration oJbimakalim: 
Animals in the treatment groups received bimakalim dissolved in 1-2-propandiol and isotonic 
saline, while the pigs in the control group received vehicle (I-2-propandiol and isotonic saline), 
Prior to each experiment bimakalim was dissolved and mLxed in a 37°C warm saline. 
Bimakalim 4,ug/kg min was administered as a continuous infusion via a femoral vein either 
over 10 min (PC+Bim) or over 15 min (Bim), 
Data analysis: 
Continuous recording of hemodynamic and wall thickness data was made on a paper recorder 
(Gould) and on a computer-aided registration system (IFD, Mescher, MiilheimlRuhr, FRG), 
Recordings at timepoints of interest were made at a paper speed of 100mmlsec, and the wall 
thickness data were collected from the recordings. \Vall thickness variables were averaged over 
10 cycles at each timepoint and included end diastolic wall thickness (EDWT, defined as the 
point when left ventricular dP/dt started its rapid upstroke after crossing the zeroline), and end 
systolic wall thickness (ESWT, defined as the point of maximal wall thickness within 20 lOS 
before peak negative left ventricular dP/dI), These data were used to calculate wall thickening 
(%delta WT) with the following formula: ((ESWT-EDWT) / EDWT) x 100, Other variables 
included peak left ventricular systolic pressure (LVSP, mmHg), mean arterial pressure (MAP, 
mmHg), and heart rate (HR, beats/min). The coronary vascular resistance (dyn x sec x cm-5) 
was calculated as diastolic aortic blood pressure x 80 I coronary blood flow; analogously, the 
total peripherial resistance was calculated as MAP x 80/ a0l1ic blood flow, 
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cm-5) was calculated as diastolic aortic blood pressure x 80 / coronary blood flow; 
analogously, the total peripherial resistance was calculated as 1v1AP x 80 I aortic blood flow. 
For comparison of variables across time between the groups, a two factor analysis of variance 
(ANOV A) of repeated measures was used. When the ANOVA was significant, pairwise 
comparisons were made with the Student's t-test with the significance level for the p values 
corrected with the BOllferroni method. For comparison across time in the control group, a one 
factor ANOVA of repeated measures was used, with a post-hoc testing strategy identical to 
that of the two factor ANOVA. A two sample rank sum test (Mann-Whitney-V) was used to 
test the differences between two groups with regard to the risk region and the % of the risk 
region infarcted. Data are reported as mean±SEM. 
Results 
Risk Region and bifarel Size: 
The risk regions (expressed as % of the left ventricle) were virtually identical in all groups 
(Control, 12.6±2,4%; Bim, 11.5±1.0%; PCI5, 11.6±1.8%; PCIOO, 12.3±0.7%; PC+Bim, 
12.6±1.0%; PC+PC, 11.l±0.6%). The risk area was intentionally kept small (10% - 15% of 
left ventricular wall volume), because in pilot studies larger risk areas were associated with a 
high incidence of ventricular fibrillation. 
The percentage of the risk region infhrcted was 66.3±S.6% for the controls. Starting 
bimakalim treatment as well as the preconditioning cycle prior to 60 min of LADCA 
occlusion significantly reduced infarct size (Bim, 35.3±6.6% and PCI5, 9.9±5.1%, p<O.05 
and p<O.Ol vs. controls, respectively). \Vhen the reperfusion period between the 
preconditioning cycle was prolonged from IS min to 100 min, the infarct size limiting effect 
was lost (61.6±S.2%). A second preconditioning cycle given at that time point restored 
protection only in part (40.9±7.7, p<0.05 vs controls and p<0.05 vs. PCI5). Analyzing the 
individual infarct sizes (depicted in figure 2), a full or some protection in the PC+PC group 
was achieved in 4 pigs, while at least 3 animals showed no protection. BimakaJim was able to 
re-establish protection in every case (21.6 ±3.S%, p<O.OOl vs control, n.s. vs. PClS and Bim, 
p<0.05 vs PC+PC). 
Hemodynamics and wall junction: The control pigs remained hemodynamically stable 
throughout the occlusion and reperfusion period and did not vary significantly from baseline 
with regard to heart rate, mean arterial pressure or double product. 
Infusion of bimakaIim significantly reduced mean arterial pressure and the double product, 
while the preconditioning cycle(s) did not significantly affect global hemodynamics (table I). 
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Bimakalim significantly reduced coronary vascular resistance, but did not significantly 
increase coronary blood flow when assessed prior to the 60 min of LADCA occlusion (table 
2). 
Wall functiOIi in the LAD region was significantly reduced in the PCIS and PC+PC group 
prior to the 60 min LADCA occlusion (table 3), but not with any other intervention. 
Comparing the time course of postischemic dysfunction after the first preconditioning cycle 
(see table 3), regional wall function shows a stepwise recovery over time. \Vithin 120 min of 
reperfusion after the 60 min LADCA occlusion no recovery of function in any of the groups 
was observed. 
Discussion 
It is currently being hoped that ischemic preconditioning will have clinical importance l4• 
Therefore, the results by Cohen et alY indicating that it is possible to become tolerant to 
multiple episodes of ischemic preconditiong were alerting. In conscious rabbits 
cardioprotection waned after multiple 5-minute coronary occlusion have occured but did 
Protected E ~ Unprotected 
Control • • •• • • • 
PC15 • • • • • 
PC100 .. .. .. .... .. .. 
PC+PC • • •• • • • 
PC+Bim 
Bim 
it +.:1: ++ 
••• • • • • 
o 10 20 30 40 50 60 70 80 90 100 
Infarct Size (%RR) 
Figure 2. Plot of myocardial infarct size expressed as percent of the risk region (RR) in each individual animal. All 
groups n = 7. The dotted line indicates the border towards protection basing on the ma.xinmi infarct size value in the 
PCI5 group. 
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reappear after an ischemia~free period. 
In our pig study the cardioprotective effect was completely lost, when the reperfusion period 
between the initial ischemic event and the subsequent sustained ischemia was prolonged to 
100 minutes. This is consistent with results obtained in anesthetized rats12, dogs l , and in 
pigs JO, all indicating that by prolonging reperfusion the myocardium looses its protection. 
Sack et al.lO could show in pigs that preconditioning's protection could be renewed by a 
second cycle of two 10 min occlusious seperated by 30 min of reperfusion after 4 days but not 
60 min after the first preconditioning cycle. Their results suggested that the release of a 
mediator from an exhaustible pool, most likely adenosine, is necessary to activate a chain of 
events leading to cardioprotection. 
In contrast to Sack et a1.!O we only used a single cycle of 10 min of ischemia instead of two 
cycles of 10 min of ischemia. \Vhile the induced cardioprotective effect appears to be 
independant of the number of preceeding cycles of ischemia, which is in line with results 
obtained in dogs", the effect on the cardiac adenosine pool could be different. A single cycle 
of 10 min of ischemia might not be severe enough to exhaust myocardial adenosine pools in 
every case, but two cycles (20 min) may do so. Henrichs et aL 16 ,could demonstrate in dogs 
that there is a significant difterence in myocardial adenine nucleoside content following a 
single 5 min occlusion and two 5 min occlusions. A different amount of preceeding adenosine 
release might explain why we observed a renewal of preconditioning's protection in 2 out of7 
animals, while Sack et al.1O did not. However, both pig studies favour a mechanism involving 
adenosine as a primary mediator to initiate cardioprotective effects, although both studies did 
not measure adenosine release. 
Thus, a leading hypothesis regarding the initiating events leading to cardioprotection, as been 
forwarded by Downey and coworkers!1, proposes that the mechanism of preconditioning 
involves activation of adenosine receptors, stimulation of Gi proteins, activation of 
phospholipase C and the formation of diacylglycerol. This results in the activation and 
translocation of protein kinase C (PKC) and the resultant phosphorylation of an unknown 
effector protein. Evidence in support of this theory was obtained from in vitro and in vivo 
rabbit models, in which various antagonists and agonists along this pathway were found to 
prevent and mimic ischemic preconditioning, respectively. 
Recently, in dog lS as well as in pig models it has been shown that adenosine mediates its 
cardioprotection via a cardiac KATP~channel linked mechanism, naming the ~TP ~channel the 
since unknown effector. However, Yao and Grossl 8 observed in dogs, that, despite the efficacy 
of adenosine in mimicking the effects of preconditioning, its protective effects did not persist 
as long as those of preconditioning. In their experiment, the adenosine induced 
cardioprotectioll totally disappeared 60 minutes after administration, whereas ischemic 
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preconditioning persisted more than 1 hourIs. How preconditioned dog hearts maintain K,\Tp-
channel activation to memorize the preconditioning for 1 hour or longer, therefore, Calmot he 
explained by adenosine alone. 
Ytrehus et af.2° showed in rabbit hearts that activation of protein kinase C may be involved in 
the memory phase of ischemic preconditioning, while several laboratories21 22 demonstrated 
that stimulation of protein kinase C activates the KATP-channel. Since 5 min of ischemia is 
sufficient to activate protein kinase en, it appears possible that even short preconditioning 
stimuli lead to activation of PKC, which may translate into opening and persistent activation 
ofKATP-channcls24 • 
Furthermore, using human atrial cells it has been demonstrated that protection can be induced 
by activation ofPKC and by the opening ofKATP-channels and that the protection induced by 
PKC activation and preconditioning can be blocked by blocking the KATP-channeps. 
The smaller infarcts in the preconditioned or bimakalim treated animals did not translate into 
a better recovery of regional wall function. This may be attributable either to the fact that the 
ischemic burden in each group has been too large to see a sign of recovery within the 
relatively short reperfusion period of two hours or that the reperfusion period was too short to 
allow the area at risk to overcome myocardial stunning". However, reperfusion periods of 
more than 60 min are sufficient to allow precise measurement of infarct size26, which was the 
primary endpoint of this study. 
In our pig study pharmacological activation of the KATP-channel could bypass the initial 
adenosine dependant pathways and thereby fully reinstalled the protective effect of 
preconditioning. This provides further evidence that the mechanism of preconditiong may 
initially act via adenosine, PKC, etc. but relies on the action of the KATP-channei as the end 
effector. 
This hypothesis is supported by two most recent observations. Firstly, in pigs Vogt et alY 
could overcome the deficit in endogenous adenosine production post-preconditioning by 
substituting with a local intramyocardial application of an adenosine AI-agonist, thereby 
reinstalling preconditioning's protection. Secondly, in dogs Yao et aU8 blocked the KATP-
channels after 1 h of reperfusion with glibenclamide, which abolished the otherwise 
cardioprotective activation of KATP-chaunels elicited by 10 min of preconditioning ischemia 
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Preischaemic as well as postischaemic application 
of a Na+lH+ exchange inhibitor 
reduces infarct size in pigs 
Sven Rohmann, Heinrich Weygandt, Klaus-Otto Minck 
Background: During reperfusion of ischaemic myocardium, Na+/H+ 
exchange promotes recovery from acidosis resulting in an accumulation of 
intracellular Na+. This leads to calcium overload via Na+/Ca2+ exchange and 
might result in cell necrosis contributing to reperfusion injUly. Methods 
and Results: We assessed whether HOE 694, a specific inhibitor ofNa+fH+ 
exchange, is able to reduce infarct size in swine myocardium. Experiments 
were performed in pentobarbitone anaesthetized, open chest pigs which 
were subjected to a 60 min occlusion of the left anterior descending 
coronary artery (LADCA) followed by two hours of reperfusion. Three 
groups of animals were studied. In the pre-reperfusion group (pre-REP, n=7) 
HOE 694 infusion (7 mg/kg/15min) was started at 45 min of occlusion of 
the LADCA and continued until the end of occlusion, wlule in pre-occlusion 
group (pre-TCO, n~7) HOE 694 infusion was started 15 min before 
occlusion and stopped at the onset of ischaemia. In the control group (n=7) 
animals received vehicle alone. At the end of the protocol, inh1rct size (as % 
of the left ventricular risk region) was determined by the p-nitro-blue-
tetrazolium method. Treatment with HOE 694 prior to the ischaemic insult 
or upon reper/\Jsion significantly reduced infarct size (4.1%(1.4%), p<O.OI 
and 38.2%(5.8%), p<0.05, respectively), compared with 77.7%(4.0%) in the 
control group. However, infarct size was significantly more reduced in the 
pre-TCO group than in the pre-REP group (p<0.05). Conclusion: Treatment 
with HOE 694 leads to a significant reduction in infarct size; even when 
administered after the onset of ischaemia. Thus, inhibition of Na+fH+ 
exchange was able to limit cell necrosis. This implicates an important role 
for Na+/H+ exchange in the pathogenesis of infarct expansion and provides 
evidence that reperfusion injury exists. However, HOE 694 was even more 
effective when given before ischaemia, indicating an additional protective 
effect during ischaemia which might be due to slowing down of a vicious 
cycle, that consumes ATP and generates H+. 
I n the last decade several intracellular processes have been identified as key players involved in the imbalance of cellular homeostasis in cardiac tissue. In the course of _ myocardial ischemia and rcperfusion these include: decreased intracellular pHI, 
intracellular Na+ overload2, and intracellular Ca2+ overload3• 
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Na+lIr exchange represents the most important mechanism for myocardial pH regulation in 
ischaemic and reperfused tissue4 5 6. Myocardial ischaemia is knowll to result in acidosis due 
to a retention of H+ from glycolytic ATP turnover, accumulation of CO2 and glycolytic 
degradation products such as lactate, and net ATP breakdown', The Na"H' exchanger of 
cardiac myocytes is stimulated by intracellular acidosis, resulting in H+ extmsion and Na+ 
influx8, Scholz et a1.9 have proposed that such an influx ofNa+ stimulates the Na+/K+ -ATPase, 
which could accelerate A TP depletion and celiular iI~ury in tissue that is metabolically 
compromised by ischaemia. Stimulation of the Na+/H+ exchanger by intracellular acidosis and 
its detrimental consequences may, however, be confined to the early minutes of ischaemia. 
The Na+/I-r exchanger has been reported to be inhibited by extracellular acidosis lO, which may 
exceed intracellular acidosis within 10 minutes of ischaemia ll . 
During reperfusion of ischemic myocardium the effect of the Na +/H+ exchanger may be 
substantial, too. \Vhile the Na+lI-r+ exchanger is inhibited by extracellular acidosis during 
ischemia, Lazdunski et a1.4 provided evidence that a rapid washout of extracellular H+ during 
reperfusion reactivates the Na+/H+ exchanger, which results in a marked influx ofNa+. Such 
an influx ofNa+, in the face ofNa+/K+-ATPase inhibition due to ATP depletion caused by the 
preceeding ischaemia, may lead to a dramatic increase in intracellular Na+ concentration. This 
sets in motion the Na+ICa2+ exchange favouring an excessive increase in the intracellular Ca2+ 
concentration (Ca2+_overioadY2 13, which has been implicated as a cmcial contributing factor 
in reperfusion injury 14. 
Based on the preceeding discussion, it is evident that activation of the Na + IH+ exchanger, 
although leading to rapid restoration of normal pH, could result in a paradoxical acceleration 
of tissue injury, To evaluate the pathophysiological role of the Na"W exchanger in infarct 
size expansion, we applied its specific inhibitor HOE 694 [(3-methylsulfonyl-4-
piperidinobenzoyl)guanidine methanesulfonate]15 either prior to 60 minutes of ischaemia or 
Control 
Pre-TCO 
Pre-REP 
o Hoe 694 7 mglkglJSmin i.v. 
Figure 1. Design of the study. Teo = total coronary artery occlusion. 
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prior to 120 minutes of reperfusion in a pig model of myocardial ischaemia and measured 
infarct size at the end of the experiment. 
Methods 
The investigation conforms with the Guide for the Care and Use of Laboratory Animals 
published by the US National Institutes of Health (NIH publication No 85-23, revised 1985). 
Experimental design 
All 21 pigs undenvent a 60 min left anterior descending coronary artery (LADCA) occlusion 
followed by 120 min of reperfusion. The animals were divided into three groups in random 
order. The design is depicted in figure I. Vehicle treated animals served as controls (CON). 
HOE 694 was infused (7 mglkg/15min Lv.) either prior to the 60 min LADCA occlusion 
(Pre-TCO) or prior to 120 min of reperfusion (Pre-REP). The dose of HOE 694 was chosen 
according to the study of Sack et al.!6 demonstrating that with a bolus injection of 7 mg/kg 
plasma levels can be achieved adequate for the inhibition ofthe Na+/H+ exchanger. 
Experimental Preparation 
Twenty-one mixed breed Landrace-type domestic pigs of either sex weighing between 23 and 
29 kg were premedicated with ketamine-HCl (IOmg/kg Lm.) 15 min prior to anaesthesia with 
Lv. bolus injection of sodium pentobarbital (30 mglkg). Following tracheotomy pigs were 
mechanically ventilated with a animal respirator (Rhema, HofheimlFRG) on nitrous oxide 
supplemented with oxygen at a ratio of 2: 1. In order to guide adjustment of ventilator settings 
arterial blood gases were measured repeatedly. Anaesthesia was maintained by continuous 
infusion of sodium pentobarbital at 3 mglkg/h through a catheter in the right jugular vein. 
Al1erial blood was sampled through a catheter placed in the right femoral artery, while the 
right brachial artery was cannulated with a polyethylene catheter, which was advanced to the 
ascending aorta for continuous recording of arterial pressure. A 8 French Millar 
micromanorneter was advanced via the carotid artery into the left ventricle for continuous 
measurement of left ventricular pressure. The heart was exposed through a midline 
thoracotomy and suspended in a pericardial cradle. Distally of its second branch the (LADCA) 
was carefully dissected free over a length of 4 mm and a loose ligature was placed around the 
vessel which could be occluded with a small vascular clip. Electromagnetic flow probes were 
situated on the ascending aorta and the LADCA proximal to the occlusion site. A Teflon 
catheter (outer diameter 0.8 Ililll) was placed into the epicardial vein draining the area at risk. 
Rectal temperature was monitored throughout the experiment and the chest cavity was 
covered with a plastic sheet and kept warm with a heat lamp to keep body temperature 
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Figure 2. Risk region (RR) expressed as percent of the left ventricle (LV) and myocardial infarct size expressed 
as percent ofRR with and without HOE 694 treatment, results are mean±SEM. All groups n = 7. 
between 37°C and 38°C. Myocardial function in the ischaemic area was measured with two 5 
mHz ultrasonic crystals aligned transmurally to measure wall thickness. A brief « 1 0 second) 
occlusion was performed to identify the ischaemic region and the crystal pair was located 
centrally in the ischaemic region. The iuner crystal was advanced to the endocardium 
tangentially through a stab wound in the epicardium. The epicardial crystal, attached to a 
Dacron patch, was positioned on the epicardium with the aid of an oscilloscope, and secured 
with three sutures. After a stabilisation period of 30 min after surgety the experimental 
protocol was started. 
Risk Region ond h!ro,.ct Size 
Following a reperfusion period of two hours the LA DCA was reoccluded and 10 ml of 10% 
fluorescein dye (fluorescein sodium solved in saline, E. Merck) were injected into the left 
atrium. After one to two min the pig was killed by electrical fibrillation with a 9-V battery and 
the heart excised. \Vann 2% agarose was injected into the ventricle via the aortic root and the 
heart was kept on icc. After the agarose had congealed, the right ventricle was removed and 
the left ventricle was sliced into four to six rings perpendicular to the LADCA. Subsequently, 
the rings were weighed and the risk region traced onto an acetate sheet under blacklight, 
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which sharply defined the borders of the risk region not perfused with fluorescein. Incubation 
for 30 min in 1.25% paranitrobluetetrazolium in phosphate buffer (PH 7.1) at 37° C delineated 
lloninfarcted tissue (deep blue) and infarcted tissue (pale). The size of the risk region and the 
infarcted region were determined by planimetry. The % risk region (risk region / area of ring) 
was calculated for the top and bottom of each ring and the mean value for each ring was 
multiplied by the weight. The weights of regions were summed and divided by the weight of 
the left ventricle to yield the % of the left ventricle at risk (%RR) and % of the left ventricular 
risk region infarcted (%IS). 
l\{yocardial O.\)'gen Consumption 
Arterial and coronary venous blood samples were obtained anaerobically for determination of 
pH, pO" and pCO, by withdrawal of 3.0 ml of blood from the aortic and anterior 
interventricular vein catheters simultaneously. 
Haemoglobin content, O2 saturation, blood P02, and pH, were measured by a computer-aided 
blood gas analyser (ABL 300 Radiometer, Copenhagen, Demnark). 
Oxygen consumption in the region of myocardium perfused by the LADCA was computed by 
multiplying the arteriovenous oxygen difference by coronary blood flow determined with the 
flowmeter probe proximal to the occlusion site. Since anterior interventricular vein blood flow 
corresponds to LADCA influx 17, this method allows determination of myocardial oxygen 
consumption in the region perfused by the LADCA1S. 
Admillistratioll ~r HOE 694 
Animals in the treatment groups received HOE 694 (E.Merck) dissolved in isotonic saline, 
while the pigs in the control group received isotonic saline, Prior to each experiment HOE 694 
was dissolved and mixed in a 37°C warm saline, The HOE 694 solution was administered as a 
continuous infusion over 15 min via a femoral vein. 
Biochemical analysis of HOE 694 in plasma samples 
The plasma samples were stored at -20°C in plastic centrifuge tubes until analysis. Plasma 
was extracted according to the method of Sack et a1. 16, using EMD 80 563 as internal standard, 
All chemicals used were of analytical grade (E. Merck). The HPLC equipment consisted of 
autosampler (Merck Hitachi AS2000A), HPLC pump (Merck Hitachi L6020A), UV-detector 
(Merck Hitachi L4000), integrator (Merck Hitachi D-2500), and a column (E. Merck 60 RP 
Select B) in the dimension 125 x 4 mm. Flow rate of the modified buffer, 0.05M, pH 4.0 
(CH,CNINH,PO, (40/60» and dodecane-I-sulfone-sodium-salt (0.5 mM) was 1.2 mllmin. 
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Retention time was 2.7 min for HOE 694 and 4.7 min for the internal standard at the described 
conditions. The limit of quantification was to 40 nglml plasma. 
Data analysis 
Continuous recording of haemodynamic and wall thickness data was made on a paper recorder 
(Gould) and on a computer-aided registration system (IFD, Mescher, MUlheimlRuhr, FRG). 
Recordings at timepoints of interest were made at a paper speed of I DOmm/sec, and the wall 
thickness data were collected from the recordings. \Vall thickness variables were averaged 
over 10 cycles at each timepoint and included end diastolic wall thickness (EDWT, defined as 
the point when left ventricular dP/dt started its rapid upstroke after crossing the zeroline), and 
end systolic wall thickness (ESWT, defined as the point of maximal wall thickness within 20 
ms before peak negative left ventricular dP/dt). These data were used to calculate wall 
thickening (%AWT) with the following formula: «ESWT-EDWT) I EDWT) x 100. Other 
variables included peak left ventricular systolic pressure (L VSP, mmHg), mean arterial 
pressure (MAP, nmlHg), and heart rate (HR, beats/min). The coronary vascular resistance 
(dyn x sec x cn15) was calculated as diastolic aortic blood pressure x 80 / coronary blood 
flow; analogously, the total peripheral resistance was calculated as MAP x 80 / aortic blood 
flow. 
Table I 
Haemooynamics assessed at baseline, directl), before the 60 min LADCA occlusion (Pre·TCO). al 45 min and 60 min of lADCA occlusion (TCO). at 
rcacti\'c hyperaemia (about) min of rcperfusion; RH), at IS min of {cperfusion (lS'REP) and at the end of the protocol 020'REP) 
Baseline Pre·TCO 4S'TCO 6O''fc0 RII Is'REP 120'REP 
Heart rate (beals/min) 
ConlTol 113±5 IIS±6 i22:±6 119±8 1I9± 10 116±7 1J6± II 
Pre·TCO 106±6 i06±6 1I1±7 !O8±7 I08H IOS±8 lOSt !O 
Pte·REP I05±8 106±8 109±8 I03±8 J08±6 III ±6 1l4±9 
lrfAP(mmHg} 
ConlTol 92±5 89±4 88±5 89±6 86>6 83±7 89±6 
Pre·TCO 99 •• 91±2 87±3 87±4 8l±S 88±6 97±6 
Pre·REP 96.3 95±3 96i6 96±7 89±7 95±8 95±9 
Double product {(mmHg • bpm) I JOOl 
ConlIol 120±12 1I8±IO 1I0± 12 99±IO 8H8 96±1I 106± !O 
Pre-TCO 123±9 1I4±5 IlS±7 111 ±8 I03±10 1I0±9 122±14 
Pre·REP 122± 14 123±14 125±17 113± 17 IIH 16 1l9± 19 126±22 
LV dP Idl ... u (mmHg Is) 
ConlIol 1944± 139 1945±158 i767± 191 1174± 189 J816±219 1836±200 1848±217 
Pre·TCO J903± 158 1991 ± 123 1798± 134 1105±1I4 1655±95 1568± 108 1818± 153 
Pre-REP 2211 ±340 2126±356 1945±350 1942±264 1750±267 1795±328 t136±3S9 
Cardiac outpul (m/ / mini 10 kg) 
ConlIO\ 997±70 996±82 931±99 959± 174 929± 101 942± 111 8SS± lOS 
Pre·TCO 851 ±17 884±76 883±130 839±97 80H 110 963± 104 792± 104 
Pre·REP 1127 ± 110 1I19±11O I053± lOS 958±83 912±70 932±99 749±93 
MAP = mean arterial blood pressure; LV "" Jeft \'cntriculat. 
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Data are reported as mean±SEM. For comparison of variables across tim~ between the groups, 
a two factor analysis of variance (ANDV A) of repeated measures was used. \Vhen the 
ANDV A was significant, pairwise comparisons were made with the S~dent's t-test with the 
significance level for the p-values corrected with the Bonferroni method. For comparison 
across time in each of the individual groups, a one factor ANDV A of repeated measures was 
employed, with a post-hoc testing strategy identical to that of the two f.1ctor ANOVA. A two 
sample rank sum test (Maml-Whitney-V) was used to test the differences between two groups 
with regard to the risk region and the % of the risk region infarcted. 
Results 
Risk Region and bifarct Size 
The risk region and infarct size are depicted in figure 2. The risk regions were virtually 
identical in all groups. The risk region was intentionally kept smal!' (10% - 15% of left 
ventricular wall volume), because in pilot studies larger risk regions were associated with an 
unacceptably high incidence of ventricular fibrillation. The percentage of the risk region 
infarcted was 77.7% (4.0%) for the controls. Starting drug treatment after 45 min of LADCA 
occlusion reduced infarct size by 51% [38.2(5.8%)]. Infusing HOE 694 before ischaemia 
reduced infarct size by 95% [4.1±(1.4%)]. The difference in infarct size between Pre-TCO and 
Pre-REP was significant (p<0.05). 
Haemodynamics, wall jimctiol1, and myocardia! o.\J'gen consumption (1\1VO;) 
The control pigs remained haemodynamically: stable throughout the occlusion and reperfusion 
period and did not vary significantly from baseline with regard to heart rate, mean arterial 
pressure or double product. 
Infusion of HOE 694 did not affect haemodynamics (table I) or coronary blood flow (table 2), 
neither in the Pre-TCO group nor in the Pre-REP group. 
Comparing baseline values with values assessed directly before occlusion in the Pre-TCO 
Table 2 
Coronary blood now (cap) and cakulated coronary ... a~ulat reSiHal\ce (CYR) during the protocol (. = p < 0.05 compared with control animals al \he 
same timepoinl (for time points, see Table I) 
Baseline Pre-TCO 45'TCO 6O'TCO RH 15'REP 120'REP 
CBF(ml/min) 
Control S4±4 S4±3 31 ±5 32±4 78±6 6S±9 66=10 
Pre·TCO 4H5 43±S 2aS 21±4 73±7 SO± II 34± 
Pre-REP 51 ±7 SO±7 34±7 31 ±6 66±8 70±11 54= Ii 
CVRfd)'n 's 'cm- j ) 
Control 123± II 116±8 226±35 212±24 78±9 IOO±14 109±16 
Pre·TCO 163±IS 160±19 283 ±53 24S±37 82± II IS2±32 • 263±56, 
Pre· REP 146±28 148±30 238±59 24S±52 J02±IS 106±20 148±2S 
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group, it was noted that none of the parameters changed significantly. Wall function (%liWT) 
in the subsequently ischaemic region did not change at all (table 3) and regional MVO, did not 
decline significantly (from 4.98(0.51) to 4.01(0.76) mllminiIOOg). 
During reperfusion the post-ischaemic depression of regional wall function (%6. \VT) was 
identical in all three groups (table 3), despite the significant differences in infarct size. In 
addition, after 120 min ofreperfusion 110 differences with regard to global or regional cardiac 
perfonnance were observed between the three groups. 
Plasma levels of HOE 694 
Table 4 summarizes the plasma levels of HOE 694 throughout the experiment. There was no 
difference in peak plasma levels following Lv. infusion between the two treatment groups 
(8.9(1.3) ~g/ml vs. 9.7(1.6 ) flg/ml, n.s.). These values correspond to a plasma concentration 
of about 2.5 x 10" M with respect to a molecular weight of 360 for HOE 694, which is 
sufficient for a selective inhibition of the Na+lJ-r exchanger. 
Discussion 
In the present study, we have investigated the effect of HOE 694, a specific inhibitor of the 
Na+/Jr exchanger, on ischaemic and postischaemic damage in anaesthetized pigs. 
The major controversy regarding the nature of reperfusion injury is whether injury at the time 
of reperfusion merely represents an acceleration of damage that would in any case have 
occurred or whether there is a specific additional injury caused by reperfusion itself. Opiel9 
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Figure 3. Infarct size in the individual animal in the control and HOE 694 
treatment groups. 
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Table 3 
Regional wall function (%..1 wall thickening) in the LADCA area sub~uenlly made ischemic for 60 min (. p < 0.05 compared with control animals al 
the same timepoint; for time points, see Table I) 
Control 
Pre·TCO 
Pre·REP 
Table 4 
Baseline 
32±4 
31±5 
38±4 
Pre·TCO 
33±5 
31±5 
39±3 
4S'TCO 
1±2 
-2±2 
-9±3 • 
6O'TCO 
-2±2 
-1±2 
-7±3 
RH 
0±2 
-2±3 
-JO±2 • 
IS'REP 
2±3 
-1±4 
-6±3 
120'REP 
Oi3 
0>2 
-5±2 
Plasma levels of HOE 694 (p.g/mO throughout the uperiment in the h\'O treatment groullS [the limepoints of sampling are identical to those in Table \; 0 
= below the limit of quantification (40 n8/m!)] 
Pre·TCO 
Pre·REP 
Ba.seli~ Pre·TCO 4S'TCO 6O'TCO RH IS'REP 6O'REP 120'REP 
o 
o 
8.9±1.3 
o 
1.6 ± 0.1 
o 
I.3±O.2 
9.7±1.6 
I.3±O.2 
4.I±O.6 
O.9±O.J 
L8±O.l 
0.6±0.1 
0.8±0.! 
OA±O.! 
OA±O.I 
emphasized that firm evidence for reperfusion injmy would require proof that a reperfusion-
associated event can be diminished in severity by an intervention given only at the time of 
reperfusion. In fact, inhibition of the Na+/H+ exchanger has been shown to prevent some 
reperfusion-associated events. HOE 694, when used during reperfusion, decreased the 
incidence ofreperfusion arrhythmias20 21 and myocardial stunning20. However, there is divided 
opinion whether these acute, transitory events can be regarded as markers of reperfusion 
injury. Jennings and colleagues22 argued that Itreperfusion injury should be restricted to mean 
cell death caused by reperfusion. 1t In this way, our study is the first to show that selective 
inhibition of the Na+/H+ exchanger by HOE 694 during reperfusion limits irreversible cell 
damage and thereby reduces infhrct size measured at the end of 120 min of reperfusion. Thus, 
this study provides evidence that reperfusion injury does exist. 
HOE 694 has been characterized as a potent inhibitor of the Na+/Ir exchanger in erythrocytes, 
thrombocytes, bovine aortic endothelial celis, and in endothelial cells of porcine brain 
capillaries", with a high affinity for the NHE-l isoform24• We administered 7 mglkgll5 min of 
HOE 694 i.v., which is a dose resuiting in plasma levels of Hoe 694 sufficient to limit 
reperfusion arrhythmias and stunning as shown in a pig model of two cycles of 10 min 
LADCA occlusiou followed by 4 h of reperfusion". In line with this pig study, HOE 694 did 
neither have an effect on haemodynamic parameters nor on cardiac contractility of our 
animals. This suggests that this agent is able to be cardioprotective without an effect on 
haemodynamic parameters. As the left ventricular ischemic regions were virtually identical 
and pigs are known to have no preexisting collaterals25 , any effect on infarct size in this model 
must be a direct drug action on the myocardium. 
The precise way by which Na+/I-r exchange mediates reperfusion injury can not be deducted 
from our shldy. On one hand, while activation of the Na+/Ir exchange can restore intracellular 
pH following an acid load, the concomitant increase in Na+ can aggravate existing 
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derangements of ionic homeostasis, particularly with respect to calcium overload2, and may 
result in exacerbation and acceleration of tissue injuryl8, In addition, the reduced cellular Na+ 
influx would require less Na+ ions to be extmded by the Na+JK+ pump, with consequently less 
ATP consmnptionlS and less generation of protons. On the other hand, the Na+/I-r exchange 
has been shown to participate in the activation of both platelets26 27 and neutrophils28, which 
arc supposed to participate in reperfusion injuf),2!1, 
Less generation of protons during ischemia has been shown to be protective30 and a longer 
preservation of normal pH has been stated to be at least in part responsible for the infarct size 
reducing effect of preconditioning in pig hearts31 • E.g. changes in intracellular pH might 
influence the activity of phospholipases" or the opening probability of ATP-sensitive 
potassium channels33 • Both are systems many authors believe to playa role in ischaemia-
reperfusion injury. 
Thus, the cardioprotective effect of HOE 694 was most pronounced when the drug was 
present prior to the ischaemic insult and during reperfusion. Inhibition of Na+/H+ exchange 
during ischaemia and reperfusion reduced infarct size by 95%, which is in the range of 
protection reported for ischemic preconditioning3-1. Furthermore, inhibition of Na+/I-r 
exchange in our model was more effective than e.g. a treatment with an ATP-sensitive 
potassium channel opene~5. 
HOE 694 had a more pronounced protective effect when present during ischaemia and 
reperfusion compared with being administered during reperfusion only. Tllis is in line with 
most other previous reports, in which Na+/I-r exchange inhibition was observed to be most 
protective when initiated before the ischaemic period36 20. The pronounced protective effect 
during ischaemia is surprising since the detrimental consequences of Na+/l-r exchanger 
stimulation should be confined to the time prior to the development of significant extracellular 
acidosis. Most recently Bugge aud Ytrehus" reported in a isolated rat heart study that E1PA 
did not protect the heart when given only during rcperfusion, but was protective when given 
prior to the onset of regional ischemia. This difference between the two rather specific Na+IJ-r 
exchange inhibitors is most likely a dose effect, since we learned in pilot dose finding studies 
that 10 times higher dosages of a Na+/lr exchange inllibitor are necessary to protect during 
reperfusion than during ischemia. While Na+IW exchange inhibitors of the HOE 694 type 
showed no side effects even in higher doses, Bugge & Ytrehus were limited to a ccrtain dose 
to avoid the EIPA typical interactions with the sodium or calcium channels. 
Our study implies that the action of HOE 694 during the first minutes of ischaemia is 
sufficicnt to protect the heart. This is supported by the observation that in early ischaemia 
intracellular Na+ rises rapidlT8 39, which can, at least partially, be suppressed by the unspecific 
Na+/H+ exchange inhibitor amiloride40• Inllibition of Na+/H+ exchange may delay or prevent 
the rapid Na+ loading in carly ischaemia and thereby Ca2+ loading via the Na+-Ca2+ exchanger. 
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Consequently, Hendrikx et al." observed in isolated perfused rabbit hearts a marked delay in 
the onset of ischaemic contracture after HOE 694 treatment. 
Interestingly, in our Shldy we did not observe a difference in postischaemic regional wall 
function, despite the marked differences in infarct size. On one hand, acidification of the 
myocyte shuts down myocardial contractility41 and thereby might save energy, while, on the 
other hand, activation of the Na+/H+ exchange induces an alkalinisation of the ce1142 thereby 
allowing to restore contractility. Blocking alkalinisation by Hoe 694 might result in a longer 
lasting detoriation of contractility, although the myocyte is viable. Studies with longer 
reperfusion periods « 12 h) would be necessary to address the question of the time course of 
recovery of myocardial function after treatment with a Na+ll-r exchange inhibitor. 
Conclusions 
Treatment with HOE 694 results in a marked reduction in infarct size. This beneficial effect is 
best explained by the decrease in Na+ influx during ischaemia as well as during reperfusion, 
resulting in less energy expenditure during ischaemia and a decrease in calcium overload 
during reperfusion in HOE 694-treated pig hearts. 
Thus, in contrast to many other interventions, Naf/I-r exchange inhibition provides a 
pronounced infarct size reducing effect even when only administered post~ischael1lically. We 
propose, therefore, that activation of the Na+ll-r exchanger contributes to reperfusion injury 
and that inhibition of the exchanger will be of benefit in reduction of such injury. 
The protective properties of specific Na+/H+ exchange inhibitors offer substantial clinical 
promise for the use of these agents as adjunct therapy in numerous reperfusion protocols and 
for the prevention of myocardial infarction. 
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Chapter 8 
Summary 
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I P'" n this thesis are represented the results of our studies on ischemic preconditioning and on drugs supposed to interact with its mechanisms. Murry et all termed 1986 a ~~ phenomenon "ischemic preconditioning", which described the effect of short ischemic 
episodes on infarct size following a sustained occlusion of the coronary artery. In their dog 
model infarct size was 29% in control animals subjected to a 40 minutes coronary aliery 
occlusion, but only 7% when the 40 minutes occlusion was preceded by 4 cycles of 5 minutes 
coronary artery occlusion and 5 minutes of reperfusion. These results impJied that brief 
ischemia, which does not lead to myocardial damage by itself, is able to trigger an 
endogenous mechanism, which conditions the myocardium to better tolerate ischemia.2 
In chapter 2 we extended the observations by Muny et a!. to the pig heart. In pigs with nearly 
identical risk regions, preconditioning with two episodes of ten minutes ischemia, each 
followed by 30 minutes of reperfusion, reduced in~1rct size from 48% of the control 
myocardium subjected to 60 minutes of coronary artery occlusion to 10%. This nearly 80% 
reduction of infarct size did neither accrue from a recruitment of collaterals nor from energy 
savings due to concolluuitant myocardial stunning. 
Since then it has been shown that preconditioning exists in every species in which it has been 
investigated including man, and research has focused on evaluating the modalities of ischemic 
preconditioning.) It became apparent that ischemic preconditioning can be stimulated not only 
by ischemia, but by e.g. heat stress;~ myocardial stretcH, rapid ventricular pacibg, and 
transient occlusion of a mesenteric or renal artery. 7 The variety of stimuli may point towards a 
common end effector, which could be the A TP-sensitive potassium chamlel. Gross and 
coworkers showed in various experiments in dogs, that blockade of ATP-sensitive potassium 
channels blocks the protection afforded by ischemic preconditioning independent of whether 
the stimulus was ischemia,8 an adenosine-mimetic; or acetylcholine:o If the ATP-sensitive 
potassium channels would be the common end effector, it would be the target to 
pharmacologically induce preconditioning protection. II 
UsiI~g the ATP-sensitive potassium channel opener bimakalim, we could show in pigs that 
bimakalim is able to reduce infarct size nearly to the same extent as ischemic preconditioning 
and found first evidence, that the peripheral vasodilatory effect observed with our 
cardioprotective dose was not necessary for its protective effects. An observation, which was 
substantiated by experiments using another opener of ATP-sensitive potassium channels, U-
89232, which is almost completely devoid of va so dilatory properties. The protective effects of 
all three, ischemic preconditioning, bimakalim, and UR 89232, could be blocked when the 
selective antagonist of ATP-sensitive potassium chmmcls, glibenclamide, was infused 
(chapters 3 to 5). 
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\Vith the increasing body of knowledge about ischemic preconditioning in well defined 
experimental settings, the question rises whether ischemic preconditioning is clinically 
relevant. 12 \Vhen a great variety of stimuli can precondition the heart, the heart of a patient 
frequently suffering from angina pectoris attacks should be preconditioned all the time. Cohen 
et al 13 showed that this might not be the case, since he reported that conscious rabbits can 
become tolerant to multiple episodes of ischemia and lose the preconditioning protection. 
\Vhen the rabbits experienced a 5-minute coronary occlusion and 10 minutes of reperfusion 
before a 30 minute coronary artery occlusion, they were protected, but not if the sustained 
ischemia was preceded by 40 to 65 five~minute occlusions during a 3R to 4-day period. If an 
ischemiaRfree interval of 2.5 to 3 days was interposed, protection was again evident". Their 
observation is consistent with results obtained in anesthetized rats,14 dogs,15 and pigs. 16 From a 
clinical point of view, these results implicate that stimulation by ischemia may not be 
sufficient to achieve protection all the time. 
In chapter 6 we could not only confirm some of the previously made observations in our pig 
model, but, by applying bimakalim, we could completely reinstall the protection, whith has 
been lost with ischemic preconditioning and could only in part be reRestablished by a second 
preconditioning cycle of 10 minutes of ischemia and 15 minutes of reperfusion. These results 
add to the clinical importance of potassium channel openers as they allow the reinstatement of 
the cardioprotection by a pharmacological approach at a timepoint when this is not possible 
by ischemic preconditioning. Future studies should also investigate the effectiveness of 
potassium channel openers, when myocardium has become unresponsive to ischemic 
preconditioning due to a larger number of sequences of brief ischemia and reperfusion. 13 It is 
quite feasible that in such studies the potassium channel opener, because of its 
pharmacodynamic properties, should be applied during the occlusionRreperfusion sequences. 
From a mechanistic point of view, these results implicate that, although ischemic 
preconditioning provides a very potent means to protect the heart, its efficacy can 
pharmacologically be optimized. 
To investigate the role of the Na+RH+ exchanger in our pig model of ischemia and reperfusion, 
we used its specific inhibitor HOE 694.17 HOE 694, whell applied prior to 60 millu:es of 
ischemia, reduced infarct size to the same extent as did ischemic preconditioning (chapter 7). 
The profound cardioprotective potential ofNa+RH+ exchange inhibition has been confirmed by 
several investigators in pigs,18 rabbits,19 and rats?O However, we were not able to investigate 
an effect of HOE 694 additive to ischemic preconditioning, since the protection afforded by 
ischemic preconditioning in our pig model was so profound that an additive effect was not 
measurable. 
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Most investigators observed cardioprotection only when the Na+-H+ exchange inhibitor was 
applied prior to the onset of ischemia. Interestingly in our stndy, the application of HOE 694 
at the onset of reperfusion significantly limited infarct size, while administration of an ATP-
sensitive potassium charutcl opener at that timepoint is ineffective (e.g. see chapter 3). This 
effect ofNa+-H+ exchange inhibition during reperfusion appears to be highly dose dependent, 
as Klein et al" did not observe protection with a dose of 3 mglkg of HOE 694, while we 
observed protection with a dose of7 mglkg. 
The in our study observed additional benefit during treatment only upon reperfusion, which 
cannot be observed with potassium channel openers, favors the idea that Na+ -H+ exchange 
inhibitors can be clinically very valuable to optimize the protection afforded by ischemic 
preconditioning and reperfusion protocols. However, more experimental studies are necessary 
to elucidate the possible synergistic role of A TP-sensitive potassium channel openers and 
Na+-H+ exchange inhibitors in the treatment of acute myocardial infarction. 
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D it proefschrift is samengesteld uit cen aantal studies over ischemische preconditionering, waarbij zijn inbegrepen studies met fannaca die ischemische preconditionering nabootsen en waarbij de acties van de fannacon mogelijk kunnen 
hijdragen tot het begrijpen van de mechanismcn die bij ischemische preconditionering zijn 
betrokken .. Murry en medewcrkers l zijn de eersten geweest die de term ischemische 
preconditionering gebmikten toen ze waarnamen dat in genarcotiseerde hOllden de grootte van 
het infarct na cen 40 minuten durende afsluiting van cen kransslagader was afgenomen van 
29% tot 7%, WaIlllCer die 40 minuten durende kransslagader afsluiting werd voorafgegaan 
door 4 cycli van 5 minuten durende afsluiting van de betreffende kransslagader en 5 minuten 
reperfusie. Downey2 concludeerde dat het hart in staat was onherstelbare schade door 
langdurig zuurstofgebrek te beperken door een cndogeen mechanisme dat getriggerd werd 
door korte perioden van zuurstofgebrek, die ap zichzelf niet tat onherstelbare schade lei den. 
In hoofdstuk 2 is aangetoond dat ischemische preconditionering niet aileen bij het hondenhart 
maar ook bij het varkenshart optreedt. Om tot ischemische preconditionering te komen 
werden in genarcotiseerde varkens 2 cycli van 10 minuten durende kransslagader afsluiting en 
30 minuten reperfusie gebruikt. Infarctgrootte na een 60 minuten durende kransslagader 
afsluiting was na ischemische preconditionering 10% tegen 4&% in varkens die niet 
gepreconditioneerd waren voordat de kransslagader voor 60 minuten werd afgesloten. Omdat 
varkens in tegenstelling tot honden geen coronair collateralen hebben, kon de laatste als een 
factor die bijdroeg aan de verminderde infarctgrootte worden uitgesloten. Besparing van de 
energiebehoefte van het hart, ten gevolge van het optreden van stunning na de ischemische 
preconditionering, was cen andere factor die kon worden uitgesloten. 
Sindsdien is aangetoond dat ischcmische preconditionering optreedt in elke species waarin het 
fenomeen is onderzocht. Dit geldt ook voor de mens. Onderzoek was naast het vinden van het 
mechanisme gericht op het vinden van andere stimuli die het hart konden beschennen3• Een 
aantal van deze stimuli zijn inductie van heat shock eiwitten door thermische stress\ stretch5, 
ventrikel paccn6 en kortdurende afsluiting van arterien die andere organen dan het hart van 
bloed voorzien.7 Deze verscheidenheid van stimuli ZOti crop kunnen duidell dat deze stimuli 
een gemeenschappelijk doelwit hebben. Activatie van ATP afhankelijke kalium kanalen zou 
zo'n gemeenschappelijke target kunnen zijn. Gross en medewerkers hebben aangetoond dat 
blokkade van deze kalium kanalen de bescherming door ischemische preconditionering 
ophetfen ongeacht welke preconditiolleringsstimulus werd gebruikts.IO• \Vanneer deze kalium 
kana len inderdaad zo'n gemeenschappelijk eindpunt is van de cascade van processen die het 
fenomeen bewerkstelligen, dan is het mogelijk het fenomeen ook farmacologisch na te 
bootsenll. Door gebruik te maken van de ATP afhankelijke kalium kanaal opener bimakalim 
werd aangetaond dat in varkens de infarctgrootte bijna evenveel was afgenomen als na 
ischemische preconditionering wamleer een kransslagader gedurende 60 milluten werd 
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afgesloten. Eigenschappen als vasodilatatie van de coronair en perifere bloedvaten speelden 
hierbij geen ro1. Deze bevindingen zijn ondersteund door gebruik te maken van cell andere 
kalium kanaal opener, U-89232, cen farmacon dat effectief was zander dat er vasodilatatie 
optrad. Behandeling met glibenclamide, cen blokker van de kalium kanalen voorkwam zowel 
de bescherming door ischcmische preconditioncring ais dat van de beide farmaca 
(hoofdstukken 3 en 5). 
Aangezien het hart beschermd kan worden door cen groat aantal stimuli djst de vraag of 
ischemische preconditionering klinisch relevant is12, Het is namelijk heel goed mogelijk dat 
harten van patienten met kransslagader aandoenillgcll bijna continu beschcrmd worden door 
deze stimuli. In dat geval zal toediening van een farmacon nag nauwelijks de beschenning 
kunnen verhagen, tenzij via een geheel ander meehanisme. Er zijn aanwijzingen dat harten 
niet altijd beschennd worden door ischemische preconditionering. Zo hebben Cohen en 
onderzoekers13 aangetoond dat wakkere konijnen resistent worden voor ischemische 
preconditioneringsstimuli, wanneer deze met een hoge frequentie worden aangeboden. Dus 
wanneer konijnen werden blootgesteld aan een enkele 5 minuten kransslagader afsIuiting en 
10 minuten later die kransslagader voor 30 minuten werd afgesioten, waren de harten 
beschermd. Dit bleek echter niet het geval wanneer 40-65 van die stimuli werden aangeboden 
over een periode van 3 tot 4 dagen. Na cen ischemische-vrije periode van 2.5 tot 3 dagen was 
het weer mogelijk harten te preconditioneren. Deze waarnemingen zijn in overeenstenlluing 
met waarnemingen in genarcotiseerde ratten,14 hondelP en varked§. In hoofdstuk 6 is 
aangetoond dat op een moment dat het in genarcotiseerde varkens niet mogelijk is de harten 
volledig te beschermen door een nieuwe ischemische preconditioneringsstimulus het tach 
mogelijk is de harten te beschermen met behuip van bimakalim. Dit resultaat draagt dus bij 
aan het klillisch belang van ATP afhankelijke kalium kanaal openers, aangezien het met deze 
fannaca l110gelijk is het hart te beschermen, wanneer dit niet kan door toediening van cen 
nieuwe ischemische preconditioneringsstimulans. Toekomstige studies zullen moeten nagaan 
of de kalium kanaal openers ook nog effectief zijn wamleer harten resistent zijn geworden 
door een groat aantal stimuli over cen korte peri ode toe te dienen, zoais in de proeven bij 
Cohen en medewerkers. l3 
Vanuit cen mechal1isch standpunt betekent dit dat de bescherming door ischemische 
preconditionering geoptimaliseerd kan worden met behulp van farmaca. Dit is nog verder 
onderzocht door gebruik te maken van de natrium-waterstof exchange inhibitor HOE 694 in 
het genarcotiseerde varkellsmodel. 17 Het bleek dat HOE 694 even cffectief was als 
ischemische preconditionering in het beperken van de infarctgrootte. De beschenning door 
beide stimuli was zo groot dat het niet 1110gelijk was 0111 na te gaan of er sprake kal1 zijn van 
een synergistisch effect. De resultaten van onze experimenten zijn in ovcreenstemming met de 
beschenlling beschreven door anderen in in vivo en in vitro modellen. 18-2o In deze studies werd 
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bescherming alleen waargenomcll wauuecr de inhibitor voor het begin van de ischemische 
peri ode werd toegediend. In de huidige studie was HOE 694 ook effectief, hoewel minder, 
wanneer het werd toegediend bij het begin van de reperfusie. Het is van belang op te merken 
dat de kalium kanaal opener in onze studies oak aileen effectief was wanneef het voor het 
begin van de 60 minuten ischemic werd toegediend (zie hoofdstuk 3). De [eden voor de 
effectiviteit tijdens reperfusie kan gelegen zijn in de dosis die gebruikt werd (7 mg/kg) 
aangezien Klein en medewerkers24 gecn beschenning tijdens reperfusie vanden met cen dosis 
van 3 mg/kg. De eigenschap dat toediening tijdens rcperfusie oak nog bescherming kan 
bieden, geeft cen duidelijke meerwaarde voor de natrium-waterstof exchange il1hibitoren en 
geeft aanleiding tot verdere studies onder andere het nagaan van een synergetische actie van 
A TP afhankelijke kalium kanaal opener en natrium-waterstof exchange inhibitorcn. 
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